Photodynamic Therapy and Diagnostics

Phyllochlorin analogs with specific structural modifications address the need for improved photosensitizers by enhancing phototoxicity and stability, making them effective for photodynamic therapy and diagnosis, especially in tumor treatment and antiviral applications.

JP2024544615APending Publication Date: 2024-12-03アールエムダブリュー チョ グループ リミテッド
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024531436
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-01
Filing Date
2022-11-28
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

There is a need for photosensitizers with high singlet oxygen quantum yields, strong photosensitivity in organic and aqueous media, high fluorescence quantum yields, lower dark toxicity, better stability, and improved solubility, and ease of purification for photodynamic therapy applications.

Method used

Development of phyllochlorin analogs and their pharmaceutically acceptable salts, characterized by specific structural formulas (I) and (II), which include various substituents and metal complexes, to enhance phototoxicity and stability while maintaining low dark toxicity.

Benefits of technology

The phyllochlorin analogs demonstrate improved phototoxicity, stability, and solubility, making them suitable for effective photodynamic therapy and diagnosis, particularly in treating tumors and antiviral therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544615000001_ABST
    Figure 2024544615000001_ABST
Patent Text Reader

Abstract

The present invention relates to phyllochlorin analogues and their pharma- ceutically acceptable salts, as well as compositions comprising phyllochlorin analogues and their pharma- ceutically acceptable salts. Phyllochlorin analogues and their pharma- ceutically acceptable salts are suitable for use in photodynamic therapy, cytoluminescence therapy and photodynamic diagnosis, for example for the treatment or detection of tumors or for antiviral therapy. The present invention also relates to the use of phyllochlorin analogues and their pharma- ceutically acceptable salts in the manufacture of phototherapeutic or photodiagnostic agents, as well as methods of photodynamic therapy, cytoluminescence therapy or photodynamic diagnosis, for example for the treatment or detection of tumors or for antiviral therapy. [Formula 1] TIFF2024544615000116.tif70159
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to phyllochlorin analogues and pharmaceutically acceptable salts thereof, as well as compositions comprising phyllochlorin analogues and pharmaceutically acceptable salts thereof. Phyllochlorin analogues and pharmaceutically acceptable salts thereof are suitable for use in photodynamic therapy, cytoluminescence therapy and photodynamic diagnosis, for example, in the treatment or detection of tumors or in antiviral therapy. The present invention also relates to the use of phyllochlorin analogues and pharmaceutically acceptable salts thereof in the manufacture of phototherapeutic or photodiagnostic agents, as well as methods for photodynamic therapy, cytoluminescence therapy or photodynamic diagnosis, for example, in the treatment or detection of tumors or in antiviral therapy.

[0002] The structure of "phyllochlorin" is as follows: [ka] [Background technology]

[0003] Porphyrins and their analogues are known photosensitive chemical compounds that can absorb photons and emit them at higher wavelengths. These unique properties have many applications, one of which is photodynamic therapy (PDT).

[0004] There are currently two generations of photosensitizers for PDT: the first generation includes heme porphyrins (blood derivatives), and the second generation is mostly chlorophyll analogues, the latter compounds known as chlorins and bacteriochlorins.

[0005] Chlorin e4 has been shown to exhibit good photosensitizing activity. It has also been shown to have protective effects against indomethacin-induced gastric lesions in rats and TAA- or CCl4-induced acute liver injury in mice. Therefore, it has been suggested that chlorin e4 may be a promising new drug candidate for anti-gastroenteritis and liver damage protection. WO2009 / 040411 suggests the use of chlorin e4 zinc complexes in photodynamic therapy, and WO2014 / 091241 suggests the use of chlorin e4 disodium in photodynamic therapy.

[0006] [ka] However, there is a continuing need for better photosensitizers. There is a need for compounds with high singlet oxygen quantum yields, and preferably compounds with strong photosensitizing properties in organic and aqueous media. There is also a need for compounds with high fluorescence quantum yields. Furthermore, there is a need for compounds and / or compositions that have higher phototoxicity, lower dark toxicity, good stability, good solubility, and / or are easily purified. Summary of the Invention

[0007] A first aspect of the present invention relates to a compound of formula (I) or a complex of formula (II): [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CHN(R 2 )2, -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3or -C(S)-N(R 3 )2 is selected; -R 2 are each independently -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2, -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )2, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 7 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 7’ ] is selected from; -R 3 and -R 4 are independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -ORβ , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 7 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 7’ ] is selected from; -R α - are each independently C1-C 42 alkylene groups, which optionally have one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) backbone carbon atoms of the alkylene group optionally replaced by a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or which is or includes a cyclic group which may be optionally substituted and which may optionally include one or more (e.g., 1, 2, 3, 4, or 5) heteroatoms N, O, S, P, or Se in its carbon skeleton; -R 5are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl, or C5-C6 heteroaryl, where phenyl or C5-C6 heteroaryl optionally contains one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, each selected from -CO2 ― and the phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 6 -OR 2 , -N(R 2 )2, -SR 2 , -S(O)R 2 , -S(O)2R 2 , or -X; -R 7 optionally one or more (e.g., 1, 2, 3, 4, or 5) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO) n -H or -O-(CH2CH2O) n-[NC5H5] substituted with -CH3 groups; -R 7’ is -CO2 ― and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; -R 9 is hydrogen or methyl, or -R 6 and -R 9 together form an oxo (=O) group; n is 1, 2, 3, 4, 5, or 6; X is a halo group; Y is a counter anion; Z is a counter cation, and M 2+ is a metal cation.

[0008] A first aspect of the present invention is a compound of formula (I) or a complex of formula (II), [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CHN(R 2 )2, -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R2 are each independently -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2, -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )2, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 7 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 7’ ] is selected from; -R 3 and -R 4 are independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SRβ , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 7 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or R α -[R 7’ ] is selected from; -R α - are each independently C1-C 42 alkylene groups, wherein the alkylene group optionally comprises one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and wherein one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) skeletal carbon atoms of the alkylene group are optionally replaced by heteroatoms or groups independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched, or which is or includes a cyclic group, which may be optionally substituted, and which may optionally include one or more (e.g., 1, 2, 3, 4, or 5) heteroatoms N, O, S, P, or Se in its carbon skeleton; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) nand selected from —CH3, phenyl, or C5-C6 heteroaryl, wherein phenyl or C5-C6 heteroaryl optionally comprises one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, each selected from -CO2 - and the phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 6 -OR 2 , -SR 2 , -S(O)R 2 , -S(O)2R 2 , or -X; -R 7 optionally one or more (e.g., 1, 2, 3, 4, or 5) —C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] substituted with -CH3 groups; -R 7’ is -CO2 -and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; -R 9 is hydrogen or methyl; n is 1, 2, 3, 4, 5, or 6; X is a halo group; Y is a counter anion; Z is a counter cation, and M 2+ is a metal cation.

[0009] The first aspect of the present invention also provides a compound of formula (I) or a complex of formula (II): [ka] During the ceremony, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CHN(R 2 )2, -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 2 are each independently -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2, -C(S)-OR 4 , -C(S)-SR 4, -C(S)-N(R 4 )2, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 7 ] selected from Y; -R 3 and -R 4 are independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R7 ] selected from Y; -R α - are each independently C1 to C 12 alkylene groups, wherein the alkylene groups can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more carbon atoms in the backbone of the alkylene groups can be optionally substituted with one or more heteroatoms O or S; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or which may be or contain a cyclic group which may be optionally substituted and which may optionally include one or more heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, halo, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, wherein phenyl or C5-C6 heteroaryl optionally comprises one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with -CH3 groups; -R 6 -OR 2 , -SR 2 , -S(O)R 2 , -S(O)2R 2 , or -X; -R 7 is optionally one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] substituted with -CH3 groups; n is 1, 2, 3 or 4; Y is a counterion; X is a halo group; M 2+ is a metal ion; a compound of formula (I) or a complex of formula (II), or a pharmaceutically acceptable salt thereof.

[0010] A second aspect of the present invention provides a compound of formula (I) or a complex of formula (II) according to the first aspect of the present invention for use in medicine.

[0011] In one embodiment of the first or second aspect of the invention, the compound of formula (I) or (II) is (i) methyl 3-(18-ethyl-13-(hydroxymethyl)-2,5,8,12,17-pentamethyl-7H,8H-porphyrin-7-yl)propanoate, (ii) 3-(18-ethyl-13-(hydroxymethyl)-2,5,8,12,17-pentamethyl-7H,8H-porphyrin-7-yl)propanoic acid methyl copper complex; (iii) 3-(18-ethyl-13-(hydroxymethyl)-2,5,8,12,17-pentamethyl-7H,8H-porphyrin-7-yl)propanoic acid methyl zinc complex; (iv) methyl 3-(18-ethyl-13-formyl-2,5,8,12,17-pentamethyl-7H,8H-porphyrin-7-yl)propanoate; or any enantiomer thereof; or a racemic mixture of any of them; Or a salt of any of them, not.

[0012] In the context of this specification, a "hydrocarbyl" substituent or hydrocarbyl moiety in a substituent contains only carbon and hydrogen atoms, but does not include any heteroatoms such as N, O, S, P, or Se in its carbon skeleton, unless otherwise specified. Hydrocarbyl groups / moieties can be saturated or unsaturated (including aromatic), straight or branched chain, or can be or include cyclic groups, and unless otherwise specified, cyclic groups do not include heteroatoms such as N, O, S, P, or Se in its carbon skeleton. Examples of hydrocarbyl groups include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl groups / moieties, and all combinations of these groups / moieties. Typically, hydrocarbyl groups are C1-C 60 Hydrocarbyl groups, more typically C1-C 40 Hydrocarbyl groups, more typically C1-C 20 More typically, the hydrocarbyl group is a C1-C 12 More typically, the hydrocarbyl group is a C1-C 10 A "hydrocarbylene" group is defined as a divalent hydrocarbyl group.

[0013] An "alkyl" substituent or alkyl moiety in a substituent can be linear (i.e., straight-chain) or branched. Examples of alkyl groups / moieties include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, and n-pentyl groups / moieties. Unless otherwise specified, the term "alkyl" does not include "cycloalkyl." Typically, alkyl groups are C1-C6 12 It is an alkyl group. More typically, the alkyl group is a C1-C6 alkyl group. An "alkylene" group is defined similarly as a divalent alkyl group.

[0014] An "alkenyl" substituent or alkenyl moiety in a substituent refers to an unsaturated alkyl group or moiety having one or more carbon-carbon double bonds. Examples of alkenyl groups / moieties include ethenyl, propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 1-hexenyl, 1,3-butadienyl, 1,3-pentadienyl, 1,4-pentadienyl, and 1,4-hexadienyl groups / moieties. 44 Unless otherwise specified, the term "alkenyl" does not include "cycloalkenyl." Typically, alkenyl groups are C2-C6 12 It is an alkenyl group. More typically, the alkenyl group is a C2-C6 alkenyl group. An "alkenylene" group is defined similarly as a divalent alkenyl group.

[0015] An "alkynyl" substituent or alkynyl moiety in a substituent refers to an unsaturated alkyl group or moiety having one or more carbon-carbon triple bonds. Examples of alkynyl groups / moieties include ethynyl, propargyl, but-1-ynyl, and but-2-ynyl. Typically, alkynyl groups are C2-C 12 It is an alkynyl group. More typically, the alkynyl group is a C2-C6 alkynyl group. An "alkynylene" group is defined similarly as a divalent alkynyl group.

[0016] A "cyclic" substituent or cyclic moiety in a substituent refers to any hydrocarbyl ring, which may be saturated or unsaturated (including aromatic) and may contain one or more heteroatoms, such as N, O, S, P, or Se, in its carbon skeleton. Examples of cyclic groups include cycloalkyl, cycloalkenyl, heterocyclic, aryl, and heteroaryl groups, discussed below. Cyclic groups may be monocyclic, bicyclic (e.g., bridged, fused, or spiro), or polycyclic. Typically, cyclic groups are 3- to 12-membered cyclic groups, meaning they contain 3 to 12 ring atoms. More typically, cyclic groups are 3- to 7-membered monocyclic groups, meaning they contain 3 to 7 ring atoms.

[0017] A "heterocyclic" substituent or heterocyclic moiety in a substituent refers to a cyclic group or moiety that includes one or more carbon atoms and one or more (e.g., 1, 2, 3, or 4) heteroatoms, such as N, O, S, P, or Se, in the ring structure. Examples of heterocyclic groups include the heteroaryl groups discussed below, as well as non-aromatic heterocyclic groups such as azetidinyl, azetinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, oxetanyl, thietanyl, pyrazolidinyl, imidazolidinyl, dioxolanyl, oxathiolanyl, thianyl, and dioxanyl groups.

[0018] A "cycloalkyl" substituent or cycloalkyl moiety in a substituent refers to a saturated hydrocarbyl ring containing, for example, 3 to 7 carbon atoms, examples of which include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Unless otherwise specified, a cycloalkyl substituent or moiety can include monocyclic, bicyclic, or polycyclic hydrocarbyl rings.

[0019] A "cycloalkenyl" substituent or cycloalkenyl moiety in a substituent refers to a non-aromatic unsaturated hydrocarbyl ring having one or more carbon-carbon double bonds and containing, for example, 3 to 7 carbon atoms, examples of which include cyclopent-1-en-1-yl, cyclohex-1-en-1-yl, and cyclohexa-1,3-dien-1-yl. Unless otherwise specified, a cycloalkenyl substituent or moiety can include monocyclic, bicyclic, or polycyclic hydrocarbyl rings.

[0020] An "aryl" substituent or aryl moiety in a substituent refers to an aromatic hydrocarbyl ring. The term "aryl" includes monocyclic aromatic hydrocarbons and polycyclic fused-ring aromatic hydrocarbons, in which all of the fused ring systems (excluding ring systems that are part of or formed by any substituent) are aromatic. Examples of aryl groups / moieties include phenyl, naphthyl, anthracenyl, and phenanthrenyl. Unless otherwise specified, the term "aryl" does not include "heteroaryl."

[0021] A "heteroaryl" substituent or heteroaryl moiety in a substituent refers to an aromatic heterocyclic group or moiety. The term "heteroaryl" includes monocyclic aromatic heterocycles and polycyclic fused-ring aromatic heterocycles, in which all of the fused ring systems (excluding ring systems that are part of or formed by any substituent) are aromatic. Examples of heteroaryl groups / moieties include: [ka] where G=O, S or NH.

[0022] For purposes of this specification, when a combination of moieties is referred to as a group, e.g., arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl, the last-mentioned moiety includes the atoms of the remainder of the molecule to which the group is attached. An example of an arylalkyl group is benzyl.

[0023] For purposes of this specification, an optionally substituted group or moiety (-R β etc.): (i) each hydrogen atom is optionally halo; -CN; -NO2; -N3; -Rx ;-OH;-OR x ;-R y -Haro;-R y -CN;-R y -NO2;-R y -N3;-R y -R x ;-R y -OH;-R y -OR x ;-SH;-SR x ;-SOR x ;-SO2H;-SO2R x ;-SO2NH2;-SO2NHR x ;-SO2N(R x )2;-R y -SH;-R y -SR x ;-R y -SORx ;-R y -SO2H;-R y -SO2R x ;-R y -SO2NH2;-R y -SO2NHR x ;-R y -SO2N(R x )2;-NH2;-NHR x ;-N(R x )2;-N + (R x )3;-R y -NH2;-R y -NHR x ;-R y -N(R x )2;-R y -N + (R x )3;-CHO;-COR x ;-COOH;-COOR x ;-OCOR x ;-R y -CHO;-R y -COR x ;-R y -COOH;-R y -COOR x or -R y -OCOR x and / or (ii) Any two hydrogen atoms attached to the same carbon atom are oxo (=O), =S, =NH, or =NR x and / or (iii) Any two hydrogen atoms attached to the same or different atoms within the same optionally substituted group or moiety may be replaced by —O—, —S—, —NH—, —N(R x )-, -N + (R x )2- or -R y -, and optionally substituted with a bridging substituent independently selected from where each -R y- is independently selected from an alkylene, alkenylene, or alkynylene group which contains 1 to 6 atoms in its backbone; one or more carbon atoms in the backbone of an alkylene, alkenylene, or alkynylene group can optionally be replaced with one or more heteroatoms N, O, or S; and the alkylene, alkenylene, or alkynylene group can optionally contain one or more halo and / or -R x may be substituted with a group; and Each-R x are independently selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C2-C6 cyclic groups, or any two or three -R attached to the same nitrogen atom x may form a C2-C7 cyclic group together with the nitrogen atom to which they are attached, and any -R x can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, —O(C1-C4 alkyl), —O(C1-C4 haloalkyl), halo, —OH, —NH2, —CN, or oxo (═O) groups.

[0024] Typically, the substituents include 1, 2, 3 or 4 substituents, more typically 1, 2 or 3 substituents, more typically 1 or 2 substituents, more typically 1 substituent.

[0025] Unless otherwise specified, any divalent bridging substituent (e.g., —O—, —S—, —NH—, —N(R x )-, -N + (R x )2- or -R y -) or moiety must be attached only to the specified group or moiety and cannot be attached to a second group or moiety, even if the second group or moiety itself may be optionally substituted.

[0026] The term "halo" includes fluoro, chloro, bromo and iodo.

[0027] Unless otherwise specified, when a group is prefixed with the term "halo," such as a haloalkyl or halomethyl group, it is understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo, and iodo. Typically, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution in the corresponding group without the halo prefix. For example, a halomethyl group may contain one, two, or three halo substituents. A haloethyl or halophenyl group may contain one, two, three, four, or five halo substituents. Similarly, unless otherwise specified, when a group begins with a particular halo group, it is understood that the group in question is substituted with one or more of the specified halo groups. For example, the term "fluoromethyl" refers to a methyl group substituted with one, two, or three fluoro groups.

[0028] Unless otherwise specified, when a group is referred to as "halo-substituted," it is understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo, and iodo. Typically, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution in the group referred to as halo-substituted. For example, a halo-substituted methyl group may contain one, two, or three halo substituents. A halo-substituted ethyl or halo-substituted phenyl group may contain one, two, three, four, or five halo substituents.

[0029] Unless otherwise specified, a reference to an element is considered to be a reference to all isotopes of that element, so for example, unless otherwise specified, a reference to hydrogen is considered to encompass all isotopes of hydrogen, including deuterium and tritium.

[0030] Unless otherwise stated, a reference to a compound or group should be understood to refer to all tautomeric forms of that compound or group.

[0031] When referring to a hydrocarbyl or other group that contains one or more heteroatoms N, O, S, P or Se in its carbon skeleton, or to a carbon atom of a hydrocarbyl or other group that is substituted by an N, O, S, P or Se atom, what is intended is: [ka] is replaced by; -CH2- is replaced by -NH-, -PH-, -O-, -S- or -Se-; -CH3 is replaced by -NH2, -PH2, -OH, -SH, or -SeH; -CH= is replaced by -N= or -P=; -CH2- is replaced by -NH-, -PH-, -O-, -S- or -Se-; or CH≡ is replaced by N≡ or P≡; provided that the resulting group contains at least one carbon atom. For example, methoxy, dimethylamino, and aminoethyl groups are considered to be hydrocarbyl groups containing one or more heteroatoms N, O, S, P, or Se in their carbon skeleton.

[0032] In the context of this specification, unless otherwise stated, C x ~C y A group is defined as a group containing x to y carbon atoms. For example, a C1-C4 alkyl group is defined as an alkyl group containing 1 to 4 carbon atoms. When calculating the total number of carbon atoms in a parent group, including any substituted and / or moieties, optional substituents and moieties are not taken into account. For the avoidance of doubt, substituted heteroatoms, e.g., N, O, S, P, or Se, should be counted as carbon atoms when calculating the number of carbon atoms in a Cx-Cy group. For example, a morpholinyl group should be considered a C6 heterocyclic group, not a C4 heterocyclic group.

[0033] Because the pi electrons of the chlorin ring are delocalized, the chlorin ring can be represented by multiple resonance structures. Resonance structures are different ways of depicting the same compound. Two of the resonance structures for the chlorin ring are shown directly below.

[0034] [ka] Typically, a complex contains a central metal atom or ion, known as a coordination center, and a binding molecule or ion, known as a ligand. Typically, a complex contains a central metal atom or ion, known as a coordination center, and a binding molecule or ion, known as a ligand. Herein, the bond between the coordination center and the ligand is represented as shown in the complex below on the left (the attraction between the anionic ligand and the central metal cation is represented by four dashed lines), but equivalently, it can be represented as shown in the complex below on the right (the attraction between the ligand molecule and the central metal atom is represented by two covalent bonds and two dashed lines): [ka] As used herein, -[NC5H5]Y means [ka] In one embodiment of the first or second aspect of the invention, X is a halo group selected from fluoro, chloro, bromo, or iodo. In one embodiment, X is chloro or bromo.

[0035] In one embodiment of the first or second aspect of the present invention, there is provided a compound of formula (I):

[0036] In one embodiment of the first or second aspect of the invention, Y is a halide (e.g., fluoride, chloride, bromide, or iodide) or other inorganic anion (e.g., bisulfate, hexafluorophosphate (PF6), nitrate, perchlorate, sulfate, bisulfate, or phosphate) or an organic anion (e.g., acetate, ascorbate, aspartate, benzoate, besylate (benzenesulfonate), bicarbonate, bis(trifluoromethanesulfonyl)imide (TFSI), acid tartrate, butyrate, camsylate (camphorsulfonate), carbonate, citrate, decanoate, edetate, esylate (ethanesulfonate), fumarate, galactarate, gluceptate, gluconate, glutamate, glycolate, hexanoate, β-hydroxybutyrate, 2-hydroxyethanesulfonate, and the counteranion is selected from hydroxymaleate, hydroxynaphthoate, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate (methanesulfonate), methylsulfate, mucate, napsylate (naphthalene-2-sulfonate), octanoate, oleate, ornithine, pamoate, pantothenate, polygalacturonate, propanoate, propionate, salicylate, stearate, succinate, tartrate, teoclate, tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (BARF), tetrakis(pentafluorophenyl)borate (F5-TPB), tetraphenylborate (TPB), tosylate (toluene-p-sulfonate), or triflate (trifluoromethanesulfonate).

[0037] In another embodiment of the first or second aspect of the invention, Y is a halide (e.g., fluoride, chloride, bromide, or iodide) or other inorganic anion (e.g., bisulfate, nitrate, perchlorate, phosphate, or sulfate) or an organic anion (e.g., acetate, aspartate, benzoate, besylate (benzenesulfonate), butyrate, camsylate (camphorsulfonate), citrate, esylate (ethanesulfonate), fumarate, galactarate, gluconate, glutamate, glycolate, 2-hydroxyethanesulfon ... The counter anion is selected from sulfonate, hydroxymaleate, lactate, malate, maleate, mandelate, mesylate (methanesulfonate), napsylate (naphthalene-2-sulfonate), ornithine, pamoate, pantothenate, propanoate, salicylate, succinate, tartrate, tosylate (toluene-p-sulfonate), or triflate (trifluoromethanesulfonate). In one embodiment, Y is fluoride, chloride, bromide, or iodide. In one embodiment, Y is chloride or bromide.

[0038] In one embodiment of the first or second aspect of the invention, Z is a counter cation selected from an inorganic cation (e.g., lithium, sodium, potassium, magnesium, calcium, or ammonium cation) or an organic cation (e.g., an amine cation (e.g., choline or meglumine cation) or an amino acid cation (e.g., arginine cation).

[0039] In one embodiment of the first or second aspect of the invention, M 2+ Zn 2+ , Cu 2+ , Fe 2+ , Pd 2+ or Pt 2+ In one embodiment, M 2+ is Zn 2+ is.

[0040] In one embodiment of the first or second aspect of the invention, -R 1is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2. In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2 or -C(S)-N(R 3 )2. In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2 is selected.

[0041] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 are selected from each -R 3 is C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2 or -C(S)-N(R 3 )2, each of which is selected from -R 3 is C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, each of which is selected from -R 3 is C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3and -R 3 is C1-C4 alkyl (preferably methyl).

[0042] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2, each of which is selected from -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group. In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, each of which is selected from -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group. In one embodiment, -R 1 is -C(O)-OR 3 or -C(O)-SR 3 -R 3 -R α -OR β or -R α -SR β -R β is a saccharidyl group. Typically in these embodiments, -R α - is C1-C 12an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m -CH2CH2- groups, all optionally substituted, where m is 1, 2, 3, or 4.

[0043] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ) and -R 2 or -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β and -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ) and -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -Rα -S(O)2R β and -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically in these embodiments, -R α - is C1-C 12 In these embodiments, -R is selected from alkylene groups, wherein 1, 2, 3, or 4 carbon atoms of the backbone of the alkylene group can be optionally replaced with a heteroatom or a group independently selected from O, S, NH, or NMe. α - is C1-C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m -CH2CH2- groups, all optionally substituted, where m is 1, 2, 3, or 4.

[0044] -R 3’ The group is another -R 3 -R bonded to the same atom as the group 3 -R refers to the group 3 and -R 3’ may be the same or different. Preferably, -R 3 and -R 3’ is different.

[0045] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ) and -R 2 or -R 3 -R α -R β or -R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ) and -R 3 -R α -R β or -R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R3’ ) where -R 3 -R α -R β or -R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is C1~C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m - group or -(CH2CH2S) m - groups, all optionally substituted, where m is 1, 2, 3, or 4.

[0046] In any of the embodiments of the previous four paragraphs, the saccharidyl group may optionally be substituted, for example, with a protecting group such as acetyl or a natural amino acid such as valine. The amino acid may be attached to the saccharidyl group, for example, by forming an ester between the carboxylic acid group of the amino acid and the hydroxyl group of the saccharidyl group.

[0047] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ -R 2 or -R 3 -R α -R β or -R β -R βis a C1-C8 alkyl group optionally substituted with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) —OH or —OAc; —R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ) and -R 3 -R α -R β or -R β -R β is a C1-C8 alkyl group optionally substituted with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) hydroxyl groups, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) and -R 3 -R α -R β or -R β -R β is a C1-C8 alkyl group optionally substituted with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) hydroxyl groups, and -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is an unsubstituted C1 to C6 alkylene group, or an unsubstituted C1 to C4 alkylene group, or an unsubstituted C1 to C2 alkylene group.

[0048] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ) and -R 2 or -R 3 -R α -H or -R α -OH;-R α - is C1-C 12 an alkylene group, which may be optionally substituted with one or more C-C alkyl, C-C haloalkyl, or halo groups; one or more carbon atoms in the backbone of the alkylene group may be optionally replaced with one or more heteroatoms; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ) and -R 3 -R α -H or -R α -OH, -R α - is C1-C 12 alkylene groups, which may be optionally substituted with one or more C-C alkyl, C-C haloalkyl, or halo groups, and one or more carbon atoms in the backbone of the alkylene group may be optionally substituted with one or more heteroatoms O or S; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R α -H or -R α -OH, -R α - is C1~C 12alkylene groups, wherein one or more carbon atoms in the backbone of the alkylene group can be optionally replaced by one or more heteroatoms O or S; 3’ is H or C1-C4 alkyl (preferably methyl).

[0049] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ) and -R 2 or -R 3 -R β and -R β Halo, -CN, -NO2, -N3, -OH, -OR x , -SH, -SR x , -SOR x , -SO2H, -SO2R x , -SO2NH2, -SO2NHR x , -SO2N(R x )2, -NH2, -NHR x , -N(R x )2, -N + (R x )3, -CHO, -COR x , -COOH, -COOR x , -OCOR x , or -NH-CO-CR z C1-C optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) substituents independently selected from —NH2 12 Alkyl or C2-C 12 alkenyl group, and each -R x are independently selected from C1-C4 alkyl, -R z is the side chain of a natural amino acid, and -R3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 Ha-R β and -R β are independently halo, -CN, -NO2, -N3, -OH, -OR x , -SH, -SR x , -SOR x , -SO2H, -SO2R x , -SO2NH2, -SO2NHR x , -SO2N(R x )2, -NH2, -NHR x , -N(R x )2, -N + (R x )3, -CHO, -COR x , -COOH, -COOR x , -OCOR x or -NH-CO-CR z C1-C optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) substituents selected from —NH2 12 is an alkyl group, and each -R x are independently selected from C1-C4 alkyl, -R z is the side chain of a natural amino acid, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 Ha-R β and -R β are independently halo, -CN, -NO2, -N3, -OH, -OR x , -SH, -SR x , -SOR x , -SO2H, -SO2R x, -SO2NH2, -SO2NHR x , -SO2N(R x )2, -NH2, -NHR x , -N(R x )2, -N + (R x )3, -CHO, -COR x , -COOH, -COOR x , -OCOR x or -NH-CO-CR z -NH2, wherein each -R x are independently selected from C1-C4 alkyl, -R z is the side chain of a natural amino acid, and -R 3’ is H or C1-C4 alkyl (preferably methyl).

[0050] In one embodiment of the first or second aspect of the invention, -R 1 is -CO-(NR zz -CHR z -CO) v -N(R zz )2 and -CO-(NR zz -CHR z -CO) v -OR zz Each -R is selected from z are independently selected from the side chains of natural amino acids, and each -R zz is independently selected from hydrogen and C1-C4 alkyl (preferably methyl); and v is 1, 2, 3, 4, 5, 6, 7, or 8.

[0051] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R3 )2 or -C(S)-N(R 3 )(R 3’ ) and -R 2 or -R 3 -R β and -R β is C1-C 20 alkyl groups, which may be optionally substituted with 1, 2, 3, or 4 halo groups; and 1, 2, 3, 4, 5, or 6 backbone carbon atoms of the alkyl group may be optionally replaced with heteroatoms or groups independently selected from O, S, NH, or NMe; -R 3’ is H or C1-C4 alkyl (preferably methyl).

[0052] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ) and -R 3’ is H or C1-C4 alkyl (preferably methyl), and -R 2 or -R 3 -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, or -R α -[R 7 ]Y. In one embodiment, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R3’ ) and -R 3’ is H or C1-C4 alkyl (preferably methyl), and -R 2 or -R 3 -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, or -R α -[R 7 ]Y, each of which is selected from -R 5 is independently selected from C1-C4 alkyl or phenyl, where phenyl is optionally substituted with one, two, or three C1-C4 alkyl or C1-C4 alkoxy groups; -R 7 is optionally substituted with one, two, or three C1-C4 alkyl or C1-C4 alkoxy groups -[NC5H 5] ] and -R α - is C1-C 12 selected from alkylene groups, wherein one, two, three, or four carbon atoms in the backbone of the alkylene group may be optionally replaced with a heteroatom or group independently selected from O, S, NH, or NMe; and Y is a counterion (preferably a halide).

[0053] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ) and -R 2 or -R 3 -R α -[P(R 5 )3]Y, and each -R 5are independently selected from phenyl or C5-C6 heteroaryl, wherein phenyl or C5-C6 heteroaryl is selected from one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CHO) n -H or -O-(CH2CH2O) n -CH3 groups, n is 1, 2, 3 or 4, Y is fluoride, chloride, bromide or iodide, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ) and -R 3 -R α -[P(R 5 )3]Y, and each -R 5 are independently selected from phenyl or C5-C6 heteroaryl, wherein phenyl or C5-C6 heteroaryl is selected from one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, O-(CH2CHO) n -H or -O-(CH2CH2O) n n is 1, 2, 3 or 4; Y is fluoride, chloride, bromide or iodide; and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 Ha-R α -[P(R 5 )3]Y, and each -R 5is independently selected from phenyl or C5-C6 heteroaryl, and the phenyl or C5-C6 heteroaryl optionally comprises one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CHO) n -H or -O-(CH2CH2O) n -CH3 groups, n is 1, 2, 3 or 4, Y is fluoride, chloride, bromide or iodide, -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically in these embodiments, -R α - is C1-C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m -CH2CH2- groups, all optionally substituted, where m is 1, 2, 3, or 4.

[0054] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-OR 3 and -R 3 is selected from hydrogen, C1-C4 alkyl (preferably methyl), or a cation (e.g., lithium, sodium, potassium, magnesium, calcium, ammonium, an amine (e.g., choline or meglumine), or a cation of an amino acid (e.g., arginine)). In one embodiment, -R 1 -C(O)-OR 3 and -R 3 is selected from C1-C4 alkyl (preferably methyl), or a cation (e.g., lithium, sodium, potassium, magnesium, calcium, ammonium, an amine (such as choline or meglumine) or amino acid (such as arginine) cation, etc.).

[0055] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-N(R 3)2. In one embodiment, -R 1 is -C(O)-N(C1-C4 alkyl)(R 3 ) or -C(O)-NHR 3 In one embodiment, -R 1 is -C(O)-N(CH3)(R 3 ) or -C(O)-NHR 3 In one embodiment, -R 1 is -C(O)-N(C1-C4 alkyl)(R 3 In one embodiment, -R 1 is -C(O)-N(CH3)(R 3 )

[0056] In one embodiment of the first or second aspect of the invention, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CHN(R 2 )2, or -R 2 In one embodiment, -R 1 is -CH2OR 2 , -CH2SR 2 , -CHN(R 2 )2, or -R 2 In one embodiment, -R 1 is -CH2OR 2 , -CH2SR 2 , or -CHN(R 2 )2. In one embodiment, -R 1 is -CH2OR 2 or -CH2SR 2 In one embodiment, -R 1 is -CH2OR 2 In one embodiment, -R 1 -R 2 and -R 2 -R α -X.

[0057] In one embodiment of the first and second aspects of the invention, each -R3 independently, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[NC5H5]Y. In one embodiment, each -R 2 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β In one embodiment, each -R 2 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group. In one embodiment, -R 2 -R α -OR β or -R α -SR β In one embodiment, -R 2 -R α -OR β or -Rα -SR β -R β is a saccharidyl group.

[0058] In one embodiment of the first or second aspect of the invention, -R 2 is -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2, -C(S)-OR 4 , -C(S)-SR 4 or -C(S)-N(R 4 )2. In one embodiment, -R 2 is -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2 or -C(S)-N(R 4 )2. In one embodiment, -R 2 is -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 or -C(O)-N(R 4 )2 is selected.

[0059] In one embodiment of the first or second aspect of the invention, -R 2 is -C(O)-N(R 4 )(R 4’ ) and -R 4 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group, and -R 4’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 2 is -C(O)-N(R 4 )(R 4’) and -R 4 -R α -OR β or -R α -SR β、 -R β is a saccharidyl group, and -R 4’ is H or C1-C4 alkyl (preferably methyl).

[0060] -R 4’ The group is another -R 4 -R bonded to the same atom as the group 4 -R refers to the group 4 and -R 4’ may be the same or different. Preferably, -R 4 and -R 4’ is different.

[0061] In one embodiment of the first or second aspect of the invention, -R 2 is -C(O)-N(R 4 )2. In one embodiment, -R 2 is -C(O)-N(C1-C4 alkyl)(R 4 In one embodiment, -R 2 is -C(O)-N(CH3)(R 4 )

[0062] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -SR 2 , -S(O)R 2 or -S(O)2R 2 In one embodiment, -R 6 -OR 2 , -SR 2 , -S(O)R 2 or -S(O)2R 2. In one embodiment, -R 6 -OR 2 or -SR 2 In one embodiment, -R 6 -OR 2 is.

[0063] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2 -H, -C(O)R 4 , -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, or -R α In one embodiment, -R 6 -OR 2 , -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2 -H, -C(O)R 4 , -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -Rα -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, or -R α In one embodiment, -R 6 -OR 2 or -SR 2 -R 2 -H, -C(O)R 4 , -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, or -R α -[NC5H5]Y.

[0064] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -N(R 2 )(R 2’), -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2’ is selected from hydrogen or C1-C4 alkyl (preferably hydrogen or methyl), -R 2 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β and optionally -R β is a saccharidyl group. In one embodiment, -R 6 -OR 2 , -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β Selected from, optionally with -R β is a succadyl group. In one embodiment, -R 6 -OR 2 , -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2 -R α -OR β or -R α -SR β and optionally, -R β is a succadyl group. In one embodiment, -R 6 -OR 2 or -SR 2 -R 2 -R α -OR β , -R α -SR β , -Rα -S(O)R β or -R α -S(O)2R β and optionally, -R β is a succadyl group. In one embodiment, -R 6 -OR 2 or -SR 2 -R 2 -R α -OR β or -R α -SR β Selected from, optionally with -R β is a succadiyl group.

[0065] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -N(R 2 )(R 2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2’ is selected from hydrogen or C1-C4 alkyl (preferably hydrogen or methyl), -R 2 is -C(O)R 4 In one embodiment, -R 6 -OR 2 , -N(R 2 )2, -N(R 2 )(R 2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2’ is selected from hydrogen or C1-C4 alkyl (preferably hydrogen or methyl), -R 2 is -C(O)R 4 and -R 4 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α-S(O)2R β -R β is a succadyl group. In one embodiment, -R 6 -OR 2 , -N(R 2 )2, -N(R 2 )(R 2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2’ is selected from hydrogen or C1-C4 alkyl (preferably hydrogen or methyl), -R 2 -C(O)R 4 and -R 4 -R α -OR β or -R α -SR β Selected from -R β is a succadiyl group.

[0066] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2 is -C(O)R 4 In one embodiment, -R 6 -OR 2 , -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2 is -C(O)R 4 and -R 4 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a succadyl group. In one embodiment, -R 6 -OR2 , -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2 is -C(O)R 4 and -R 4 -R α -OR β or -R α -SR β -R β is a succadiyl group.

[0067] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 or -SR 2 -R 2 is -C(O)R 4 In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 ) 2 Each -R is selected from 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group. In one embodiment, -R 6 -OR 2 or -SR 2 -R 2 is -C(O)R 4 and -R 4 -R α -OR β or -R α -SR β -R β is a succadiyl group.

[0068] In one embodiment of the first or second aspect of the invention, -R 6-OR 2 , -N(R 2 )2, -N(R 2 )(R 2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2’ is selected from hydrogen or C1-C4 alkyl (preferably hydrogen or methyl), -R 2 -R β , -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a succadyl group, -R α - is C1-C 12 In one embodiment, -R is selected from alkylene groups, wherein 1, 2, 3, or 4 carbon atoms of the backbone of the alkylene group can be optionally replaced by a heteroatom or group independently selected from O, S, NH, or NMe. 6 -OR 2 , -N(R 2 )(R 2’ ) or -SR 2 -R 2’ is selected from hydrogen or C1-C4 alkyl (preferably hydrogen or methyl), -R 2 -R β , -R α -OR β or -R α -SR β -R β is a succadyl group, -R α - is C1-C 12 It is an alkylene group, in which 1, 2, 3, or 4 carbon atoms of the backbone of the alkylene group can be optionally replaced with a heteroatom or group independently selected from O, S, NH, or NMe.

[0069] In any of the embodiments of the previous five paragraphs, the saccharidyl group may optionally be replaced with a protecting group, e.g., acetyl, or a natural amino acid, such as valine. The amino acid may be attached to the saccharidyl group, e.g., by forming an ester between the carboxylic acid group of the amino acid and the hydroxyl group of the saccharidyl group.

[0070] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -N(R 2 )(R 2’ ), -SR 2 , -S. (O)R 2 or -S(O)2R 2 and -R2 ’ is selected from hydrogen, C1-C4 alkyl, or -CO2(C1-C4 alkyl), and -R 2 is -C(O)R 4 , -C(O) - OR 4 , - C(O)-N(R 4 )(R 4’ ), -R α- [N(R 5 )3]Y, - R α- [P(R 5 )3]Y, or - R α- [R 7 ]Y, -R4 ’ is selected from hydrogen or C1-C4 alkyl, -R 4 -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, or -R α -[R 7 ]Y. In one embodiment, -R 6 -OR 2 , -N(R 2 )(R 2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 -R2’ is selected from hydrogen, C1-C4 alkyl, or —CO2(C1-C4 alkyl), and —R 2 is -C(O)R 4 , -C(O)-OR 4 , -C(O)-N(R 4 )(R 4’ ), -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, or -R α -[R 7 ]Y is selected from -R 4’ is selected from hydrogen or C1-C4 alkyl, -R 4 -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, or -R α -[R 7 ]Y, each of which is selected from -R 5 is independently selected from C1-C4 alkyl or phenyl, where phenyl is optionally substituted with one, two, or three C1-C4 alkyl or C1-C4 alkoxy groups; -R 7 is —[NC5H5] optionally substituted with one, two, or three C1-C4 alkyl or C1-C4 alkoxy groups, and —R α- - is C1-C 12 In one embodiment, -R is selected from alkylene groups, wherein one, two, three, or four carbon atoms of the backbone of the alkylene group may be optionally replaced by a heteroatom or group independently selected from O, S, NH, or NMe, and Y is a counterion (preferably a halide). 6 -OR 2 or -N(R 2 )(R 2’ ) and -R 2’ is selected from hydrogen, C1-C4 alkyl, or —CO2(C1-C4 alkyl), and —R 2 is -C(O)R 4 , -C(O)-OR 4 , -C(O)-N(R 4 )(R 4’), -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, or -R α -[R 7 ]Y is selected from -R 4’ is selected from hydrogen or C1-C4 alkyl, -R 4 -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, or -R α -[R 7 ]Y, each of which is selected from -R 5 is independently selected from C1-C4 alkyl or phenyl, wherein phenyl is optionally substituted with one, two, or three C1-C4 alkyl or C1-C4 alkoxy groups; -R 7 is —[NC5H5] optionally substituted with one, two, or three C1-C4 alkyl or C1-C4 alkoxy groups, and —R α - is C1-C 12 is selected from an alkylene group, wherein one, two, three, or four carbon atoms of the backbone of the alkylene group may optionally be replaced by a heteroatom or group independently selected from O, S, NH, or NMe, and Y is a counterion (preferably a halide).

[0071] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2 is selected from hydrogen, C1-C4 alkyl, —CO(C1-C4 alkyl), or —CO2(C1-C4 alkyl). In one embodiment, —R 6 -OR 2 or -N(R 2 )2, and -R 2is selected from hydrogen, C1-C4 alkyl, —CO(C1-C4 alkyl) or —CO2(C1-C4 alkyl).

[0072] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -N(R 2 )(R 2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2’ is selected from hydrogen or C1-C4 alkyl, -R 2 -R 4 , -C(O)R 4 , -C(O)-OR 4 or -C(O)-N(R 4 )(R 4’ ) and -R 4’ is selected from hydrogen or C1-C4 alkyl, -R 4 is C1-C 12 In one embodiment, -R is selected from alkyl groups, which may be optionally substituted with one, two, three, or four halo groups, and one, two, three, or four carbon atoms of the backbone of the alkyl group may be optionally replaced by a heteroatom or group independently selected from O, S, NH, or NMe. 6 -OR 2 or -N(R 2 )(R 2’ ) and -R 2’ is selected from hydrogen, or C1-C4 alkyl, -R 2 -R 4 , -C(O)R 4 , -C(O)-OR 4 or -C(O)-N(R 4 )(R 4’ ) and -R 4’ is selected from hydrogen, or C1-C4 alkyl, -R 4 is C1-C 12alkyl groups, which may be optionally substituted with one, two, three, or four halo groups, and one, two, three, or four backbone carbon atoms of the alkyl group may optionally be replaced by a heteroatom or group independently selected from O, S, NH, or NMe.

[0073] In one embodiment of the first or second aspect of the invention, -R 9 is hydrogen or methyl. In one embodiment, -R 9 is methyl. In a preferred embodiment, -R 9 is hydrogen.

[0074] In one embodiment of the first or second aspect of the invention, -R 6 and -R 9 together form an oxo (=O) group.

[0075] In one embodiment of the first or second aspect of the invention, each -R α -C1-C independently 12 Alkenyl group, -(CH2CH2O) m - group, -(CH2CH2S) m - group, -(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m -CHCH- groups, all optionally substituted, and m is 1, 2, 3, or 4. In one embodiment, each -R α -C1-C independently 12 Alkylene group, -(CH2CH2O) m - group or -(CH2CH2S) m - groups, all optionally substituted, and m is 1, 2, 3, or 4. In one embodiment, each -R α -C1-C independently 12 Alkylene group or -(CH2CH2O) m - groups, both of which are optionally substituted, and m is 1, 2, 3, or 4. In one embodiment, each -R α - is independently optionally substituted -(CH2CH2O) m - group, and m is 1, 2, 3 or 4.

[0076] In one embodiment of the first or second aspect of the invention, each -R α - is independently a C1-C8 alkylene group, or a C1-C6 alkylene group, or a C2-C4 alkylene group, all optionally substituted.

[0077] In one embodiment of the first or second aspect of the invention, each -R α - is independently unsubstituted or substituted with one or more substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. In one embodiment, each -R α - is independently unsubstituted or substituted with one or two substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. In one embodiment, each -R α - is unsubstituted.

[0078] In one embodiment of the first and second aspects of the invention, each -R β are independently saturated or unsaturated hydrocarbyl groups which may be linear or branched or which may be or include cyclic groups, which may be optionally substituted, and which may optionally include one or more heteroatoms N, O or S in its carbon skeleton.

[0079] In one embodiment of the first or second aspect of the invention, at least one -R β is independently a C1-C6 alkyl group, or a C1-C4 alkyl group, or a methyl group, all of which are optionally substituted. β are independently a C1-C6 alkyl group, or a C1-C4 alkyl group, or a methyl group, all optionally substituted.

[0080] In one embodiment of the first or second aspect of the invention, at least one -R βis independently a saccharidyl group. In one embodiment, each -R β are independently saccharidyl groups.

[0081] In one embodiment of the first or second aspect of the invention, each -R β is independently unsubstituted or substituted with one or more substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. β is independently unsubstituted or substituted with one or two substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. In one embodiment, each -R β is non-substituted.

[0082] In one embodiment of the first and second aspects of the invention, each -R 3 independently, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[NC5H5]Y. In one embodiment, each -R 3 independently, -R α -OR β , -R α -SR β , -R α -S(O)Rβ or -R α -S(O)2R β In one embodiment, each -R 3 independently, -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group. In one embodiment, each -R 3 independently, -R α -OR β or -R α -SR β In one embodiment, each -R 3 independently, -R α -OR β or -R α -SR β -R β is a saccharidyl group.

[0083] In one embodiment of the first and second aspects of the invention, each -R 4 independently, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5)3]Y or -R α -[NC5H5]Y. In one embodiment, each -R 4 independently, -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β In one embodiment, each -R 4 independently -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group. In one embodiment, each -R 4 independently -R α -OR β or -R α -SR β In one embodiment, each -R 4 independently, -R α -OR β or -R α -SR β -R β is a saccharidyl group.

[0084] In one embodiment of the first or second aspect of the invention, -R 2 , -R 3 or -R 4 At least one of the following is independently -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group. In one embodiment, -R 2 , -R 3 or -R 4At least one of the following is independently -R α -OR β or -R α -SR β -R β is a saccharidyl group.

[0085] For purposes of the present invention, a "saccharidyl group" is any group comprising at least one monosaccharide subunit, each of which may be optionally substituted and / or modified. Typically, a saccharidyl group is composed of one or more monosaccharide subunits, each of which may be optionally substituted and / or modified.

[0086] Usually, the carbon atom of a single monosaccharide subunit of each saccharidyl group is directly attached to the remainder of the compound, most typically via a single bond.

[0087] For purposes of this specification, when a first atom or group is said to be "directly bonded" to a second atom or group, it is to be understood that the first atom or group is covalently bonded to the second atom or group and that there are no intervening atom(s) or group(s). For example, in the group -(C=O)N(CH), the carbon atom of each methyl group is directly bonded to the nitrogen atom and the carbon atom of the carbonyl group is directly bonded to the nitrogen atom, but the carbon atom of the carbonyl group is not directly bonded to the carbon atoms of either methyl group.

[0088] Typically, each saccharidyl group is derived from the corresponding saccharide by replacing a hydroxyl group of the saccharide with a group defined by the remainder of the compound.

[0089] The single bond between the anomeric carbon of a monosaccharide subunit and a substituent is called a glycosidic bond. A glycosidic group is attached to the anomeric carbon of a monosaccharide subunit by a glycosidic bond. The bond between the saccharidyl group and the rest of the compound can be a glycosidic or non-glycosidic bond. Typically, the bond between the saccharidyl group and the rest of the compound is a glycosidic bond, and the saccharidyl group is a glycosyl group. When the bond between the saccharidyl group and the rest of the compound is a glycosidic bond, the glycosidic bond can be in the α or β configuration. Typically, such glycosidic bond is in the β configuration.

[0090] For purposes of the present invention, when a saccharidyl group "contains x monosaccharide subunits," this means that the saccharidyl group has x monosaccharide subunits and no more. In contrast, when a saccharidyl group "comprises x monosaccharide subunits," this means that the saccharidyl group has x or more monosaccharide subunits.

[0091] Each saccharidyl group can be independently selected from a monosaccharide, disaccharide, oligosaccharide, or polysaccharide group. As will be understood, a monosaccharide group contains a single monosaccharide subunit. Similarly, a disaccharide group contains two monosaccharide subunits. As used herein, an "oligosaccharide group" contains two to nine monosaccharide subunits. Examples of oligosaccharide groups include trisaccharide, tetrasaccharide, pentasaccharide, hexasaccharide, heptasaccharide, octasaccharide, and nonasaccharide groups. As used herein, a "polysaccharide group" contains 10 or more monosaccharide subunits (such as 10 to 50, or 10 to 30, or 10 to 20, or 10 to 15 monosaccharide subunits).

[0092] Each monosaccharide subunit within a disaccharide, oligosaccharide, or polysaccharide group can be the same or different. Each monosaccharide subunit within a disaccharide, oligosaccharide, or polysaccharide group can be linked to another monosaccharide subunit within the group via a glycosidic or non-glycosidic bond. Typically, each monosaccharide subunit within a disaccharide, oligosaccharide, or polysaccharide group is linked to another monosaccharide subunit within the group via a glycosidic bond, which can be in the α or β configuration.

[0093] Each oligosaccharidyl or polysaccharidyl group may be a linear, branched or macrocyclic oligosaccharidyl or polysaccharidyl group. Typically, each oligosaccharidyl or polysaccharidyl group is a linear or branched oligosaccharidyl or polysaccharidyl group.

[0094] In one embodiment, at least one -R β is a monosaccharide or disaccharide group.

[0095] In a further embodiment, at least one -R β is a monosaccharidyl group. For example, at least one -R β can be a glycosyl group containing a single monosaccharide subunit, where the monosaccharide subunit can be optionally substituted and / or modified. Typically, at least one -R β is a glycosyl group containing a single monosaccharide subunit, where the monosaccharide subunit can be optionally substituted. More typically, at least one -R β is a glycosyl group containing a single monosaccharide subunit, where the monosaccharide subunit is unsubstituted.

[0096] In one embodiment, at least one -R β is an aldosyl group, where the aldosyl group can be optionally substituted and / or modified. For example, at least one -R βmay be selected from a glycerosyl, aldotetrosyl (such as erythrosyl or threosyl), aldopentosyl (such as ribosyl, arabinosyl, xylosyl or lyxosyl) or aldohexosyl (such as allosyl, altrosyl, glucosyl, mannosyl, gulosyl, idosyl, galactosyl or talosyl) group, any of which may be optionally substituted and / or modified.

[0097] In another embodiment, at least one -R β is a ketosyl group, where the ketosyl group can be optionally substituted and / or modified. For example, at least one -R β may be selected from an erythrulosyl, ketopentosyl (such as ribulosyl or xylulosyl) or ketohexosyl (such as psicosyl, fructosyl, sorbosyl or tagatosyl) group, any of which may be optionally substituted and / or modified.

[0098] Each monosaccharide subunit can exist in a closed (cyclic) or open (acyclic) form. Typically, at least one -R β Each monosaccharide subunit in β can be a glycosyl group containing a single closed-ring monosaccharide subunit, where the monosaccharide subunit can be optionally substituted and / or modified. Typically, in such a scenario, at least one -R β is a pyranosyl or furanosyl group, such as an aldopyranosyl, aldofuranosyl, ketopyranosyl, or ketofuranosyl group, any of which may be optionally substituted and / or modified. More typically, at least one -R β is a pyranosyl group, such as an aldopyranosyl or ketopyranosyl group, either of which can be optionally substituted and / or modified.

[0099] In one embodiment, at least one -R βis selected from a ribopyranosyl, arabinopyranosyl, xylopyranosyl, lyxopyranosyl, allopyranosyl, altropyranosyl, glucopyranosyl, mannopyranosyl, gulopyranosyl, idopyranosyl, galactopyranosyl or talopyranosyl group, any of which may be optionally substituted and / or modified.

[0100] In a further embodiment, at least one -R β is a glucosyl group, such as a glucopyranosyl group, where the glucosyl or glucopyranosyl group may be optionally substituted and / or modified. Typically, at least one -R β is a glucosyl group, where the glucosyl group can be optionally substituted. More typically, at least one -R β is an unsubstituted glucosyl group.

[0101] Each monosaccharide subunit can be in the D-configuration or the L-configuration. Typically, each monosaccharide subunit is present in the configuration most commonly found in nature.

[0102] In one embodiment, at least one -R β is a D-glucosyl group, such as a D-glucopyranosyl group, where the D-glucosyl or D-glucopyranosyl group may be optionally substituted and / or modified. Typically, at least one -R β is a D-glucosyl group, where the D-glucosyl group can be optionally substituted. More typically, at least one -R β is an unsubstituted D-glucosyl group.

[0103] For purposes of the present invention, in the substituted monosaccharide group or monosaccharide subunit: (a) One or more hydroxyl groups of a monosaccharide group or monosaccharide subunit may each independently be -H, -F, -Cl, -Br, -I, -CF3, -CCl3, -CBr3, -CI3, -SH, -NH2, -N3, -NH=NH2, -CN, -NO2, -COOH, -R b , -OR b、-S-R b 、-R a -O-R b 、-R a -S-R b 、-SO-R b 、-SO2-R b 、-SO2-OR b 、-O-SO-R b 、-O-SO2-R b 、-O-SO2-OR b 、-NR b -SO-R b 、-NR b -SO2-R b 、-NR b -SO2-OR b 、-R a -SO-R b 、-R a -SO2-R b 、-R a -SO2-OR b 、-SO-N(R b )2、-SO2-N(R b )2、-O-SO-N(R b )2、-O-SO2-N(R b )2、-NR b -SO-N(R b )2、-NR b -SO2-N(R b )2、-R a -SO-N(R b )2、-R a -SO2-N(R b )2、-N(R b )2、-N(R b )3 + 、-R a -N(R b )2、-R a -N(R b )3 + 、-P(R b )2、-PO(R b )2、-OP(R b )2、-OPO(R b )2、-R a -P(R b )2、-R a -PO(R b )2、-OSi(R b )3、-Ra -Si(R b )3, -CO-R b , -CO-OR b , -CO-N(R b )2, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , -NR b -CO-N(R b )2, -R a -CO-R b , -R a -CO-OR b , or -R a -CO-N(R b )2; and / or (b) One, two, or three hydrogen atoms directly attached to a carbon atom of a monosaccharide group or monosaccharide subunit are each independently -F, -Cl, -Br, -I, -CF3, -CCl3, -CBr3, -CI3, -OH, -SH, -NH2, -N3, -NH=NH2, -CN, -NO2, -COOH, -R b , -OR b , -SR b , -R a -OR b , -R a -SR b , -SO-R b , -SO2-R b , -SO2-OR b , -O-SO-R b , -O-SO2-R b , -O-SO2-OR b , -NR b -SO-R b , -NR b -SO2-R b , -NR b -SO2-OR b , -R a -SO-R b , -R a -SO2-R b , -R a -SO2-ORb , -SO-N(R b )2, -SO2-N(R b )2, -O-SO-N(R b )2, -O-SO2-N(R b )2, -NR b -SO-N(R b )2, -NR b -SO2-N(R b )2, -R a -SO-N(R b )2, -R a -SO2-N(R b )2, -N(R b )2, -N(R b )3 + , -R a -N(R b )2, -R a -N(R b )3 + , -P(R b )2, -PO(R b )2, -OP(R b )2, -OPO(R b )2, -R a -P(R b )2, -R a -PO(R b )2, -OSi(R b )3, -R a -Si(R b )3, -CO-R b , -CO-OR b , -CO-N(R b )2, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , -NR b -CO-N(R b )2, -R a -CO-R b , -R a -CO-OR b , or -R a -CO-N(R b )2; and / or (c) One or more hydroxyl groups of a monosaccharide group or monosaccharide subunit, together with the hydrogen bonded to the same carbon atom as the hydroxyl group, may each independently be =O, =S, or =NR. b , or =N(R b )2 + and / or (d) Any two hydroxyl groups of a monosaccharide group or monosaccharide subunit together form -OR c -, -SR c -, -SO-R c -, -SO2-R c -, or -NR b -R c - is replaced by; where: Each-R a - is independently a substituted or unsubstituted alkylene, alkenylene, or alkynylene group optionally containing one or more heteroatoms each independently selected from O, N, and S in its carbon skeleton and preferably containing 1 to 10 carbon atoms; Each-R b - is independently hydrogen or a substituted or unsubstituted straight-chain, branched, or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group optionally containing one or more heteroatoms each independently selected from O, N, and S in its carbon skeleton and preferably containing 1 to 15 carbon atoms; Each-R c - is independently a chemical bond, or a substituted or unsubstituted alkylene, alkenylene, or alkynylene group, optionally containing one or more heteroatoms each independently selected from O, N, and S in its carbon skeleton, and preferably containing 1 to 10 carbon atoms; However, the monosaccharide group or monosaccharide subunit has at least one, preferably at least two or at least three, -OH, -OR b , -O-SO-R b , -O-SO2-R b, -O-SO2-OR b , -O-SO-N(R b )2, -O-SO2-N(R b )2, -OP(R b )2, -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, or -OR c - is subject to inclusion.

[0104] Typically, in substituted monosaccharide groups or monosaccharide subunits, (a) One or more hydroxyl groups of a monosaccharide group or monosaccharide subunit are each independently -H, -F, -CF3, -SH, -NH2, -N3, -CN, -NO2, -COOH, -R b , -OR b , -SR b , -N(R b )2, -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , or -NR b -CO-N(R b )2; and / or (b) One or two of the hydrogen atoms directly attached to a carbon atom of a monosaccharide group or a monosaccharide subunit are each independently -F, -CF3, -OH, -SH, -NH2, -N3, -CN, -NO2, -COOH, -R b , -OR b , -SR b , -N(R b )2, -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b, -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , or -NR b -CO-N(R b )2; and / or (c) one hydroxyl group of the monosaccharide group or monosaccharide subunit is replaced with =0, with the hydrogen bonded to the same carbon atom as the hydroxyl group; and / or (d) Any two hydroxyl groups of a monosaccharide group or monosaccharide subunit together form -OR c -, -NR b -R c - is replaced by; where: Each-R b - is independently hydrogen or a substituted or unsubstituted straight-chain, branched, or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group containing 1 to 8 carbon atoms and optionally containing in its carbon skeleton one, two, or three heteroatoms each independently selected from O and N; Each-R c - is independently a substituted or unsubstituted alkylene, alkenylene, or alkynylene group optionally containing in its carbon skeleton one, two, or three heteroatoms each independently selected from O and N, and containing one to eight carbon atoms; However, the monosaccharide group or monosaccharide subunit has at least two, preferably at least three, -OH, -OR b , -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, or -OR c - is subject to inclusion.

[0105] In one embodiment, -R β is a saccharidyl group, and one or more hydroxyl groups of the saccharidyl group are each independently -O-CO-R b are substituted with -R b is independently C1-C4 alkyl, preferably methyl. In one embodiment, -R β is a saccharidyl group, and all hydroxyl groups of the saccharidyl group are each independently -O-CO-R b are substituted with -R b are independently C1-C4 alkyl, preferably methyl.

[0106] In the modified monosaccharide group or monosaccharide subunit, (a) the ring of the modified monosaccharide group or monosaccharide subunit, or the ring that forms the closed ring of the modified monosaccharide group or monosaccharide subunit, is partially unsaturated; and / or (b) The ring oxygen of the modified monosaccharide group or monosaccharide subunit, or the ring oxygen of the closed ring form of the modified monosaccharide group or monosaccharide subunit, is -S- or -NR d -, where each -R d - is independently hydrogen or a substituted or unsubstituted straight-chain, branched, or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group optionally containing one or more heteroatoms each independently selected from O, N, and S in its carbon skeleton and preferably containing 1 to 15 carbon atoms.

[0107] Alternatively, if the modified monosaccharide subunit forms part of a disaccharide, oligosaccharide, or polysaccharide group, -R dmay be a further monosaccharide subunit or subunits forming part of a disaccharide, oligosaccharide or polysaccharide group, and such further monosaccharide subunits or subunits may optionally be substituted and / or modified.

[0108] Typically, in modified monosaccharide groups or monosaccharide subunits, (a) the ring of the modified monosaccharide group or monosaccharide subunit, or what would become the ring in the closed form of the modified monosaccharide group or monosaccharide subunit, contains a single C=C; and / or (b) The ring oxygen of a modified monosaccharide group or monosaccharide subunit, or the ring oxygen of the closed ring form of a modified monosaccharide group or monosaccharide subunit, is -NR d -, where each -R d - is independently hydrogen or a substituted or unsubstituted straight-chain, branched, or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group containing from 1 to 8 carbon atoms and optionally containing in its carbon skeleton one, two, or three heteroatoms each independently selected from O and N.

[0109] Typical examples of substituted and / or modified monosaccharide subunits include those corresponding to the following: (i) deoxysugars such as deoxyribose, fucose, fuculose and rhamnose, in which the monosaccharidyl group or the hydroxyl group of the monosaccharide subunit is replaced by -H; (ii) amino sugars, such as glucosamine and galactosamine, in which the monosaccharide group or the hydroxyl group of the monosaccharide subunit is substituted with -NH, most typically at the 2-position; and (iii) Sugar acids containing a -COOH group, such as aldonic acids (e.g., gluconic acid), urosonic acid, uronic acids (e.g., glucuronic acid), and aldaric acids (e.g., gulic acid or galactaric acid).

[0110] In one embodiment of the first or second aspect of the invention, at least one -R β teeth, [ka] is a saccharidyl group selected from:

[0111] Preferably, in the compound or complex according to the first or second aspect of the invention, at least one -R β teeth, [ka] is.

[0112] In one embodiment of the first or second aspect of the invention, -R 2 , -R 3 or -R 4 At least one of the following is independently -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β (preferably -R α -OR β or -R α -SR β -R β teeth, [ka] Selected from TIFF2024544615000015.tif66159.

[0113] In one embodiment of the first or second aspect of the invention, R2 , -R 3 or -R 4 At least one of the following is independently -R α -[N(R 5 )3]Y, -R α -[P(R 5)3]Y, -R α -[R 7 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )], or -R α -[R 7’ In one embodiment, -R 2 , -R 3 or -R 4 independently -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, or -R α -[R 7 ]Y. In one embodiment, -R 2 , -R 3 or -R 4 At least one of [ka] is selected from.

[0114] In the first or second aspect of the present invention, each -R 5 may be the same or different. In a preferred embodiment, each -R 5 is the same.

[0115] In one embodiment of the first or second aspect of the invention, each -R 5 is independently unsubstituted or substituted with one or two substituents. In one embodiment, each -R 5 is non-substituted.

[0116] In one embodiment of the first or second aspect of the invention, -R 7 is unsubstituted or substituted with one or two substituents. In one embodiment, -R 7 is non-substituted.

[0117] In one embodiment, -R 7is not substituted with a halo group at the 4-position of the pyridine ring. 7 is unsubstituted with a halo group at the 4-position of the pyridine ring. 7 is non-substituted.

[0118] In one embodiment of the first or second aspect of the invention, -R 1 and -R 6 each independently contain 1 to 100 atoms other than hydrogen, preferably 1 to 80 atoms other than hydrogen, preferably 1 to 60 atoms other than hydrogen, preferably 1 to 50 atoms other than hydrogen, and 1 to 45 atoms other than hydrogen.

[0119] In certain preferred embodiments, the first or second aspect of the invention relates to a compound of formula (I) or a complex of formula (II) [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, -R 1 teeth, (a)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, and R 3 , are each independently -R β and -R β is a C1-C4 alkyl group, and more preferably, R 1 is -C(O)-OR 3 and R 3 -R β and -R β is a C1-C4 alkyl group; or (b)-C(O)-OR 3 , C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ), R 3 -R α -OR β or -R α -SR β -Rβ is a saccharidyl group, and R 3’ is H or C1-C4 alkyl; -R 6 -OR 2 or -SR 2 -R 2 -R α -OR β or -R α -SR β -R β is a succadyl group; -R α - are each independently C1 to C 12 alkylene groups, which can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more carbon atoms in the backbone of the alkylene group can be optionally replaced with one or more heteroatoms O or S; -R 9 is hydrogen or methyl (preferably -R 9 is hydrogen); M 2+ is a metal cation.

[0120] In certain preferred embodiments, the first or second aspect of the invention relates to a compound of formula (I) or a complex of formula (II) [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, selected from R 3 are each independently -R β and -R β is a C1-C4 alkyl group, and more preferably, R 1 is -C(O)-OR 3 and R 3 -R βand -R β is a C1-C4 alkyl group, -R 6 -OR 2 or -SR 2 -R 2 -R α -OR β or -R α -SR β -R β is a succadiyl group, -R α - C1-C 12 an alkylene group, which can be optionally substituted with one or more C-C alkyl, C-C haloalkyl, or halo groups, and one or more atoms of the backbone of the alkylene group can be optionally substituted with one or more heteroatoms O or S; -R 9 is hydrogen or methyl (preferably -R 9 is hydrogen), and M 2+ is a metal cation.

[0121] In certain preferred embodiments, the first or second aspect of the invention relates to a compound of formula (I) or a complex of formula (II) [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) and R 3 -R α -OR β or -R α -SR β Selected from -R β is a succadyl group, and R 3’ is H or C1-C4 alkyl; -R 6 -OR2 or -SR 2 -R 2 -R α -OR β or -R α -SR β and -R β is a succadiyl group, -R α - is C1-C 12 an alkylene group, which can be optionally substituted with one or more C-C alkyl, C-C haloalkyl, or halo groups, and one or more atoms of the backbone of the alkylene group can be optionally substituted with one or more heteroatoms O or S; -R 9 is hydrogen or methyl (preferably -R 9 is hydrogen); M 2+ is a metal cation.

[0122] In certain preferred embodiments, the first or second aspect of the invention relates to a compound of formula (I) or a complex of formula (II) [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CHN(R 2 )(R 2’ ), -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) and preferably -R 1 is -C(O)-OR3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ), more preferably R 1 is -C(O)-N(R 3 )(R 3’ ) is]; -R 2 are each independently -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )(R 4’ ), -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )(R 4’ ), -R α -H, -R β , -R α -R β , -R α -OH, -R α OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r-(CH2) s -[R 7 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 7’ ] is selected from -R 3 and -R 4 are independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 7 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 7’ ] is selected from -R 2 , -R 3 and -R 4 At least one of the following is -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 7 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 7’ ] is selected from -R 2’ , -R 3’ and -R 4 are each independently selected from hydrogen or C1-C6 alkyl, [preferably -R 2’ , -R 3’ and -R 4’ are each independently hydrogen or C1-C3 alkyl, more preferably -R 2’ , -R 3’ and -R 4’are each independently selected from hydrogen or methyl; -R α - are each independently C1-C 42 alkylene groups, which optionally have one or more (e.g., 1, 2, 3, 4, or 5) C-C alkyl, C-C haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) backbone carbon atoms of the alkylene group optionally replaced by a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or which is or includes a cyclic group which may be optionally substituted and which may optionally include one or more (e.g. 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n and selected from —CH3, phenyl, or C5-C6 heteroaryl, wherein phenyl or C5-C6 heteroaryl optionally comprises one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, each selected from -CO2 ―and the phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 6 -OR 2 , -N(R 2 )2, -SR 2 , -S(O)R 2 , -S(O)2R 2 , or -X, [preferably -R 6 -OR 2 , -SR 2 , -S(O)R 2 , -S(O)2R 2 , or -X]; -R 7 optionally one or more (e.g., 1, 2, 3, 4, or 5) -C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n [NC5H5] substituted with -CH3 groups, -R 7’ is -CO2 ― and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO) n -H or -O-(CH2CH2O) n [NC5H5] further substituted with -CH3 groups, -R 9 is hydrogen or methyl [preferably -R 9 is hydrogen], Q is O, S, NH 3 or NMe [preferably Q is O]; X is a halo group; Y is a counter anion, Z is a counter cation; M 2+ is a metal cation, n is 1, 2, 3, 4, 5, or 6; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6, and s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12.

[0123] In certain preferred embodiments, the first or second aspect of the invention relates to a compound of formula (I) or a complex of formula (II) [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably -R 1 is -C(O)-N(R 3 )(R 3’ )], -R 2 -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )(R 4’ ), -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )(R 4’ ), -R α-H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 7 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 7’ ] is selected from -R 3 and -R 4 are independently -H and -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -Rα -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 7 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 7’ ] is selected from -R 2 , -R 3 and -R 4 At least one of the -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R7 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 7’ ] is selected from -R 3’ and -R 4’ are each independently hydrogen or C1-C3 alkyl [preferably -R 3’ and -R 4’ are each independently selected from hydrogen or methyl; -R α - are independently C1-C 42 alkylene groups, which optionally have one or more (e.g., 1, 2, 3, 4, or 5) C-C alkyl, C-C haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) backbone carbon atoms of the alkylene group optionally replaced by a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which is or includes a linear, branched or cyclic group which may be optionally substituted and which may optionally include one or more (e.g. 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5 are each independently selected from C1-C3 alkyl or phenyl, and phenyl is optionally selected from 1-C6 alkyl, —O(C1-C6 alkyl), —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n-H or -O-(CH2CH2O) n and may be substituted with 1, 2, 3, 4, or 5 substituents independently selected from —CH3; -R 5’ is -CO2 ― C replaced by 1-C3 Alkyl or -CO2 ― phenyl optionally substituted with C1-C6 alkyl, —O(C1-C6 alkyl), —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n may be further substituted with 1, 2, 3, or 4 substituents independently selected from -CH3; -R 6 -OR 2 , -N(R 2 )2, -SR 2 , -S(O)R 2 , -S(O)2R 2 , or -X, [preferably -R 6 -OR 2 , -SR 2 , -S(O)R 2 , -S(O)2R 2 , or -X]; -R 7 is optionally C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] substituted with 1, 2, 3, 4, or 5 substituents independently selected from -CH3; -R 7’ is -CO2 ― -[NC5H5] optionally substituted with C1-C6alkyl, -O(C1-C6alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -CH3, -R9 is hydrogen or methyl [preferably -R 9 is hydrogen], Q is O, S, NH 3 or NMe [preferably Q is O]; X is a halo group; Y is a counter anion, Z is a counter cation, M 2+ is a metal cation, n is 1, 2, 3, 4, 5, or 6; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6, and s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12.

[0124] In these two preferred embodiments of the previous paragraph, each -R 5 may be the same or different, and preferably, each -R 5 are the same.

[0125] In another preferred form of one embodiment of the first or second aspect of the invention, the compound is a compound of formula (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (IM), (IN) or (IO): [ka] TIFF2024544615000023.tif178159TIFF2024544615000024.tif237159 or a metal cation complex thereof, or a pharmaceutically acceptable salt thereof, During the ceremony, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R3 )(R 3’ ) are selected from; -R 2 -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )(R 4’ ), -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )(R 4’ ), -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, or -R α -X is selected from -R 3 and -R 4 are independently -H and -R α -H, -R β , -R α -R β ,-R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β)2, or -R α -X is selected from -R 3’ and -R 4’ are each independently hydrogen or C1-C3 alkyl [preferably -R 3’ and -R 4’ are each independently selected from hydrogen or methyl; -R 6 -OR 2 , -N(R 2 )2, -SR 2 , -S(O)R 2 , -S(O)2R 2 , or -X [preferably -R 6 -OR 2 , -SR 2 , -S(O)R 2 , -S(O)2R 2 , or -X is selected from -R 9 is hydrogen or methyl [preferably -R 9 is hydrogen], -R α - are each independently C1-C 12 alkylene groups, which optionally have one or more (e.g., 1, 2, 3, 4, or 5) C-C alkyl, C-C haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) backbone carbon atoms of the alkylene group optionally replaced by a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or which is or includes a cyclic group which may be optionally substituted and which may optionally include one or more (e.g. 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon skeleton; -R δ is selected from C1-C3 alkyl; -R εis C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -CH3, X is a halo group; Y is a counter anion, Z is a counter cation; n is 1, 2, 3, or 4; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; t is 0, 1, 2, 3, 4, or 5, and u is 0, 1, 2, 3 and 4.

[0126] The compounds of formula (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (IM), (IN), (IO) and their complexes and salts according to the first and second aspects of the present invention comprise a compound selected from the group consisting of the moiety -[(CH2) p O] r -(CH2) s - includes During the ceremony, p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6, and s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12.

[0127] In one embodiment, p is 2, 3, or 4, r is 1, and s is 2, 3, or 4. In a preferred embodiment, 3-[(CH) p O] r -(CH2) s - is -(CH2)3-O-(CH2)3-, where p is 3, r is 1 and s is 3.

[0128] In another embodiment, p is 2 or 3, r is 2 or 3, and s is 2 or 3. In a preferred embodiment, -[(CH) p O] r -(CH2) s - is -(CH2CH2O)2-(CH2)2-, where p is 2, r is 2, and s is 2.

[0129] In yet another embodiment, -[(CH) p O] r -(CH2) s -Ha-(CH2) 1-12 - r is 0, and s is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12.

[0130] In another preferred embodiment, the first and second aspects of the present invention relate to a compound of formula (I') or a complex of formula (II'), [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, -U- is -O-, -N(R u )- or -S-, -V- is -CH2-, -O-, -N(R v )- or -S-, -W-, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 7 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 7’ ] and -R 10 is —OH or —O—(C1-C4 alkyl), -R α - is C1-C12 alkylene groups, which can be optionally substituted with one or more (e.g., one, two, three, or four) C-C alkyl, C-C haloalkyl, or halo groups; and one or more (e.g., one, two, three, or four) carbon atoms in the backbone of the alkylene group can be optionally replaced by a heteroatom or group independently selected from O, S, NH, or NMe; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl, or C5-C6 heteroaryl, wherein phenyl or C5-C6 heteroaryl optionally includes one or more of C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with a -CH3 group, -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, each of which is CO2 ― and the phenyl or C5-C6 heteroaryl is optionally substituted with one or more of C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups, -R 7 is optionally one or more of C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O)n -[NC5H5] substituted with -CH3 groups, -R 7’ is -CO2 ‐ and optionally substituted with one or more of C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; -R u is hydrogen or C1-C4 alkyl, -R v is hydrogen or C1-C4 alkyl, n is 1, 2, 3, 4, 5, or 6; Y is a counter anion, Z is a counter cation, and M 2+ is a metal cation.

[0131] In another preferred embodiment, the first and second aspects of the present invention relate to a compound of formula (I') or a complex of formula (II'), [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, -U- is -O-, -N(R u )- or -S-, -V- is -CH2-, -O-, -N(R v )- or -S-, -W-, -R α- [N(R 5 )3]Y, -R α- [P(R 5 )3]Y, or -R α- [R 7 ]Y, -R 10 is —OH or —O—(C1-C4 alkyl), -R α - is C1-C12 alkylene groups (preferably C1-C9 alkylene groups, preferably C2-C6 alkylene groups), in which one or more (e.g., 1, 2, 3, or 4, preferably 1 or 2) carbon atoms in the backbone of the alkylene group can be optionally replaced by a heteroatom or group independently selected from O, S, NH, or NMe (preferably, O, NH, or NMe, preferably O); -R 5 are independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl, or C5-C6 heteroaryl, wherein phenyl or C5-C6 heteroaryl can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), or -O(C1-C4 haloalkyl); -R 7 is —[NC5H5] optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, O(C1-C4 alkyl) or —O(C1-C4 haloalkyl); -R u is hydrogen or C1-C4 alkyl, -R v is hydrogen or C1-C4 alkyl, n is 1, 2, 3, 4, 5, or 6; Y is a counter anion, and M 2+ is a metal cation.

[0132] Preferably, in the compound or complex according to the first or second aspect of the invention, the compound or complex comprises: [ka] Y is a counteranion, and q is 0, 1, 2, 3, or 4 (preferably q is 1); or a metal cation complex thereof, or a pharmaceutically acceptable salt thereof.

[0133] Preferably, in the compound or complex according to the first or second aspect of the invention, the compound or complex comprises: [ka] TIFF2024544615000029.tif219159TIFF2024544615000030.tif217159TIFF2024544615000031.tif203159TIFF2024544615000032.tif209159TIFF2024544615000033.tif208159TIFF2024544615000034.tif195159TIFF2024544615000035.tif206159TIFF2024544615000036.tif204159 or a metal cation complex thereof, or a pharmaceutically acceptable salt thereof.

[0134] In one embodiment, the compound or complex according to the first or second aspect of the present invention is in the form of a pharmaceutically acceptable salt. In one embodiment, the compound or complex is in the form of an inorganic salt, such as a lithium, sodium, potassium, magnesium, calcium, or ammonium salt. In one embodiment, the compound or complex is in the form of a sodium or potassium salt. In one embodiment, the compound is in the form of a sodium salt. In another embodiment, the compound or complex is in the form of an organic salt, such as an amine salt (e.g., a choline or meglumine salt) or an amino acid salt (e.g., an arginine salt).

[0135] The compound or complex according to the first or second aspect of the invention has at least two chiral centres. The compound or complex of the first or second aspect of the invention is preferably substantially enantiomerically pure, meaning that the compound or complex has less than 10%, preferably less than 5%, preferably less than 3%, preferably less than 2%, preferably less than 1%, preferably less than 0.5% by total weight of other stereoisomers as measured by XRPD or SFC.

[0136] Preferably, the compound or complex according to the first or second aspect of the invention has an HPLC purity of greater than 97%, more preferably greater than 98%, more preferably greater than 99%, more preferably greater than 99.5%, more preferably greater than 99.8%, and most preferably greater than 99.9%. As used herein, % HPLC purity is measured by the area normalization method.

[0137] A third aspect of the invention provides a composition comprising a compound or complex according to the first or second aspect of the invention and a pharmaceutically acceptable carrier or diluent.

[0138] In one embodiment, the composition according to the third aspect of the present invention further comprises polyvinylpyrrolidone (PVP). In one embodiment, the composition comprises 0.01 to 10 wt% PVP as a percentage of the total weight of the composition, preferably 0.1 to 5 wt% PVP as a percentage of the total weight of the composition, preferably 0.5 to 5 wt% PVP as a percentage of the total weight of the composition. In one embodiment, the PVP is K30.

[0139] In one embodiment, the composition according to the third aspect of the present invention further comprises dimethyl sulfoxide (DMSO), hi one embodiment, the composition comprises 0.01 to 99 w / w% DMSO as a percentage of the total weight of the composition, preferably 40 to 99 w / w% DMSO as a percentage of the total weight of the composition, preferably 65 to 99 w / w% DMSO as a percentage of the total weight of the composition.

[0140] In one embodiment, the composition according to the third aspect of the invention further comprises an immune checkpoint inhibitor. In one embodiment, the immune checkpoint inhibitor is an inhibitor of PD-1 (programmed cell death protein 1), PD-L1 (programmed death-ligand 1) or CTLA4 (cytotoxic T-lymphocyte-associated protein 4). In one embodiment, the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab or ipilimumab.

[0141] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for use in photodynamic therapy or cytoluminescent therapy.

[0142] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are useful for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; interstitial pneumonia; Suitable for the treatment of: intermittent claudication; dermatological conditions; acne; psoriasis; diseases characterized by areas of benign or malignant cell hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.

[0143] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the treatment of diseases characterised by areas of benign or malignant cell hyperproliferation or angiogenesis.

[0144] Preferably, the compounds or complexes according to the first or second aspect of the invention and the pharmaceutical compositions according to the third aspect of the invention are suitable for the treatment of benign or malignant tumours.

[0145] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0146] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for use in photodynamic diagnosis.

[0147] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are useful for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; interstitial pneumonia; Suitable for detecting intermittent claudication; dermatological conditions; acne; psoriasis; diseases characterized by areas of benign or malignant cell hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.

[0148] Preferably, the compounds or complexes according to the first or second aspect of the invention and the pharmaceutical compositions according to the third aspect of the invention are suitable for detecting areas affected by benign or malignant cell hyperproliferation or angiogenesis.

[0149] Preferably, the compounds or complexes according to the first or second aspect of the invention and the pharmaceutical compositions according to the third aspect of the invention are suitable for the detection of benign or malignant tumours.

[0150] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the detection of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0151] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for fluorescent or phosphorescent detection of the diseases listed above, preferably fluorescent or phosphorescent detection and quantification of the diseases.

[0152] Preferably, the compound or complex according to the first or second aspect of the invention, and the pharmaceutical composition according to the third aspect of the invention, are adapted for administration simultaneously with or before the administration of radiation or sound, preferably before the administration of radiation.

[0153] When the compounds or complexes according to the first or second aspect of the invention, or the pharmaceutical compositions according to the third aspect of the invention, are for use in photodynamic therapy or cytoluminescence therapy, then they are preferably adapted for administration 5 to 100 hours before irradiation, preferably 6 to 72 hours before irradiation, preferably 24 to 48 hours before irradiation.

[0154] When the compounds or complexes according to the first or second aspect of the invention, or the pharmaceutical compositions according to the third aspect of the invention, are for use in photodynamic diagnosis, then they are preferably suitable for administration 3 to 60 hours before irradiation, preferably 8 to 40 hours before irradiation.

[0155] Preferably, the radiation used in photodynamic therapy, cytoluminescence therapy, or photodynamic diagnosis is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources (e.g., a laser light and an LED light) are used, both of which are suitable for providing radiation in the wavelength range of 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. In another embodiment of the present invention, the radiation can be provided by prostate, anal, vaginal, oral, or nasal devices for insertion into body cavities. In another embodiment of the present invention, the radiation can be provided by mediated photoactivation, for example, by inserting a fiber-optic laser into the lung, liver, lymph nodes, or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.

[0156] The pharmaceutical composition according to the third aspect of the present invention may be in a form suitable for oral, parenteral (including intravenous, subcutaneous, intramuscular, intradermal, intratracheal, intraperitoneal, intratumoral, intraarticular, intraperitoneal, intracranial and epidural), transdermal, respiratory (aerosol), rectal, vaginal or topical (including buccal, mucosal and sublingual) administration. The pharmaceutical composition may also be in a form suitable for administration by enema or by injection into a tumor. Preferably, the pharmaceutical composition is in a form suitable for oral, parenteral (such as intravenous, intraperitoneal and intratumoral) or respiratory tract administration, preferably in a form suitable for oral or parenteral administration, preferably in a form suitable for oral administration.

[0157] In one preferred embodiment, the pharmaceutical composition is in a form suitable for oral administration. Preferably, the pharmaceutical composition is provided in the form of tablets, capsules, hard or soft gelatin capsules, caplets, lozenges, or drops; as a powder or granules; or as an aqueous solution, suspension, or dispersion. More preferably, the pharmaceutical composition is provided in the form of an aqueous solution, suspension, or dispersion for oral administration, or in the form of a lyophilized powder that can be mixed with water before administration. Preferably, the pharmaceutical composition is in a form suitable for providing 0.01 to 10 mg / kg / day, preferably 0.1 to 2 mg / kg / day, preferably about 1 mg / kg / day, of the compound or complex according to the first or second aspect of the present invention.

[0158] In another preferred embodiment, the pharmaceutical composition is in a form suitable for parenteral administration. Preferably, the pharmaceutical composition is in a form suitable for intravenous administration. Preferably, the pharmaceutical composition is provided in the form of an aqueous solution for parenteral administration, or in the form of a lyophilized powder that can be mixed with water before administration. Preferably, the pharmaceutical composition is an aqueous solution or suspension having a pH of 6 to 8.5. Preferably, the pharmaceutical composition is in a form suitable for providing 0.01 to 10 mg / kg / day, preferably 0.1 to 2 mg / kg / day, preferably about 1 mg / kg / day, of the compound or complex according to the first or second aspect of the present invention.

[0159] In another preferred embodiment, the pharmaceutical composition is in a form suitable for administration to the respiratory tract. Preferably, the pharmaceutical composition is provided in the form of an aqueous solution, suspension, or dispersion for administration to the respiratory tract, or in the form of a lyophilized powder that can be mixed with water prior to administration to provide an aqueous solution, suspension, or dispersion for administration to the respiratory tract. In another preferred embodiment, the pharmaceutical composition is in a form suitable for providing 0.01 to 10 mg / kg / day, preferably 0.1 to 2 mg / kg / day, preferably about 1 mg / kg / day, of a compound or complex according to the first or second aspect of the present invention.

[0160] A fourth aspect of the present invention relates to a method for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infections caused by the SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant cell hyperproliferation or angiogenesis. There is provided use of a compound or complex according to the first or second aspect of the invention in the manufacture of a medicament for the treatment of a disease characterised by areas of growth; benign or malignant tumour; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumour; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organ, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0161] A fourth aspect of the present invention provides the use of a compound or complex according to the first or second aspect of the present invention in the manufacture of a phototherapeutic agent for use in photodynamic therapy or cytoluminescence therapy. Preferably, the phototherapeutic agent is a compound or complex according to the first or second aspect of the present invention for use in a treatment of a disease such as atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; a fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infection; HIV; AIDS; infection with the SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; a dermatological condition; acne; psoriasis; or a combination thereof. It is suitable for the treatment of diseases characterized by areas of hyperproliferation of benign or malignant cells or angiogenesis; benign or malignant tumors; early stage cancers; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0162] Preferably, the medicament or phototherapeutic agent according to the fourth aspect of the invention is suitable for the treatment of diseases characterised by areas of benign or malignant cell hyperproliferation or neovascularisation.

[0163] Preferably, the medicament or phototherapeutic agent according to the fourth aspect of the invention is suitable for the treatment of benign or malignant tumours.

[0164] Preferably, the medicament or phototherapeutic agent according to the fourth aspect of the invention is suitable for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0165] A fourth aspect of the invention also provides the use of a compound or complex according to the first or second aspect of the invention in the manufacture of a photodiagnostic agent for use in photodynamic diagnosis.

[0166] Preferably, the photodiagnostic agent according to the fourth aspect of the present invention is suitable for use in treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infections caused by the SARS virus (preferably severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne. ; psoriasis; diseases characterized by areas of benign or malignant cell hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0167] Preferably, the photodiagnostic agent according to the fourth aspect of the present invention is suitable for detecting areas affected by benign or malignant cell hyperproliferation or by angiogenesis.

[0168] Preferably, the photodiagnostic agent according to the fourth aspect of the present invention is suitable for detecting benign or malignant tumors.

[0169] Preferably, the photodiagnostic agent according to the fourth aspect of the present invention is suitable for the detection of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumour; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0170] Preferably, the photodiagnostic agent of the fourth aspect of the present invention is suitable for fluorescent or phosphorescent detection of said disease, preferably for fluorescent or phosphorescent detection and quantification of said disease.

[0171] Preferably, the drug, phototherapeutic agent or photodiagnostic agent is adapted for administration simultaneously with or before the administration of radiation or sound, preferably before the administration of radiation.

[0172] If the drug or phototherapeutic agent is for use in photodynamic therapy or cytoluminescence therapy, then it is preferably adapted for administration 5 to 100 hours before irradiation, preferably 6 to 72 hours before irradiation, preferably 24 to 48 hours before irradiation.

[0173] If the photodiagnostic agent is used for photodynamic diagnosis, then it is preferably adapted for administration 3 to 60 hours before irradiation, preferably 8 to 40 hours before irradiation.

[0174] Preferably, the radiation used in photodynamic therapy, cytoluminescence therapy, or photodynamic diagnosis is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources (e.g., a laser light and an LED light) are used, both of which are suitable for providing radiation in the wavelength range of 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. In another embodiment of the present invention, the radiation can be provided by prostate, anal, vaginal, oral, or nasal devices for insertion into body cavities. In another embodiment of the present invention, the radiation can be provided by mediated photoactivation, for example, by inserting a fiber-optic laser into the lung, liver, lymph nodes, or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.

[0175] A fifth aspect of the present invention provides a method for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infections caused by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or non-cancerous conditions. or diseases characterized by areas of malignant cell hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancers; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas. The method comprises administering a therapeutically effective amount of a compound or complex according to the first or second aspect of the invention to a human or animal in need thereof.

[0176] The fifth aspect of the present invention also provides a method for photodynamic or cytoluminescent therapy of a human or animal disease, the method comprising administering a therapeutically effective amount of a compound or complex according to the first or second aspect of the present invention to a human or animal in need thereof. Preferably, the human or animal disease is atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infection; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; or cutaneous conditions. psoriasis; diseases characterized by areas of benign or malignant cell hyperproliferation or angiogenesis; benign or malignant tumors; early-stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.

[0177] Preferably, the method of the fifth aspect of the invention is a method of treating areas of benign or malignant cellular hyperproliferation or neovascularization.

[0178] Preferably, the method of the fifth aspect of the invention is a method of treating a benign or malignant tumor.

[0179] Preferably, the method of the fifth aspect of the invention is a method of treating early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0180] The fifth aspect of the present invention also provides a method for photodynamic diagnosis of human or animal disease, the method comprising administering to the human or animal a diagnostically effective amount of a compound or complex according to the first or second aspect of the present invention. Preferably, the human or animal disease is atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infection; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; or cutaneous conditions. The human or animal disease is preferably a cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organ, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas. Preferably, the human or animal disease is characterized by benign or malignant cell hyperproliferation or by areas of angiogenesis. Preferably, the human or animal disease is a benign or malignant tumor. Preferably, the human or animal disease is early stage cancer, cervical dysplasia, soft tissue sarcoma, germ cell tumor, retinoblastoma, age-related macular degeneration, lymphoma, Hodgkin's lymphoma, head and neck cancer, oral cancer, or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organ, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas. Preferably, the method of photodynamic diagnosis is suitable for fluorescent or phosphorescent detection of said disease, preferably fluorescent or phosphorescent detection and quantification of said disease.

[0181] In any of the methods of the fifth aspect of the invention, the human or animal is preferably further subjected to irradiation or sound simultaneously with or after administration of a compound or complex according to the first or second aspect of the invention. Preferably, the human or animal is subjected to irradiation after administration of a compound or complex according to the first or second aspect of the invention.

[0182] If the method is a photodynamic therapy or cytoluminescence therapy method, then the human or animal is preferably irradiated 5 to 100 hours after administration of the compound or complex according to the first or second aspect of the invention, preferably 6 to 72 hours, preferably 24 to 48 hours after administration.

[0183] If the method is a method of photodynamic diagnosis, then the human or animal is preferably irradiated 3 to 60 hours, preferably 8 to 40 hours, after administration of the compound or complex according to the first or second aspect of the invention.

[0184] Preferably, the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources (e.g., a laser light and an LED light) are used, both radiation sources being suitable for providing irradiation at wavelengths in the range of 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. In another embodiment of the present invention, irradiation can be provided by prostate, anal, vaginal, oral, or nasal devices for insertion into body cavities. In another embodiment of the present invention, irradiation can be provided by mediated photoactivation, for example, by inserting a fiber-optic laser into the lung, liver, lymph nodes, or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.

[0185] In any of the methods of the fifth aspect of the invention, preferably the human or animal is a human.

[0186] A sixth aspect of the invention provides a pharmaceutical combination or kit comprising: (a) a compound or complex according to the first or second aspect of the present invention, and (b) Immune checkpoint inhibitors.

[0187] In one embodiment, the immune checkpoint inhibitor is an inhibitor of PD-1 (programmed cell death protein 1), PD-L1 (programmed death-ligand 1), or CTLA4 (cytotoxic T-lymphocyte-associated protein 4). In one embodiment, the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, or ipilimumab.

[0188] Preferably, the combination or kit of the sixth aspect is for use in the treatment of a disease, disorder, or condition that responds to PD-1, PD-L1, or CTLA4 inhibition. Preferably, the combination or kit of the sixth aspect is for use in the treatment of cancer. In one embodiment, the cancer is melanoma, lung cancer (e.g., non-small cell lung cancer), kidney cancer, bladder cancer, head and neck cancer, or Hodgkin's lymphoma.

[0189] The sixth aspect also provides the use of a combination or kit of the sixth aspect of the invention in the manufacture of a medicament for the treatment of a disease, disorder or condition, wherein the disease, disorder or condition responds to PD-1, PD-L1 or CTLA4 inhibition. The sixth aspect also provides the use of a combination or kit of the sixth aspect of the invention in the manufacture of a medicament for the treatment of cancer. In one embodiment, the cancer is melanoma, lung cancer (e.g., non-small cell lung cancer), kidney cancer, bladder cancer, head and neck cancer, or Hodgkin's lymphoma.

[0190] The sixth aspect of the present invention also provides a method of treating a disease, disorder, or condition that responds to PD-1, PD-L1, or CTLA4 inhibition, the method comprising administering a therapeutically effective amount of the combination or kit of the sixth aspect of the present invention to a human or animal in need thereof. The sixth aspect of the present invention also provides a method of treating cancer, the method comprising administering a therapeutically effective amount of the combination or kit of the sixth aspect of the present invention to a human or animal in need thereof. In one embodiment, the cancer is melanoma, lung cancer (e.g., non-small cell lung cancer), kidney cancer, bladder cancer, head and neck cancer, or Hodgkin's lymphoma.

[0191] For the combination or kit of the sixth aspect of the invention, the compound or complex according to the first or second aspect of the invention and the immune checkpoint inhibitor may be provided together in one pharmaceutical composition, or separately in two pharmaceutical compositions, which may be administered at the same time or at different times.

[0192] Preferably, the combination or kit of the sixth aspect is adapted for administration simultaneously with or before the administration of radiation or sound, preferably adapted for administration before the administration of radiation, hi one embodiment, the combination or kit of the sixth aspect is adapted for administration 5 to 100 hours before radiation, preferably 6 to 72 hours before radiation, preferably 24 to 48 hours before radiation.

[0193] Preferably, the radiation used in photodynamic therapy or cytoluminescence therapy is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources (e.g., a laser light and an LED light) are used, both radiation sources being suitable for providing radiation in the wavelength range of 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. In another embodiment of the present invention, the radiation can be provided by prostate, anal, vaginal, oral, or nasal devices for insertion into body cavities. In another embodiment of the present invention, the radiation can be provided by mediated photoactivation, for example, by inserting a fiber-optic laser into the lung, liver, lymph nodes, or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.

[0194] For the avoidance of doubt, it is to be understood that, so far as is practicable, any embodiment of a given aspect of the invention may occur in combination with any other embodiment of the same aspect of the invention. Further, so far as is practicable, any preferred or optional embodiment of any aspect of the invention shall be taken as a preferred or optional embodiment of any other aspect of the invention.

[0195] Details of the synthesis experiment Synthesis Example 1 - Synthesis of methyl 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-(1-(3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)propoxy)ethyl)-7H,8H-porphyrin-7-yl)propanoate (Compound 1) [ka]

[0196] Synthesis of (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-((3-hydroxypropyl)thio)tetrahydro-2H-pyran-3,4,5-triyl triacetate [ka] Step 1: A 100 mL single-neck RBF equipped with a 50 mL addition funnel and nitrogen inlet was charged with 1,2,3,4,6-penta-O-acetyl-β-D-glucose (2.00 g, 5.12 mmol, 1 equiv.), a stir bar, and dry DCM (20 mL). The resulting solution was cooled in an ice-water bath under N2 with stirring (420 rpm) for 10 min. After this, 33% w / w HBr / AcOH (8.2 mL, 47 mmol, 9.1 equiv.) was charged to the addition funnel and added dropwise to the solution over 5 min. After complete addition, the reaction mixture was stirred in the ice-water bath for 1 h. The mixture was diluted with EtO (100 mL) and washed with H0 (3 × 100 mL) and then saturated aqueous NaHCO (2 × 100 mL), before being dried (MgSO) and concentrated to give crude 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide as a yellow syrup, which was used without further purification (2.08 g, 99%).

[0197] 1 H NMR (400 MHz, CDCl3) δ 6.61 (d, J = 4.1 Hz, 1H), 5.56 (dd, J = 9.7, 9.7 Hz, 1H), 5.16 (dd, J = 10.1, 9.3 Hz, 1H), 4.83 (dd, J = 10.0, 4.1 Hz, 1H), 4.37-4.22 (m, 2H), 4.17-4.08 (m, 1H), 2.10 (s, 3H), 2.10 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H).

[0198] Step 2: Crude glucopyranosyl bromide was dissolved in acetone (20 mL) and added to a 100 mL RBF containing thiourea (0.507 g, 6.66 mmol, 1.3 equiv.) and 3A molecular sieves (2.0 g). The resulting mixture was refluxed overnight under N2 with stirring (420 rpm) at 80 °C ambient temperature. The product precipitated as a colorless solid. The reaction mixture was diluted with ether (20 mL), filtered through a glass sinter funnel, and briefly washed with ether. The product was separated from the molecular sieves by washing the sinter with MeOH. The filtrate was concentrated to give pure 2,3,4,6-tetra-O-acetyl-β-D-glucospiranoyl-1-S-isothiouronium bromide as a colorless solid (1.51 g, 60%).

[0199] 1 H NMR (400 MHz, DMSO-d6) δ 9.16 (br s, 4H), 5.69 (d, J = 10.0 Hz, 1H), 5.32 (dd, J = 9.4, 9.4 Hz, 1H), 5.16-5.05 (m, 2H), 4.25-4.14 (m, 2H), 4.13-4.03 (m, 1H), 2.06 (s, 3H), 2.02 (s, 3H), 2.00 (s, 3H), 1.97 (s, 3H).

[0200] Step 3: To a 100 mL RBF containing 2,3,4,6-tetra-O-acetyl-β-D-glucospiranoyl-1-S-isothiouronium bromide (1.51 g, 3.10 mmol, 1 equiv.) was added DCM (20 mL) (only partial dissolution), followed by a solution of NaSO (2.00 g, 10.5 mmol, 3.4 equiv.) in water (20 mL). The heterogeneous mixture was refluxed (ambient temperature = 70 °C) for 1 h, during which time all material had dissolved. A concentrated aliquot of the organic layer showed clean conversion to the thiol. The organic phase was separated and washed with HO (20 mL) then brine (20 mL) before being dried (MgSO) and concentrated by rotary evaporation to give (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-mercaptotetrahydro-2H-pyran-3,4,5-triyl triacetate as a colorless oil that solidified on standing (1.09 g, 96%).

[0201] 1 H NMR (400 MHz, CDCl3) δ 5.19 (dd, J = 9.9, 9.9 Hz, 1H), 5.09 (dd, J = 9.9, 9.9 Hz, 1H), 4.97 (dd, J = 9.9, 9.9 Hz, 1H), 4.54 (dd, J = 9.9, 9.9 Hz, 1H), 4.25 (dd, J = 12.5, 4.8 Hz, 1H), 4.12 (dd, J = 12.5, 2.3 Hz, 1H), 3.72 (ddd, J = 9.9, 4.8, 2.3 Hz, 1H), 2.31 (d, J = 9.9 Hz, 1H), 2.09 (s, 3H), 2.08 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H).

[0202] Step 4: To a single-neck 100 mL RBF was added a small stir bar, (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-mercaptotetrahydro-2H-pyran-3,4,5-triyl triacetate (3.78 g, 9.54 mmol, 1 equiv.), CHCl3 (15 mL), and triethylamine (2.65 mL, 19.1 mmol, 2 equiv.). To the resulting solution was added 3-bromopropan-1-ol (1.06 mL, 11.7 mmol, 1.2 equiv.), and the mixture was stirred (420 rpm) under N2. After 4 h, TLC (50% EtOAc / hexanes, R f (thioglucose) = 0.60, R f (bromide) = 0.55, R f Only traces of starting material remained (product = 0.2). The reaction mixture was diluted with DCM (20 mL) and water (20 mL), and the organic layer was collected and washed with brine (20 mL). The organic phase was dried (MgSO4) and concentrated by rotary evaporation to give the crude coupled product as a pale yellow syrup (5.08 g). The crude product was purified by column chromatography (70% EtOAc / hexanes) to give (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-((3-hydroxypropyl)thio)tetrahydro-2H-pyran-3,4,5-triyl triacetate as a very pale yellow oil that solidified to a gray wax upon standing (3.79 g, 94%).

[0203] 1 H NMR (400 MHz, CDCl3) δ 5.22 (dd, J = 9.4, 9.4 Hz, 1H), 5.12-4.98 (m, 2H), 4.48 (d, J = 10.1 Hz, 1H), 4.23 (dd, J = 12.4, 4.9 Hz, 1H), 4.15 (dd, J = 12.4, 2.4 Hz, 1H), 3.77-3.67 (m, 3H), 2.89-2.70 (m, 2H), 2.08 (s, 3H), 2.06 (s, 3H), 2.02 (s, 2H), 2.00 (s, 3H), 1.90-1.75 (m, 3H).

[0204] Synthesis of phyllochlorinpropyloxythioglucose: Methyl 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-(1-(3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)propoxy)ethyl)-7H,8H-porphyrin-7-yl)propanoate (Compound 1) [ka] Step 1: To a 100 mL RBF containing phyllochlorin methyl ester (0.500 g, 0.957 mmol, 1 equiv.) and a stir bar was added HBr / AcOH (33% w / w, 9 mL), and the dark blue mixture was stirred (420 rpm) under N2 for 2 h at 30 °C (external temperature). A stream of N2 was passed through the sample for several minutes to remove some of the HBr before concentrating the bulk by rotary evaporation. The mixture was further dried under high vacuum (0.2 mbar) at an external temperature of 40 °C for 30 min. The residue was reconstituted in DCM (20 mL), followed by the addition of KCO (1.32 g, 9.57 mmol, 10 equiv.), followed by (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-((3-hydroxypropyl)thio)tetrahydro-2H-pyran-3,4,5-triyl triacetate (1.21 g, 2.87 mmol, 3 equiv.). The dark solution was stirred at 30 °C (external temperature) for 1 h, at which point a concentrated aliquot of the reaction mixture showed the disappearance of the bromide resonance. The reaction mixture was transferred to a separatory funnel and washed with HO (20 mL) and then brine (20 mL), before being dried (NaSO) and concentrated to give the crude coupled product as a dark green film (1.78 g). The residue was purified by Biotage automated column chromatography (MeOH / DCM gradient). The sample was loaded onto the cartridge as a solution in DCM. This compound had an R of 0.25 in 1% MeOH / DCM. f Phyllochlorin methyl ester propyloxythio-D-glucose peracetate was obtained as a dark green film.

[0205] Step 2: To a solution of phyllochlorin methyl ester propyloxythio-D-glucose peracetate (0.400 g, 0.419 mmol, 1 equiv.) in a mixture of DCM (5 mL) and MeOH (5 mL), a 4.6 M solution of NaOMe in MeOH (0.46 mL, 2.10 mmol, 5 equiv.) was added dropwise. The dark green solution was stirred at ambient temperature for 20 min. The reaction was quenched with AcOH (10 drops) and concentrated by rotary evaporation. The residue was partitioned between DCM (20 mL) and HO (20 mL). The organic phase was collected, and the aqueous phase was re-extracted with DCM (20 mL). The combined organic phases were dried (NaSO) and concentrated by rotary evaporation to give the crude deacetylated product as a dark green film (334 mg). The product was purified by Biotage autocolumn chromatography. The sample was loaded onto the cartridge as a solution in 5% MeOH / DCM. The product, compound 1, had an R of 0.4 in 10% MeOH / DCM. f had the following characteristics:

[0206] Synthesis Example 2 - Synthesis of phyllochlorin N-3-hydroxypropyl-N-methylpropylamidopropyloxythio-D-glucose (Compound 2) [ka]

[0207] Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-(3-hydroxypropyl)-N-methylpropanamide (phyllochlorin N-3-hydroxypropyl-N-methylpropylamide) [ka] To a 100 mL RBF equipped with a nitrogen inlet and containing a small stir bar was added phyllochlorin (2.00 g, 3.93 mmol, 1 equiv.), dichloromethane (50 mL), PyBOP (2.26 mg, 1.1 equiv.), triethylamine (1.64 mL, 3 equiv.), and 3-(methylamino)-propanol (0.42 g, 1.2 equiv.). The mixture was stirred at room temperature for 3 h. Analysis by HPLC indicated the reaction was complete. The reaction mixture was transferred to a separatory funnel and washed with water (2 × 30 mL). The organic layer was dried (NaSO) and concentrated by rotary evaporation to give the crude product as a blue / brown film (5.1 g). The crude mixture was loaded directly onto a silica column and eluted with 1.5–2% MeOH / DCM. f Pure fractions containing a green / blue spot by TLC (5% MeOH / DCM) of 0.30 were combined to give phyllochlorin N-3-hydroxypropyl-N-methylpropylamide (1.29 g, 57%).

[0208] 1 H NMR (400 MHz, CDCl3) δ 9.75-9.70 (m, 2H), 8.85 (brs, 1H), 8.16 (dd, 1H), 6.38 (dd, 1H), 6.15 (dd, 1H), 4.70-4.65 (m, 1H), 4.58-4.50 (m, 1H), 4.00 (s, 3H), 3.89-3.82 (m, 3H), 3.65 (s, 3H), 3.53 (s, 3H), 3.37 (s, 3H), 3.31-3.15 (m, 4H), 2.65-2.53 (m, 2H), 2.37-2.22 (m, 3H), 2.16 (3, 3H), 1.80 - 1.70 (m, 7H), 1.48-1.40 (m, 2H), -2.10 (s, 1H), -2.22 (m, 1H).

[0209] Acetylation of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-(3-hydroxypropyl)-N-methylpropanamide (phyllochlorin N-3-hydroxypropyl-N-methylpropylamide) [ka] To a single-neck 50 mL RBF was added phyllochlorin N-3-hydroxypropyl-N-methylpropylamide (1.20 mg, 2.07 mmol, 1 equiv.), pyridine (10 mL), acetic anhydride (2.0 mL, 21.2 mmol, 10 equiv.), and DMAP (5 mg). The solution was stirred at 30 °C (external heat block) for 1 h. Analysis by TLC indicated the reaction was complete. Ethyl acetate (10 mL) and water (15 mL) were added, and the mixture was stirred vigorously for 10 min. The layers were separated, and the ethyl acetate layer was washed with 0.5 M HCl (3 × 15 mL), saturated NaHCO₃ (3 × 15 mL), dried (Na₂SO₄), and concentrated to give the crude product as a dark solid. The residue was purified by silica column chromatography (4 × 18 cm) using a stepwise solvent system of 1–2.5% MeOH / DCM. Phyllochlorin N-3-acetoxypropyl-N-methylpropylamide was isolated as a deep greenish-blue flaky solid (0.97 g, 78%).

[0210] 1H NMR (400 MHz, CDCl3) δ 9.72 (brs, 2H), 8.86 (m, 2H), 8.16 (dd, 1H), 6.48 (d, 1H), 6.16 (d, 1H), 4.69 (m, 1H), 4.52 (m, 1H), 4.02 (m, 3H), 3.93 (t, 1H), 3.85 (q, 2H), 3.65 (s, 3H), 3.53 (s, 3H), 3.37 (s, 3H), 3.20 (t, 1H), 2.65 (s, 1H), 2.62-2.50 (m, 2H), 2.35-2.20 (m, 5H), 1.96 (s, 2H), 1.81-1.70 (m, 7H), 1.68-1.49 (m, 2H), 1.30-1.20 (m, 1H), -2.13 (br, 1H), -2.22 (br, 1H).

[0211] Bromination / Thio-D-glucose substitution [ka] To a 250 mL RBF containing phyllochlorin N-3-acetoxypropyl-N-methylpropylamide (0.82 g, 1.32 mmol, 1 equiv.) and a stir bar, HBr / AcOH (33% w / w, 14 mL) was added, and the dark blue mixture was stirred (420 rpm) under N2 at 30 °C (external) for 2 h. At this point, a concentrated aliquot 1H NMR analysis showed clean conversion to the bromide. A stream of N was passed through the sample for several minutes to remove some of the HBr before concentrating the bulk by rotary evaporation. The mixture was further dried under high vacuum (approximately 0.4 mbar) at an external temperature of 40 °C for 30 min. The residue was reconstituted in DCM (20 mL), followed by the addition of KCO (1.82 g, 13.19 mmol, 10 equiv.) and then 2,3,4,6-tetra-O-acetyl-1-(3'-hydroxypropyl)thio-D-glucopyranoside (1.53 g, 3.63 mmol, 2.75 equiv.). The dark solution was stirred overnight at 30 °C (external temperature), at which point a concentrated aliquot of the reaction mixture showed the disappearance of the bromide resonance. The reaction mixture was transferred to a separatory funnel and washed with HO (20 mL) and then brine (20 mL), before being dried (NaSO) and concentrated to give the crude coupled product as a dark green film (2.4 g). The residue was purified by silica column chromatography (3 x 21 cm) using a stepwise solvent system of 1-2% MeOH / DCM. The product-containing fractions (R of 0.3 in 2% MeOH / DCM) were f ) were mixed to give the crude product as a dark green film (1.75 g) which was used without further purification.

[0212] General deacetylation [ka] To a solution of phyllochlorin N-3-acetoxypropyl-N-methylpropylamidopropyloxythio-D-glucose peracetate (1.75 g, 1.68 mmol, 1 equiv.) in a mixture of DCM (10 mL) and MeOH (20 mL) was added dropwise a 4.6 M solution of NaOMe in MeOH (1.80 mL, 8.38 mmol, 5 equiv.). The dark green solution was stirred at ambient temperature for 90 min. The reaction was quenched with AcOH (0.55 g) and concentrated by rotary evaporation to give the deacetylated product as a dark green film (1.75 g). The crude product was purified by silica column chromatography (4 x 20 cm, 5-12% MeOH / DCM). The pure fractions (R = 0.2 in 10% MeOH / DCM) were purified. fThe resulting solids (TLC) were combined to give the product, Compound 2, as a dark blue-green flaky solid (0.48 g, 44% over two steps) (HPLC purity: 97.3%).

[0213] 1 H NMR (400 MHz, CDCl3) δ 10.20-9.87 (m, 1H), 9.74 (brs, 1H), 8.97-8.80 (brs, 2H), 6.10-5.85 (m, 1H), 4.72-4.47 (m, 2H), 3.97 (s, 3H), 3.90-3.74 (m, 3H), 3.70-3.60 (m, 4H), 3.55-3.40 (m, 4H), 3.40-3.35 (s, 3H), 3.28-3.05 (m, 5H), 2.80-2.52 (m, 5H), 2.50-2.40 (m, 3H), 2.38-2.25 (m, 5H), 2.20-2.10 (m, 6H), 2.08-1.97 (m, 4H), 1.95-1.80 (m, 3H), 1.80-1.67 (m, 8H), 1.45-1.33 (m, 2H), -2.40 (brs, 1H).

[0214] Synthesis Example 3 - Synthesis of phyllochlorin 13-hydroxymethyl methyl ester (compound 3) [ka] Step 1: To a 250 mL RBF was added phyllochlorin methyl ester (2.00 g, 3.826 mmol, 1 equiv.), THF (75 mL), osmium tetroxide (5 mg, 0.038 mmol, 0.01 equiv.), deionized water (5 mL), AcOH (5 mL), and sodium periodate (1.80 g, 8.418 mmol, 2.2 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen in the dark at ambient temperature for 3 hours. An additional amount of sodium periodate (0.35 g, 0.4 equiv.) was added, and the solution was stirred overnight. The reaction mixture was concentrated using a rotary evaporator to remove THF, then redissolved in DCM (60 mL), transferred to a separatory funnel, washed with brine (40 mL), saturated NaHCO3 (40 mL), water (40 mL), dried (Na2SO4), and concentrated by rotary evaporation to give a reddish-brown powdery solid (approximately 2.5 g). The residue was subjected to column chromatography (4 x 15 cm) using a gradient of 0-2% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) f =0.7) were combined to give the intermediate aldehyde, phyllochlorin 13-formylmethyl ester (1.65 g, 82%) (HPLC purity: 95%).

[0215] Step 2: To a 250 mL RBF was added phyllochlorin 13-formylmethyl ester (1.00 g, 1.906 mmol, 1 equiv.), MeOH (20 mL), DCM (10 mL), and sodium borohydride (145 mg, 3.812 mmol, 2 equiv.). The resulting mixture was stirred (300 rpm) under nitrogen at ambient temperature for 1 h. The reaction mixture was diluted with water (40 mL) and stirred for 10 min. The mixture was then diluted with DCM (40 mL) and brine (30 mL). The DCM layer was collected, and the aqueous was further extracted with DCM (2 × 20 mL). The combined DCM layers were washed with brine (30 mL), dried (NaSO), and concentrated by rotary evaporation to give a dark green solid (approximately 1.2 g). The residue was subjected to column chromatography (3 × 17 cm) eluting with a gradient of 1–2% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) f=0.7) were combined to give compound 3 (0.82 g, 82%) (HPLC purity: 99.5%).

[0216] 1 H NMR (400 MHz, CDCl3) δ 9.72 (s, 1H), 9.63 (m, 1H), 8.86 (m, 2H), 5.88 (m, 2H), 4.58 (m, 1H), 4.51 (m, 1H), 4.00 (s, 3H), 3.84 (q, 2H), 3.63 (s, 3H), 3.58 (s, 3H), 3.48 (m, 3H), 3.35 (s, 3H), 2.63-2.48 (m, 2H), 2.20-2.00 (m, 2H), 1.98-1.90 (m, 1H), 1.79 (d, 3H), 1.75 (d, 3H), -2.21 (brs, 1H), -2.37 (brs, 1H).

[0217] Synthesis Example 4 - Synthesis of phyllochlorin 13-hydroxymethyl-β-D-glucoside ether methyl ester (compound 4) [ka] Step 1: To a 25 mL RBF was added phyllochlorin 13-hydroxymethylmethyl ester (compound 3) (100 mg, 0.190 mmol, 1 equiv.), glucose pentaacetate (89 mg, 0.228 mmol, 1.2 equiv.), and DCM (4 mL). The resulting mixture was stirred (420 rpm) under nitrogen while cooling to <5 °C. Boron trifluoride diethyl etherate (5 drops via a 1 mL disposable syringe) was added, and stirring was continued, allowing the solution to warm slowly to approximately 10 °C over 1 h. Further boron trifluoride diethyl etherate (8 drops via a 1 mL disposable syringe) was added, and the mixture was allowed to warm slowly to room temperature. After 5 h, the reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel, and washed with saturated NaHCO (10 mL) and then water (20 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to give a blue-black film (225 mg). The residue was subjected to column chromatography (3 x 16 cm) eluting with a gradient of 0.5 to 1.5% MeOH / DCM. The partially purified phyllochlorin 13-hydroxymethyl-β-glucoside ether methyl ester peracetate (180 mg) was used directly in the next step.

[0218] Step 2: To a solution of phyllochlorin 13-hydroxymethyl-β-glucoside ether methyl ester peracetate (180 mg, 0.190 mmol, 1 equiv.) in MeOH (2 mL) and DCM (2 mL), NaOMe (4.6 M in MeOH, 0.05 mL, 0.23 mmol, 1.2 equiv.) was added, and the mixture was stirred (420 rpm) under N2 for 1 h with HPLC monitoring. The reaction was concentrated by rotary evaporation to give a black film. The residue was purified by column chromatography (3 x 15 cm) eluting with a gradient of 5-10% MeOH / DCM. Fractions containing a green spot (R in 5% MeOH / DCM) were purified. f =0.1) was mixed to give compound 4 (38 mg, 29% in two steps) (HPLC purity: 99.6%).

[0219] 1H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 9.76 (s, 1H), 9.08 (m, 2H), 6.15 (d, 1H), 6.00 (d, 1H), 5.11 (d, 1H), 4.95 (t, 2H), 4.83 (t, 1H), 4.65-4.58 (m, 2H), 4.55 (d, 1H), 4.11 (q, 1H), 3.95 (s, 3H), 3.90 (m, 1H), 3.82 (q, 2H), 3.72-3.65 (m, 1H), 3.62 (s, 3H), 3.53 (s, 3H), 3.51 (s, 3H), 3.26 (m, 1H), 3.21-3.15 (m, 3H), 3.12 (m, 1H), 2.80-2.70 (m, 1H), 2.45-2.35 (m, 2H), 1.85-1.75 (m, 1H), 1.75-1.67 (m, 6H), -2.46 (s, 1H), -2.58 (s, 1H).

[0220] Synthesis Example 5 - Synthesis of phyllochlorin 13-hydroxymethyl N-3-hydroxypropyl-N-methyl-propylamidoacetate (Compound 5) [ka] Step 1: To a 100 mL RBF equipped with a nitrogen inlet and containing a small stir bar was added phyllochlorin (2.00 g, 3.93 mmol, 1 equiv.), dichloromethane (50 mL), PyBOP (2.26 mg, 1.1 equiv.), triethylamine (1.64 mL, 3 equiv.), and 3-(methylamino)-propanol (0.42 g, 1.2 equiv.). The mixture was stirred at room temperature for 3 h. Analysis by HPLC indicated the reaction was complete. The reaction mixture was transferred to a separatory funnel and washed with water (2 × 30 mL). The organic layer was dried (NaSO) and concentrated by rotary evaporation to give the crude product as a blue / brown film (5.1 g). The crude mixture was loaded directly onto a silica column and eluted with 1.5–2% MeOH / DCM. fPure fractions containing a green / blue spot by TLC (5% MeOH / DCM) of 0.30 were combined to give phyllochlorin N-3-hydroxypropyl-N-methyl-propylamide (1.29 g, 57%).

[0221] 1 H NMR (400 MHz, CDCl3) δ 9.75-9.70 (m, 2H), 8.85 (br s, 1H), 8.16 (dd, 1H), 6.38 (dd, 1H), 6.15 (dd, 1H), 4.70-4.65 (m, 1H), 4.58-4.50 (m, 1H), 4.00 (s, 3H), 3.89-3.82 (m, 3H), 3.65 (s, 3H), 3.53 (s, 3H), 3.37 (s, 3H), 3.31-3.15 (m, 4H), 2.65-2.53 (m, 2H), 2.37-2.22 (m, 3H), 2.16 (3, 3H), 1.80 - 1.70 (m, 7H), 1.48-1.40 (m, 2H), -2.10 (s, 1H), -2.22 (m, 1H).

[0222] Step 2: To a single-neck 25 mL RBF was added phyllochlorin N-3-hydroxypropyl-N-methyl-propylamide (300 mg, 0.517 mmol, 1 equiv.), pyridine (2 mL), acetic anhydride (0.49 mL, 5.17 mmol, 10 equiv.), and DMAP (1 mg). The solution was stirred at 30 °C for 1 h. Analysis by TLC indicated the reaction was complete. Ethyl acetate (15 mL) and water (10 mL) were added, and the mixture was vigorously stirred for 10 min. The layers were separated, and the ethyl acetate layer was washed with 0.5 M HCl (2 × 10 mL), saturated NaHCO (2 × 10 mL), then dried (NaSO), and concentrated to give phyllochlorin N-3-hydroxypropyl-N-methyl-propylamide acetate as a dark green solid, which was not further purified (288 mg, 89%) (HPLC purity: 95.6%).

[0223] Step 3: To a 100 mL RBF was added phyllochlorin N-3-hydroxypropyl-N-methyl-propylamidoacetate (280 mg, 0.450 mmol, 1 equiv.), THF (15 mL), osmium tetroxide (1 mg, 0.005 mmol, 0.01 equiv.), deionized water (1 mL), AcOH (1 mL), and sodium periodate (202 mg, 0.946 mmol, 2.1 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen in the dark at ambient temperature overnight. The reaction mixture was concentrated using a rotary evaporator to remove THF, then redissolved in DCM (75 mL), transferred to a separatory funnel, washed with brine (30 mL), saturated NaHCO3 (30 mL), and water (40 mL), then dried (Na2SO4) and concentrated by rotary evaporation to give a reddish-brown powdery solid (approximately 0.28 g). The residue was subjected to column chromatography (3 x 15 cm) eluting with a gradient of 1-2.5% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) f =0.65) were combined to give the intermediate aldehyde, phyllochlorin 13-formyl N-3-hydroxypropyl-N-methyl-propylamidoacetate (200 mg, 71%).

[0224] Step 4: To a 50 mL RBF was added phyllochlorin 13-formyl N-3-hydroxypropyl-N-methyl-propylamidoacetate (190 mg, 0.305 mmol, 1 equiv.), MeOH (10 mL), DCM (5 mL), and sodium borohydride (23 mg, 0.609 mmol, 2 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen at ambient temperature for 30 minutes. The reaction mixture was diluted with water (20 mL) and stirred for 10 minutes. The mixture was then extracted with chloroform (3 × 10 mL). The combined chloroform layers were washed with water (20 mL), dried (NaSO), and concentrated by rotary evaporation to give a dark green oil. The residue was subjected to column chromatography (3 × 12 cm) eluting with a gradient of 2–3% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) was f =0.4) were combined to give compound 5 (173 mg, 91%).

[0225] 1 H NMR (400 MHz, CDCl3) δ 9.70 (m, 2H), 8.85 (m, 2H), 6.05-5.90 (m, 2H), 4.70-4.65 (m, 1H), 4.55-4.48 (m, 1H), 4.10 (t, 1H), 4.01 (m, 3H), 3.95-3.88 (m, 4H), 3.83 (q, 2H), 3.70 (m, 1H), 3.62 (s, 3H), 3.50 (s, 3H), 3.35 (m, 3H), 3.18 (t, 1H), 3.15 (s, 1H), 2.70-2.65 (m, 1H), 2.60-2.50 (m, 1H), 2.35-2.20 (m, 4H), 2.05 (s, 1H), 2.00-1.95 (m, 2H), 1.80-1.70 (m, 7H), 1.60 (m, 2H), -2.24 (brs, 1H), -2.40 (brs, 1H).

[0226] Synthesis Example 6 - Synthesis of phyllochlorin N-3-hydroxypropyl-N-methyl-propylamide 13-hydroxymethyl-β-D-glucoside ether (compound 6) [ka] Step 1: To a 50 mL RBF was added phyllochlorin 13-hydroxymethyl N-3-hydroxypropyl-N-methyl-propylamidoacetate (compound 5) (160 mg, 0.256 mmol, 1 equiv.), glucose pentaacetate (150 mg, 0.384 mmol, 1.5 equiv.), and DCM (10 mL). The resulting mixture was stirred (420 rpm) under nitrogen while cooling to approximately 0 °C. Boron trifluoride diethyl etherate (0.2 mL) was added, and stirring was continued. The solution was allowed to warm slowly to room temperature over 2 h and then stirred overnight at room temperature in the dark. The reaction was monitored by HPLC. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel, and washed with saturated NaHCO (20 mL) and then water (20 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to yield a blue-black film (350 mg). The residue was subjected to column chromatography (3 × 16 cm) eluting with a gradient of 1–2% MeOH / DCM. The partially purified phyllochlorin 13-hydroxymethyl-β-glucoside ether N-3-hydroxypropyl-N-methyl-propylamidoperacetate (260 mg) was used directly in the next step.

[0227] Step 2: To a solution of phyllochlorin 13-hydroxymethyl-β-glucoside ether N-3-hydroxypropyl-N-methyl-propylamidomeracetate (250 mg, 0.255 mmol, 1 equiv.) in MeOH (2 mL) and DCM (2 mL), NaOMe (4.6 M in MeOH, 0.06 mL, 0.23 mmol, 1.2 equiv.) was added, and the mixture was stirred (420 rpm) under N2 for 1 h. The reaction was concentrated by rotary evaporation to give a black film. The residue was purified by column chromatography (3 x 16 cm) eluting with a gradient of 5-12% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) f The fractions containing <0.1 were combined to give compound 6 as a dark green solid (75 mg, 39% over two steps) (HPLC purity: 95.5%).

[0228] 1H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 9.76 (s, 1H), 9.07 (m, 2H), 6.16 (d, 1H), 6.00 (d, 1H), 5.12 (d, 1H), 4.96 (t, 2H), 4.85 (t, 1H), 4.68-4.53 (m, 4H), 4.44 (t, 1H), 3.98 (m, 3H), 3.90 (m, 1H), 3.83 (q, 2H), 3.72-3.65 (m, 1H), 3.63 (s, 3H), 3.50 (s, 3H), 3.22-3.15 (m, 2H), 3.15-3.10 (m, 1H), 2.90 (s, 2H), 2.80 (s, 2H), 2.45-2.35 (m, 1H), 1.75-1.60 (m, 8H), 1.60-1.55 (m, 1H), -2.35 (s, 1H), -2.53 (s, 1H).

[0229] Synthesis Example 7 - Synthesis of phyllochlorin 13-hydroxymethyl-β-D-maltose ether methyl ester heptaacetate (Compound 7) [ka] To a 50 mL RBF was added phyllochlorin 13-hydroxymethylmethyl ester (compound 3) (100 mg, 0.190 mmol, 1 equiv.), maltose octaacetate (193 mg, 0.285 mmol, 1.5 equiv.), and DCM (10 mL). The resulting mixture was stirred (420 rpm) under nitrogen while cooling to approximately 0 °C. Boron trifluoride diethyl etherate (0.2 mL) was added, and stirring was continued. The solution was allowed to warm slowly to room temperature over 2 h and then stirred overnight at room temperature in the dark. The reaction was monitored by HPLC. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel, and washed with saturated NaHCO (15 mL) followed by water (20 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to yield a blue-black film (500 mg). The residue was subjected to column chromatography (3 × 12 cm) eluting with a gradient of 1–2% MeOH / DCM, and the major dark band was collected (R in 5% MeOH / DCM). f =0.80), Compound 7 was obtained as a dark green fluffy solid contaminated with excess maltose octaacetate (265 mg, quantitative) (HPLC purity: 94.7%).

[0230] 1H NMR (400 MHz, CDCl3) δ 9.74 (s, 1H), 9.63 (s, 1H), 8.89 (m, 2H), 6.20 (d, 1H), 6.05 (d, 1H), 5.32 (d, 1H), 5.38 (dd, 1H), 5.00 (m, 2H), 4.90 (m, 1H), 4.75 (m, 2H), 4.65 (m, 1H), 4.60 (m, 1H), 4.52 (m, 1H), 4.35 (dd, 1H), 4.28 (m, 2H), 4.05 (m, 2H), 4.01 (s, 3H), 3.95 (m, 1H), 3.86 (m, 2H), 3.67 (s, 3H), 3.60 (s, 3H), 3.51 (s, 3H), 3.37 (m, 3H), 2.65-2.50 (m, 2H), 2.30 (s, 3H), 2.10 (m, 5H), 2.02 (m, 7H), 1.92 (s, 3H), 1.83 (s, 3H), 1.80 (m, 5H), 1.75 (t, 3H), -2.20 (s, 1H), -2.41 (s, 1H).

[0231] Synthesis Example 8 - Synthesis of phyllochlorin 13-hydroxymethyl-β-D-maltose ether methyl ester (Compound 8) [ka] To a solution of phyllochlorin 13-hydroxymethyl-β-D-maltose ether methyl ester heptaacetate (compound 7) (230 mg, 0.164 mmol, 1 equiv.) in MeOH (3 mL) and DCM (3 mL) was added NaOMe (4.6 M in MeOH, 0.04 mL, 0.164 mmol, 1 equiv.), and the mixture was stirred (420 rpm) under N2 for 2 h. HPLC analysis after 2 h showed conversion to the deacetylated product. The reaction was concentrated by rotary evaporation to give a black film. The residue was purified by column chromatography (3 x 12 cm) eluting with a gradient of 8-12% MeOH / DCM. The product (R in 10% MeOH / DCM) was purified. f=0.1) were combined to give compound 8 as a blue-black solid (80 mg, 47%) (HPLC purity: 97.8%).

[0232] 1 H NMR (400 MHz, DMSO-d6) δ 9.81 (s, 1H), 9.76 (s, 1H), 9.08 (s, 1H), 9.05 (s, 1H), 6.10 (d, 1H), 5.92 (d, 1H), 5.54 (d, 1H), 5.45 (d, 1H), 5.26 (d, 1H), 5.08 (d, 1H), 4.98-4.90 (m, 2H), 4.86 (t, 1H), 4.65-4.58 (m, 3H), 4.55 (d, 1H), 3.95 (m, 4H), 3.81 (m, 3H), 3.71-3.65 (m, 1H), 3.61 (s, 3H), 3.55-3.45 (m, 9H), 3.35 (s, 3H), 3.26 (m, 2H), 3.14-3.06 (m, 1H), 2.80-2.70 (m, 1H), 2.45-2.35 (m, 2H), 1.85-1.75 (m, 1H), 1.75-1.67 (m, 6H), -2.36 (s, 1H), -2.53 (s, 1H).

[0233] Synthesis Example 9 - Synthesis of phyllochlorin 13-hydroxymethyl-N-meglumine-propylamidopentaacetate (Compound 9) [ka] Step 1: To a 50 mL RBF was added phyllochlorin (0.50 g, 0.983 mmol, 1 equiv.), DMTMM (0.30 g, 1.081 mmol, 1.1 equiv.), DCM (15 mL), and meglumine (0.23 g, 1.179 mmol, 1.2 equiv.). The resulting mixture was stirred under nitrogen at ambient temperature for 1 h. An additional amount of meglumine (0.10 g, 0.51 mmol, 0.5 equiv.) was added, and the solution was stirred for an additional 3 h. The reaction mixture was transferred to a separatory funnel, diluted with chloroform (30 mL), and washed with 0.5 M HCl (50 mL). The aqueous layer was re-extracted with chloroform, and the combined organics were washed with pH 7 buffer. The organic phase was dried (Na2SO4) and concentrated by rotary evaporation to give a blue / black film. This was purified by column chromatography (silica) using a gradient of 5% MeOH / DCM (50 mL), then 7% MeOH / DCM (100 mL), then 9% MeOH / DCM (100 mL), then 10% MeOH / DCM (200 mL) to give phyllochlorin N-meglumine-propylamide as a dark blue / green solid (432 mg, 64%).

[0234] 1 H NMR (400 MHz, d6-DMSO) δ 9.74 (s, 1H), 9.72 (s, 1H), 9.11 (s, 1H), 9.07 (s, 1H), 8.34 (dd, 1H), 6.44 (d, 1H), 6.17 (d, 1H), 5.10 & 4.75 (2 xd, 1H), 4.65-4.40 (m, 5H), 4.30 (m, 1H), 4.00 (m, 3H), 3.90 (m, 1H), 3.80 (m, 2H), 3.68 (m, 1H), 3.62 (s, 3H), 3.60-3.50 (m, 5H), 3.50-3.40 (m, 2H), 3.30-3.08 (m, 1H), 3.00 (s, 1H), 2.90 (s, 2H), 2.86-2.60 (m, 1H), 2.45-2.35 (m, 1H), 1.75-1.65 (m, 6H), 1.75-1.50 (m, 1H), -2.26 (s, 1H), -2.42 (s, 1H).

[0235] Step 2: To a single-neck 25 mL RBF was added phyllochlorin N-meglumine-propylamide (500 mg, 0.729 mmol, 1 equiv.), pyridine (3 mL), acetic anhydride (1.38 mL, 14.58 mmol, 20 equiv.), and DMAP (1 mg). The solution was stirred at 30 °C for 1 h. Ethyl acetate (20 mL) and water (10 mL) were added, and the mixture was stirred vigorously for 10 min. The layers were separated, and the ethyl acetate layer was washed with 0.5 M HCl (2 × 10 mL), saturated NaHCO3 ( 2×10mL ), dried (Na2SO4) and concentrated to give phyllochlorin N-meglumine-propylamidopentaacetate as a dark green solid (660 mg, quantitative) (HPLC purity: 99.1%).

[0236] 1 H NMR (400 MHz, CDCl3) δ 9.72 (m, 2H), 8.85 (m, 2H), 8.17 (dd, 1H), 6.39 (dd, 1H), 6.14 (dd, 1H), 5.41 (dd, 1H), 5.28 (m, 1H), 5.21 (m, 1H), 4.99 (m, 1H), 4.65 (m, 1H), 4.50 (m, 1H), 4.25 (dd, 1H), 4.08 (dd, 1H), 4.02 (s, 3H), 3.85 (q, 2H), 3.65 (s, 3H), 3.53 (s, 3H), 3.47 (dd, 1H), 3.38 (s, 3H), 3.24 (dd, 1H), 2.60-2.50 (m, 1H), 2.45-2.35 (m, 4H), 2.15 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 1.96 (s, 3H), 1.95 (s, 3H), 1.93 (m, 1H), 1.80-1.73 (m, 6H), -2.10 (brs, 1H), -2.23 (brs, 1H).

[0237] Step 3: To a 100 mL RBF was added phyllochlorin N-meglumine-propylamidopentaacetate (600 mg, 0.670 mmol, 1 equiv.), THF (25 mL), osmium tetroxide (1.7 mg, 0.007 mmol, 0.01 equiv.), deionized water (1.5 mL), AcOH (1.5 mL), and sodium periodate (358 mg, 1.674 mmol, 2.5 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen in the dark at ambient temperature overnight. The reaction mixture was concentrated using a rotary evaporator to remove THF, then redissolved in DCM (75 mL), transferred to a separatory funnel, washed with brine (30 mL), saturated NaHCO (30 mL), and water (40 mL), then dried (Na SO ) and concentrated by rotary evaporation to give a reddish-brown powdery solid (approximately 0.80 g). The intermediate aldehyde, phyllochlorin 13-formyl-N-meglumine-propylamidopentaacetate (HPLC purity: 97%), was used without further purification.

[0238] Step 4: To a 100 mL RBF was added phyllochlorin 13-formyl-N-meglumine-propylamidopentaacetate (600 mg, 0.668 mmol, 1 equiv.), MeOH (15 mL), DCM (7 mL), and sodium borohydride (51 mg, 1.336 mmol, 2 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen at ambient temperature for 30 minutes. The reaction mixture was diluted with water (20 mL) and stirred for 20 minutes. The mixture was then extracted with chloroform (3 × 10 mL). The combined chloroform layers were washed with water (20 mL), dried (NaSO), and concentrated by rotary evaporation to give a dark green oil. The residue was subjected to column chromatography (4 × 20 cm) eluting with a gradient of 1–3% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) was f =0.5) were combined to give compound 9 (267 mg, 44% over two steps).

[0239] 1H NMR (400 MHz, CDCl3) δ 9.70 (m, 2H), 8.86 (m, 2H), 6.05-5.90 (m, 2H), 5.40 (m, 1H), 5.20 (m, 2H), 4.98 (m, 1H), 4.72-4.65 (m, 1H), 4.55-4.48 (m, 1H), 4.25 (dd, 1H), 4.10-4.00 (m, 4H), 3.83 (q, 2H), 3.62 (s, 3H), 3.50 (s, 3H), 3.40-3.35 (m, 4H), 3.26 (dd, 1H), 2.60-2.50 (m, 2H), 2.35-2.20 (m, 4H), 2.13 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 1.96 (s, 3H), 1.94 (s, 3H), 1.85 (m, 2H), 1.80-1.70 (m, 7H), -2.23 (brs, 1H), -2.39 (brs, 1H).

[0240] Synthesis Example 10 - Synthesis of phyllochlorin N-meglumine-propylamido-13-hydroxymethyl-β-D-glucoside ether (Compound 10) [ka] Step 1: To a 50 mL RBF was added phyllochlorin 13-hydroxymethyl-N-meglumine-propylamidopentaacetate (compound 9) (255 mg, 0.283 mmol, 1 equiv.), glucose pentaacetate (166 mg, 0.425 mmol, 1.5 equiv.), and DCM (10 mL). The resulting mixture was stirred (420 rpm) under nitrogen while cooling to approximately 0 °C. Boron trifluoride diethyl etherate (0.2 mL) was added, and stirring was continued. The solution was allowed to slowly warm to room temperature over 2 h, then stirred overnight at room temperature in the dark. The reaction was monitored by HPLC. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel, and washed with saturated NaHCO (15 mL) and then water (20 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to yield a blue-black film (approximately 0.50 g). The residue was subjected to column chromatography (3 x 16 cm) eluting with a gradient of 0.5-2% MeOH / DCM. Fractions containing the major dark green band were combined to give a green oil (300 mg). The partially purified phyllochlorin 13-hydroxymethyl-β-glucoside ether-N-meglumine-propylamidoperacetate was used directly in the next step.

[0241] Step 2: To a solution of phyllochlorin 13-hydroxymethyl-β-glucoside ether-N-meglumine-propylamidoperacetate (300 mg, 0.244 mmol, 1 equiv.) in MeOH (3 mL) and DCM (3 mL), NaOMe (4.6 M in MeOH, 0.053 mL, 0.244 mmol, 1 equiv.) was added, and the mixture was stirred (420 rpm) under N2. After 30 min, additional MeOH (3 mL) was added. HPLC analysis after 1 h showed conversion to the deacetylated product. AcOH (3 drops) was added, and the reaction was concentrated by rotary evaporation to give a black residue. The residue was purified by column chromatography (3 x 12 cm) eluting with a gradient of 10-20% MeOH / DCM. The major green band (R in 10% MeOH / DCM) f=0.1) were combined to give compound 10 as a dark green solid (70 mg, 29% over two steps) (HPLC purity: 94.9%).

[0242] 1 H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 9.76 (s, 1H), 9.08 (m, 2H), 6.58 (d, 1H), 6.20 (d, 1H), 6.15 (d, 1H), 6.01 (d, 1H), 5.09 (t, 2H), 4.95 (t, 2H), 4.90 (t, 1H), 4.82 (m, 3H), 4.76 (m, 1H), 4.61 (m, 4H), 4.55 (m, 2H), 4.46 (m, 3H), 4.38 (m, 1H), 4.30 (m, 2H), 4.10 (m, 1H), 4.00 (m, 3H), 3.90 (m, 2H), 3.83 (q, 2H), 3.68 (m, 3H), 3.63 (s, 3H), 3.55 (m, 9H), 3.42 (m, 6H), 3.20-3.00 (m, 11H), 2.90 (m, 3H), 1.75-1.67 (m, 7H), 1.60-1.52 (m, 1H), -2.33 (s, 1H), -2.52 (s, 1H).

[0243] Synthesis Example 11: Synthesis of 13-hydroxymethyl-β-D-glucosyl-N-methylpropylamide tetraacetate (Compound 11) [ka] Step 1: A three-necked 250 mL RBF equipped with an internal thermometer, nitrogen inlet, and rubber septum was charged with tert-butyl (3-hydroxypropyl)(methyl)carbamate (2.68 g, 14.17 mmol, 1.05 equiv.), a stir bar, 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl trichloroacetimidate (10.00 g, 13.5 mmol, 1 equiv.), dry DCM (100 mL), and crushed 4A molecular sieves (5.0 g). The resulting suspension was placed under a nitrogen atmosphere and stirred (420 rpm) for 0.5 h before being cooled to −15 °C (internal temperature) using an EtOH / ice / NaCl bath. A solution of TMSOTf (0.2 M in DCM, 3.3 mL, 0.67 mmol) was added dropwise over 1 min and stirring was continued at low temperature for 0.5 h, at which point TLC analysis indicated the reaction was complete (25% EtOAc / hexane, R f (starting material) = 0.4, R f (product) = 0.2, visualized by UV). The reaction was quenched with triethylamine (8 drops), filtered through Celite®, and washed with an additional amount of DCM. The filtrate was concentrated to give the crude glycosylated product as a yellow syrup (15.4 g), which was dissolved in a minimum amount of DCM, and the solution was purified by column chromatography (4 × 22 cm silica) using a gradient solvent of 25 to 35% EtOAc in hexanes to give 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranose-N-Boc-N-methylproproxyamine as a colorless syrup (7.95 g, 77%) (R in 35% EtOAc in hexanes). f 0.4).

[0244] 1H NMR (400 MHz, CDCl3) δ 8.05-7.99 (m, 2H), 7.98-7.93 (m, 2H), 7.92-7.88 (m, 2H), 7.86-7.79 (m, 2H), 7.59-7.46 (m, 3H), 7.46-7.24 (m, 9H), 5.90 (dd, J = 9.7, 9.7 Hz, 1H), 5.68 (dd, J = 9.7, 9.7 Hz, 1H), 5.52 (dd, J = 9.7, 7.8 Hz, 1H), 4.84 (d, J = 7.8 Hz, 1H), 4.64 (dd, J = 12.2, 3.2 Hz, 1H), 4.49 (dd, J = 12.2, 5.2 Hz, 1H), 4.20-4.13 (m, 1H), 3.95 (ddd, J = 9.7, 5.2, 3.2 Hz, 1H), 3.61-3.50 (m, 1H), 3.24-2.99 (m, 2H), 2.66 (s, 3H), 1.82-1.68 (m, 2H), 1.39 (s, 9H).

[0245] Step 2: 2,3,4,6-Tetra-O-benzoyl-β-D-glucopyranose-N-Boc-N-methylproproxyamine (7.95 g, 10.35 mmol, 1 equiv.) in a 500 mL RBF was charged with DCM (50 mL) and a stir bar. The mixture was stirred briefly (250 rpm) until a solution formed, after which TFA (10 mL) was added. The mixture was stirred for 0.5 h and analyzed by TLC (30% EtOAc / Hexanes, R f (starting material) = 0.4, R f The reaction was monitored by UV visualization (product = 0). The reaction was concentrated by rotary evaporation and then reconcentrated from CHCl (2 × 30 mL) to give 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranose-N-methylpropyloxyammonium trifluoroacetate as a pale syrup (11.0 g), which was used without further purification.

[0246] 1H NMR (400 MHz, CDCl3) δ 8.69 (br s, 1H), 8.15 (br s, 1H), 8.08-8.02 (m, 2H), 7.99-7.88 (m, 4H), 7.87-7.80 (m, 2H), 7.67 (br s, 1H), 7.63-7.48 (m, 3H), 7.52-7.24 (m, 9H), 5.99 (dd, J = 9.8, 9.8 Hz, 1H), 5.71 (dd, J = 9.8, 9.8 Hz, 1H), 5.38 (dd, J = 9.8, 7.8 Hz, 1H), 4.82 (d, J = 7.8 Hz, 1H), 4.74 (dd, J = 12.3, 2.8 Hz, 1H), 4.47 (dd, J = 12.3, 5.0 Hz, 1H), 4.22-4.06 (m, 2H), 3.73 (app. p, J = 5.1 Hz, 1H), 3.31-3.18 (m, 1H), 3.14-3.01 (m, 1H), 2.79 (t, J = 5.3 Hz, 3H), 2.04 (app. p, J = 5.4 Hz, 2H).

[0247] Step 3: A 500 mL RBF was charged with a stir bar, phyllochlorin (4.05 g, 7.96 mmol, 1 equiv.), and DCM (60 mL). 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranose-N-methylpropyloxyammonium trifluoroacetate (6.91 g, 10.35 mmol, 1.3 equiv.) was dissolved in DCM (20 mL) and transferred to the RBF. Triethylamine (6.62 mL, 47.8 mmol, 6 equiv.) was added, followed by PyBOP (4.97 g, 9.55 mmol, 1.2 equiv.), and the mixture was stirred for 0.5 h. TLC analysis indicated consumption of starting material and presence of product (5% MeOH / DCM, R f (phyllochlorin) = 0.25, R f(Product) = 0.95, visualized by UV). The mixture was transferred to a separatory funnel and washed with 1 M HCl (2 × 75 mL), then with pH 7 phosphate buffer (100 mL), then dried (NaSO) and concentrated by rotary evaporation to give the crude product as a green film (16.3 g). The crude product was purified by Biotage automated column chromatography (0–2% MeOH / DCM) to give phyllochlorin β-D-glucosyl-N-methylpropylamidotetrabenzoate as a green film (4.75 g, 52%) (HPLC purity: 95.9%).

[0248] Step 4: To a 500 mL RBF containing phyllochlorin β-D-glucosyl-N-methylpropylamidotetrabenzoate (4.65 g, 4.01 mmol, 1 equiv.) was added DCM (50 mL), MeOH (50 mL), and a stir bar. The mixture was stirred briefly (300 rpm) until a dark solution formed, whereupon a solution of NaOMe (4.6 M in MeOH, 0.44 mL, 2.01 mmol, 0.5 equiv.) was added and the mixture was stirred for 2 h. TLC analysis at this point indicated complete reaction (10% MeOH / DCM, R f (starting material) = 0.95, R f (Product) = 0). The reaction mixture was concentrated, and the residue was purified by Biotage autocolumn chromatography (5-12% MeOH / DCM) to give phyllochlorin β-D-glucosyl-N-methylpropylamide as a blue / green flaky solid (2.34 g, 79%) (HPLC purity: 99.4%).

[0249] Step 5: To a single-neck 50 mL RBF was added phyllochlorin β-D-glucosyl-N-methylpropylamide (190 mg, 0.256 mmol, 1 equiv.), pyridine (2 mL), acetic anhydride (0.48 mL, 5.12 mmol, 20 equiv.), and DMAP (1 mg). The solution was stirred at 30 °C for 1 h. Ethyl acetate (20 mL) and water (10 mL) were added, and the mixture was stirred vigorously for 10 min. The layers were separated, and the ethyl acetate layer was washed with 0.5 M HCl (2 × 10 mL), saturated NaHCO (2 × 10 mL), dried (NaSO), and concentrated to give phyllochlorin β-D-glucosyl-N-methylpropylamide tetraacetate as a dark green solid (270 mg, quantitative) (HPLC purity: 99.1%).

[0250] 1 H NMR (400 MHz, CDCl3) δ 9.82-9.72 (m, 2H), 8.88-8.82 (m, 2H), 8.22-8.12 (m, 1H), 6.38 (m, 1H), 6.16 (m, 1H), 5.08-4.92 (m, 1H), 4.80-4.60 (m, 2H), 4.54 (m, 1H), 4.16 (m, 1H), 4.00 (s, 3H), 3.97-3.77 (m, 3H), 3.65 (s, 3H), 3.52 (s, 3H), 3.50-3.42 (m, 1H), 3.40 (s, 1H), 3.38 (s, 2H), 3.10-3.00 (m, 1H), 2.65-2.50 (m, 4H), 2.38-2.20 (m, 2H), 2.14-1.80 (8xs), 1.78-1.70 (m, 6H), -2.10 (brs, 1H), -2.23 (brs, 1H).

[0251] Step 6: To a 50 mL RBF was added phyllochlorin β-D-glucosyl-N-methylpropylamide tetraacetate (250 mg, 0.275 mmol, 1 equiv.), THF (15 mL), osmium tetroxide (0.7 mg, 0.003 mmol, 0.01 equiv.), deionized water (1 mL), AcOH (1 mL), and sodium periodate (123 mg, 0.577 mmol, 2.1 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen in the dark at ambient temperature overnight. The reaction mixture was concentrated using a rotary evaporator to remove THF, then redissolved in DCM (50 mL), transferred to a separatory funnel, washed with brine (30 mL), saturated NaHCO (30 mL), and water (40 mL), then dried (Na SO ) and concentrated by rotary evaporation to give a reddish-brown powdery solid (220 mg). The intermediate aldehyde, phyllochlorin 13-formyl-β-D-glucosyl-N-methylpropylamidotetraacetate (HPLC purity: 97%), was used without further purification.

[0252] Step 7: To a 100 mL RBF was added phyllochlorin 13-formyl-β-D-glucosyl-N-methylpropylamide tetraacetate (210 mg, 0.230 mmol, 1 equiv.), MeOH (5 mL), DCM (3 mL), and sodium borohydride (17 mg, 0.461 mmol, 2 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen at ambient temperature for 30 minutes. The reaction mixture was diluted with water (10 mL) and stirred for 10 minutes. The mixture was then extracted with chloroform (3 × 10 mL). The combined chloroform layers were washed with water (30 mL), dried (NaSO), and concentrated by rotary evaporation to give a dark green oil (260 mg). The residue was subjected to column chromatography (3 × 16 cm) eluting with a gradient of 1–3% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) was f =0.45) were combined to give compound 11 (95 mg, 38% over two steps).

[0253] 1H NMR (400 MHz, CDCl3) δ 9.90-9.72 (m, 2H), 9.0-8.87 (m, 2H), 6.10-5.83 (m, 2H), 4.92 (m, 1H), 4.78 (brs, 1H), 4.70-4.52 (m, 2H), 4.15 (dd, 1H), 4.07-4.02 (m, 3H), 3.96-3.75 (m, 3H), 3.70-3.60 (m, 3H), 3.40-3.35 (m, 3H), 3.30-3.20 (m, 1H), 3.0 (m, 1H), 2.90 (m, 1H), 2.75 (m, 1H), 2.60-2.50 (m, 3H), 2.20-2.05 (m, 2H), 2.03-1.78 (7xm, 16H), 1.75-1.68 (m, 6H), -2.35 - -2.55 (m, 2H).

[0254] Synthesis Example 1: Synthesis of 2-phyllochlorin 13-hydroxymethyl-β-D-glucoside ether-β-D-glucosyl-N-methylpropylamide (Compound 12) [ka] Step 1: To a 50 mL RBF was added phyllochlorin 13-hydroxymethyl-β-D-glucosyl-N-methylpropylamide tetraacetate (compound 11) (90 mg, 0.098 mmol, 1 equiv.), glucose pentaacetate (58 mg, 0.148 mmol, 1.5 equiv.), and DCM (5 mL). The resulting mixture was stirred (420 rpm) under nitrogen while cooling to approximately 0 °C. Boron trifluoride diethyl etherate (0.2 mL) was added, and stirring was continued. The solution was allowed to slowly warm to room temperature over 2 h, then stirred overnight at room temperature in the dark. The reaction was monitored by HPLC. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel, and washed with saturated NaHCO (15 mL) and then water (20 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to yield a blue-black film (200 mg). The residue was subjected to column chromatography (3 × 16 cm) eluting with a gradient of 1–3% MeOH / DCM to obtain the coupled intermediate (R in 5% MeOH / DCM). f =0.6). The partially purified phyllochlorin 13-hydroxymethyl-β-glucoside ether-β-D-glucosyl-N-methylpropylamide tetraacetate (91 mg) was used directly in the next step.

[0255] Step 2: To a solution of phyllochlorin 13-hydroxymethyl-β-glucoside ether-β-D-glucosyl-N-methylpropylamide tetraacetate (91 mg, 0.073 mmol, 1 equiv.) in MeOH (4 mL) and DCM (2 mL), NaOMe (4.6 M in MeOH, 0.015 mL, 0.073 mmol, 1 equiv.) was added, and the mixture was stirred (420 rpm) under N2 for 1 h with HPLC monitoring. Acetic acid (2 drops) was added, and the reaction was concentrated by rotary evaporation to give a black oil. The residue was purified by column chromatography (3 x 12 cm) eluting with a gradient of 10-20% MeOH / DCM. The major green band (R in 5% MeOH / DCM) was purified. f The fractions containing 1,2-dichloro-2,4 ...

[0256] 1 H NMR (400 MHz, DMSO-d6) δ 9.84 (s, 1H), 9.75 (s, 1H), 9.07 (m, 2H), 6.59 (brs, 1H), 6.21 (brs, 1H), 6.15 (d, 1H), 6.00 (d, 1H), 5.10-4.70 (brm, 12H), 4.70-4.35 (brm, 8H), 4.27 (m, 1H), 4.18 (d, 1H), 4.10 (d, 1H), 3.98 (m, 3H), 3.90 (m, 1H), 3.83 (q, 2H), 3.78-3.60 (m, 8H), 3.51 (m, 4H), 3.22-3.00 (m, 14H), 2.92 (m, 4H), 2.8m (m, 2H), 2.60 (m, 1H), 2.40 (m, 1H), 1.80-1.65 (m, 9H), -2.34 (brs, 1H), -2.52 (brs, 1H).

[0257] Synthesis Example 13-Synthesis of フィロクロリン13-ヒドロキシメチル-N,N-ビス-PEG3OMeプロピルアミド (Compound 13)

change

[0258] 1 H NMR (400 MHz, CDCl3) δ 9.71 (m, 2H), 8.86 (m, 2H), 8.16 (dd, 1H), 6.38 (dd, 1H), 6.15 (dd, 1H), 4.62 (m, 1H), 4.54 (m, 1H), 4.05 (s, 1H), 4.01 (s, 3H), 3.85 (q, 2H), 3.64 (s, 3H), 3.53 (s, 3H), 3.50-3.42 (m, 7H), 3.41-3.36 (m, 9H), 3.30-3.25 (m, 5H), 3.25 (s, 3H), 3.20 (m, 2H), 3.00 (m, 2H), 2.97-2.92 (m, 4H), 2.81 (m, 2H), 2.61-2.42 (m, 2H), 2.21-2.11 (m, 1H), 2.08-2.00 (m, 1H), 1.79-1.72 (m, 6H), -2.11 (brs, 1H), -2.23 (brs, 1H).

[0259] Step 2: To 250 mL of RBF was added phyllochlorin N,N-bis-PEG3OMepropylamide (680 mg, 0.850 mmol, 1 equiv.), THF (30 mL), osmium tetroxide (2 mg, 0.008 mmol, 0.01 equiv.), deionized water (2 mL), AcOH (2 mL), and sodium periodate (454 mg, 2.125 mmol, 2.5 equiv.). The resulting mixture was stirred (300 rpm) under nitrogen in the dark at ambient temperature overnight. The reaction mixture was concentrated using a rotary evaporator to remove THF, then redissolved in DCM (100 mL), transferred to a separatory funnel, washed with brine (30 mL), saturated NaHCO3 (30 mL), and water (40 mL), then dried (Na2SO4), and concentrated by rotary evaporation to give a reddish-brown oil (760 mg). The intermediate aldehyde, phyllochlorin 13-formyl-N,N-bis-PEG3OMe-propylamide (HPLC purity: 97%), was used without further purification.

[0260] Step 3: To a 100 mL RBF was added phyllochlorin 13-formyl-N,N-bis-PEG3OMe-propylamide (682 mg, 0.850 mmol, 1 equiv.), MeOH (15 mL), DCM (10 mL), and sodium borohydride (64 mg, 1.701 mmol, 2 equiv.). The resulting mixture was stirred (300 rpm) under nitrogen at ambient temperature for 1 h. The reaction mixture was diluted with water (25 mL) and stirred for 10 min. The mixture was then diluted with chloroform (20 mL), washed with brine (20 mL), dried (Na2SO4), and concentrated by rotary evaporation to give a dark green oil (790 mg). The residue was subjected to column chromatography (4 x 18 cm) eluting with a gradient of 1-6% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) was f =0.20) were combined to give compound 13 (496 mg, 73% over two steps) (HPLC purity: 96%).

[0261] 1H NMR (400 MHz, CDCl3) δ 9.71 (m, 2H), 8.86 (m, 2H), 5.98 (m, 2H), 4.65 (m, 1H), 4.54 (m, 1H), 4.02 (s, 3H), 3.84 (q, 2H), 3.64 (s, 3H), 3.53 (s, 3H), 3.48-3.42 (m, 5H), 3.41-3.36 (m, 10H), 3.27-3.24 (m, 9H), 3.13 (m, 2H), 2.90-2.70 (m, 6H), 2.61-2.52 (m, 3H), 2.50-2.35 (m, 2H), 2.26-2.17 (m, 1H), 1.98-1.90 (m, 1H), 1.78-1.73 (m, 1H), -2.19 (brs, 1H), -2.37 (brs, 1H).

[0262] Synthesis Example 1: Synthesis of 4-phyllochlorin 13-hydroxymethyl-β-D-glucoside ether-N,N-bis-PEG3OMepropylamide (Compound 14) [ka] Step 1: To a 50 mL RBF was added phyllochlorin 13-hydroxymethyl-N,N-bis-PEG3OMepropylamide (compound 13) (380 mg, 0.473 mmol, 1 equiv.), glucose pentaacetate (277 mg, 0.709 mmol, 1.5 equiv.), and DCM (10 mL). The resulting mixture was stirred (300 rpm) under nitrogen while cooling to approximately 0 °C. Boron trifluoride diethyl etherate (0.2 mL) was added, and stirring was continued. The solution was allowed to slowly warm to room temperature over 2 h, then stirred at room temperature overnight in the dark. The reaction was monitored by HPLC. The reaction mixture was diluted with saturated NaHCO3 (20 mL) and stirred for 10 min. The mixture was transferred to a separatory funnel and extracted with DCM (2 × 10 mL). The combined DCM layers were washed with water (20 mL), and the organic phase was dried (NaSO) and concentrated by rotary evaporation to give a blue-black film (750 mg). The residue was subjected to column chromatography (3 x 18 cm) eluting with a gradient of 1-3% MeOH / DCM to obtain the product (R in 5% MeOH / DCM). f =0.35). The partially purified phyllochlorin 13-hydroxymethyl-β-glucoside ether N,N-bis-PEG3OMepropylamide tetraacetate (330 mg) was used directly in the next step.

[0263] Step 2: To a solution of phyllochlorin 13-hydroxymethyl-β-glucoside ether N,N-bis-PEG3OMe propylamide tetraacetate (320 mg, 0.282 mmol, 1 equiv.) in MeOH (4 mL) and DCM (3 mL), NaOMe (4.6 M in MeOH, 0.061 mL, 0.282 mmol, 1 equiv.) was added, and the mixture was stirred (300 rpm) under N2 overnight. Acetic acid (1 drop) was added, and the reaction was concentrated by rotary evaporation to give a black oil. The residue was purified by column chromatography (3 x 16 cm) eluting with a gradient of 5-10% MeOH / DCM. The green spot (R in 5% MeOH / DCM) f =0.1) were combined to give compound 14 as a dark green solid (130 mg, 28% over two steps).

[0264] 1 H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 9.75 (s, 1H), 9.07 (m, 2H), 6.15 (d, 1H), 6.00 (d, 1H), 5.11 (d, 1H), 4.95 (m, 2H), 4.83 (m, 1H), 4.66-4.54 (m, 3H), 3.98 (s, 3H), 3.90 (m, 1H), 3.83 (q, 2H), 3.72-3.65 (m, 2H), 3.63 (s, 3H), 3.51 (m, 4H), 3.45-3.38 (m, 11H), 3.30-3.25 (m, 6H), 3.22 (m, 5H), 3.13 (s, 3H), 3.10 (s, 3H), 2.88-2.78 (m, 1H), 2.45-2.38 (m, 1H), 1.80-1.65 (m, 7H), -2.34 (brs, 1H), -2.52 (brs, 1H).

[0265] Synthesis Example 15-Synthesis of Phyllochlorin 13-hydroxymethyl-β-D-1-glucose-2-ethoxy-N-ethanaminetetraacetate (Compound 15) [ka] Step 1: A three-necked 100 mL RBF was charged with (2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-(2-azidoethoxy)ethoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (1.00 g, 2.167 mmol, 1 equiv.), 10% Pd / C (25 mg), methanol (100 mL), and a stir bar. A hydrogen balloon was attached, and the flask was evacuated and refilled with nitrogen (three times), and evacuated and refilled with hydrogen (twice). The resulting solution was then stirred (550 rpm) under a hydrogen atmosphere for 1 hour. The solution was filtered through Celite® (0.5 × 3 cm), washed with DCM (approximately 30 mL), and the solvent was then removed under reduced pressure to give 1.02 g of crude amine product, which was used directly in the next step.

[0266] Step 2: To a 50 mL RBF was added phyllochlorin (0.85 g, 1.67 mmol, 1 equiv.), PyBOP (1.04 g, 2.01 mmol, 1.2 equiv.), DCM (20 mL), and triethylamine (1.39 mL, 10.03 mmol, 6 equiv.). The resulting mixture was stirred (250 rpm) under nitrogen at ambient temperature for 15 minutes, and then the amine (1.02 g) in DCM (5 mL) was added in one portion. The resulting mixture was stirred overnight in the dark under nitrogen. The reaction mixture was diluted with DCM (30 mL), transferred to a separatory funnel, and washed with 1 M HCl (2 × 75 mL) followed by pH 7 buffer (1 × 100 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to give a blue / black oil (approximately 2.5 g), which was purified by column chromatography (4 x 25 cm silica) eluting with 1% to 2.5% MeOH / DCM. The product-containing fractions (R in 5% MeOH / DCM) were f Approximately 0.4%) were mixed to give phyllochlorin β-D-1-glucose-N-ethoxyethylamide tetraacetate as a blue / black solid (0.65 g, 42%), which was deprotected without further purification.

[0267] Step 3: To a 100 mL RBF was added phyllochlorin β-D-1-glucose-N-ethoxyethylamide tetraacetate (290 mg, 0.313 mmol, 1 equiv.), THF (15 mL), osmium tetroxide (1.2 mg, 0.005 mmol, 0.01 equiv.), deionized water (1 mL), AcOH (1 mL), and sodium periodate (167 mg, 0.782 mmol, 2.5 equiv.). The resulting mixture was stirred (300 rpm) under nitrogen in the dark at ambient temperature overnight. The reaction mixture was concentrated using a rotary evaporator to remove THF and then redissolved in DCM (50 mL). The mixture was transferred to a separatory funnel and washed with brine (30 mL), saturated NaHCO3 (30 mL), and water (40 mL), then dried (Na2SO4) and concentrated by rotary evaporation to give phyllochlorin 13-formyl-β-D-1-glucose-2-ethoxy-N-ethanaminetetraacetate as a reddish-brown oil (270 mg), which was used without further purification.

[0268] Step 4: To a 100 mL RBF was added phyllochlorin 13-formyl-β-D-1-glucose-2-ethoxy-N-ethanamine tetraacetate (270 mg, 0.291 mmol, 1 equiv.), MeOH (6 mL), DCM (4 mL), and sodium borohydride (22 mg, 0.582 mmol, 2 equiv.). The resulting mixture was stirred (300 rpm) at ambient temperature under nitrogen for 30 min. The reaction mixture was diluted with water (10 mL) and stirred for 10 min. The mixture was then extracted with chloroform (3 × 10 mL). The combined chloroform layers were washed with water (30 mL), dried (NaSO), and concentrated by rotary evaporation to give a dark green oil (approximately 500 mg). The residue was subjected to column chromatography (3 × 16 cm) eluting with a gradient of 1–4% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) f =0.25) were combined to give compound 15 (160 mg, 55% over two steps).

[0269] 1 H NMR (400 MHz, CDCl3) δ 9.74 (s, 1H), 0.58 (s, 1H), 8.88 (m, 2H), 5.77 (q, 2H), 5.51 (m, 1H), 4.88 (m, 2H), 4.79 (m, 1H), 4.65 (m, 1H), 4.56 (m, 1H), 4.01 (m, 4H), 3.88-3.80 (m, 3H), 3.70 (m, 1H), 3.64 (s, 3H), 3.59 (m, 1H), 3.51-3.44 (m, 4H), 3.30 (s, 3H), 3.20-3.10 (m, 5H), 3.05 (m, 3H), 2.60 (m, 1H), 2.30-2.10 (m, 3H), 1.95 (s, 3H), 1.94 (s,3H), 1.91 (s, 3H), 1.83 (s, 3H), 1.80 (m, 3H), 1.73 (t, 4H), -2.32 (brs, 1H), -2.41 (brs, 1H).

[0270] Synthesis Example 16: Synthesis of phyllochlorin 13-hydroxymethyl-β-D-glucoside ether-β-D-1-glucose-2-ethoxy-N-ethanamine (Compound 16) [ka] Step 1: To a 50 mL RBF was added phyllochlorin 13-hydroxymethyl-β-D-1-glucose-2-ethoxy-N-ethanaminetetraacetate (compound 15) (150 mg, 0.161 mmol, 1 equiv.), glucose pentaacetate (94 mg, 0.242 mmol, 1.5 equiv.), and DCM (8 mL). The resulting mixture was stirred (300 rpm) under nitrogen while cooling to approximately 0 °C. Boron trifluoride diethyl etherate (0.2 mL) was added, and stirring was continued. The solution was allowed to slowly warm to room temperature over 2 h, then stirred overnight at room temperature in the dark. The reaction was monitored by HPLC. The reaction mixture was diluted with saturated NaHCO3 (20 mL) and stirred for 10 min. The mixture was transferred to a separatory funnel, extracted with DCM (3 × 10 mL), and washed with water (20 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to give a blue-black film (360 mg). The residue was subjected to column chromatography (3 x 15 cm) eluting with a gradient of 1-3% MeOH / DCM. The intermediate coupled product (R in 5% MeOH / DCM) was obtained. f = 0.4) were combined to give partially purified phyllochlorin 13-hydroxymethyl-β-glucoside ether β-D-1-glucose-2-ethoxy-N-ethanamine peracetate (75 mg), which was used directly in the next step.

[0271] Step 2: To a solution of phyllochlorin 13-hydroxymethyl-β-glucoside ether β-D-1-glucose-2-ethoxy-N-ethanamine peracetate (75 mg, 0.060 mmol, 1 equiv.) in MeOH (3 mL) and DCM (1.5 mL), NaOMe (4.6 M in MeOH, 0.012 mL, 0.060 mmol, 1 equiv.) was added, and the mixture was stirred (300 rpm) under N for 2 h. Acetic acid (1 drop) was added, and the reaction was concentrated by rotary evaporation to give a dark green oil. The residue was purified by column chromatography (3 x 12 cm) eluting with a gradient of 10–20% MeOH / DCM. Fractions containing the major green compound were combined to give compound 16 as a dark green solid (26 mg, 17% over two steps).

[0272] 1 H NMR (400 MHz, DMSO-d6) δ 9.84 (s, 1H), 9.74 (s, 1H), 9.08 (m, 2H), 8.01 (m, 1H), 6.59 (m, 1H), 6.22 (m, 1H), 6.16 (d, 1H), 6.00 (d, 1H), 5.11 (m, 1H), 5.05-4.79 (m, 13H), 4.70-4.60 (m, 4H), 4.50 (m, 5H), 4.40 (m, 1H), 4.26 (m, 1H), 4.20-4.10 (m, 4H), 3.94 (m, 5H), 3.83 (m, 4H), 3.70-3.60 (m, 10H), 3.60-3.50 (m, 11H), 3.30-3.10 (m, 19H), 3.05 (m, 6H), 2.98-2.85 (m, 3H), 2.40 (m, 1H), 1.78-1.68 (m, 8H), -2.36 (brs, 1H), -2.54 (brs, 1H).

[0273] Synthesis Example 17 - Synthesis of phyllochlorin 13-hydroxymethyl (compound 17) [ka] To a 250 mL RBF was added phyllochlorin 13-hydroxymethylmethyl ester (compound 3) (810 mg, 1.538 mmol, 1 equiv.), acetone (25 mL), and 15% w / v potassium hydroxide (50 mL). The resulting mixture was stirred (300 rpm) under nitrogen at 40 °C for 1 h. The reaction mixture was concentrated on a rotary evaporator to remove acetone, and then DCM (50 mL) was added to the aqueous residue. The mixture was acidified to pH 5 using 1 M HCl (approximately 50 mL), and the DCM layer was collected. The aqueous layer was further extracted with DCM (2 × 20 mL), and the combined DCM layers were washed with water (50 mL) and then with pH 7 phosphate buffer (30 mL). The DCM layer was collected, dried (NaSO), and concentrated by rotary evaporation to give compound 17 as a dark green solid (790 mg, quantitative) (HPLC purity: 99.0%).

[0274] 1 H NMR (400 MHz, CDCl3) δ 9.69 (s, 1H), 9.51 (s, 1H), 8.81 (s, 2H), 5.73 (s, 2H), 4.58 (m, 1H), 4.48 (m, 1H), 3.94 (s, 3H), 3.79 (q, 2H), 3.60 (s, 3H), 3.48 (s, 3H), 3.27 (s, 3H), 2.54-2.42 (m, 2H), 2.17 (m, 1H), 2.14-2.00 (m, 2H), 1.76 (d, 3H), 1.71 (t, 3H), -2.42 (brs, 1H).

[0275] Synthesis Example 18: Synthesis of phyllochlorin ((3-(3-(methylamino)propoxy)propyl)triphenylphosphonium chloride propylamide 13-hydroxymethyl (Compound 18) [ka] To a 50 mL RBF was added phyllochlorin 13-hydroxymethyl (compound 17) (200 mg, 0.390 mmol, 1 equiv.), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) (140 mg, 0.507 mmol, 1.3 equiv.), DCM (8 mL), and (3-(3-(methylamino)propoxy)propyl)triphenylphosphonium chloride (270 mg, 0.467 mmol, 1.2 equiv.) predissolved in DCM (2 mL). The resulting mixture was stirred (300 rpm) under nitrogen at ambient temperature (approximately 25 °C) for 2 h. Triethylamine (0.1 mL, 0.721 mmol, 1.8 equiv.) was added, and the mixture was stirred at room temperature overnight. The reaction was monitored by HPLC. The mixture was diluted with DCM (15 mL), washed successively with water (15 mL), 0.05 M HCl (15 mL), and brine (15 mL), then dried (Na2SO4) and concentrated by rotary evaporation to give a blue-black film (0.6 g). The residue was subjected to column chromatography (3 x 18 cm) eluting with a gradient of 5-10% MeOH / DCM. The major green spot (R in 5% MeOH / DCM) f The fractions containing 1H 2 O (<0.1) were combined to give compound 18 (68 mg, 19%) (HPLC purity: 99.7%).

[0276] 1H NMR (400 MHz, CDCl3) δ 9.88-9.68 (m, 2H), 8.82 (m, 2H), 7.62-7.55 (m, 2H), 7.54-7.50 (m, 2H), 7.45-7.32 (m, 7H), 7.30-7.22 (m, 2H), 6.18-5.90 (m, 2H), 4.71-4.41 (m, 2H), 3.96 (m, 3H), 3.82 (m, 2H), 3.62 (s, 3H), 3.55-3.50 (m, 2H), 3.35-3.25 (m, 2H), 3.20 (s, 2H), 3.18-2.95 (m, 2H), 2.50-2.40 (m, 2H), 2.40-2.35 (m, 1H), 2.28 (s, 2H), 2.18 (s, 1H), 2.08-1.95 (m, 1H), 1.90-1.75 (m, 2H), 1.75-1.60 (m, 13H), 1.40-1.30 (m, 2H), 1.08-0.88 (m, 1H), 0.70-0.45 (m, 2H), -2.16 (brs, 1H), -2.28 (brm, 1H).

[0277] Synthesis Example 19: Synthesis of phyllochlorin 13-hydroxymethyl-β-D-glucoside ether ((3-(3-(methylamino)propoxy)propyl)triphenylphosphonium chloride propylamide (Compound 19) [ka] Step 1: To a 50 mL RBF was added phyllochlorin ((3-(3-(methylamino)propoxy)propyl)triphenylphosphonium chloride propylamide 13-hydroxymethyl (compound 18) (68 mg, 0.0737 mmol, 1 equiv.), glucose pentaacetate (43 mg, 0.111 mmol, 1.5 equiv.), and DCM (3 mL). The resulting mixture was stirred (420 rpm) under nitrogen while cooling to approximately 0 °C. Boron trifluoride diethyl etherate (0.1 mL) was added, and stirring was continued, allowing the solution to slowly warm to room temperature over 2 h. The reaction mixture was then stirred at room temperature in the dark overnight. The reaction was then quenched with H The reaction mixture was monitored by PLC. The reaction mixture was diluted with DCM (15 mL), water (10 mL), and saturated NaHCO3 (5 mL) and stirred for 10 min. The mixture was transferred to a separatory funnel, extracted with DCM (2 × 10 mL), washed with water (20 mL), and the organic phase was dried (Na2SO4) and concentrated by rotary evaporation to yield a blue-black film (approximately 200 mg). The resulting residue was subjected to column chromatography (3 × 16 cm) eluting with a gradient of 2–3.5% MeOH / DCM. The major green band was collected to yield partially purified phyllochlorin-β-glucoside ether tetraacetate (approximately 80 mg), which was used directly in the next step.

[0278] Step 2: To a solution of phyllochlorin-β-glucoside ether tetraacetate (80 mg, 0.0639 mmol, 1 equiv.) in MeOH (2 mL) and DCM (2 mL), NaOMe (4.6 M in MeOH, 0.007 mL, 0.0319 mmol, 0.5 equiv.) was added, and the mixture was stirred (420 rpm) under N2 for 1 h. The reaction was concentrated by rotary evaporation to give a black film. The residue was purified by column chromatography (3 x 16 cm) eluting with a gradient of 8–12% MeOH / DCM. Fractions containing the major green band were combined to give compound 19 as a dark green solid (22 mg, 28% over two steps).

[0279] 1H NMR (400 MHz, DMSO-d6) δ 9.85 (m, 1H), 9.76 (m, 1H), 9.05 (m, 2H), 7.72-7.55 (m, 15H), 6.17 (m, 1H), 6.00 (m, 1H), 5.10 (d, 1H), 4.94 (m, 2H), 4.81 (m, 1H), 4.63-4.53 (m, 3H), 4.10 (q, 2H), 3.95-3.88 (m, 4H), 3.83 (m, 2H), 3.72-3.65 (m, 1H), 3.63 (m, 3H), 3.50 (m, 5H), 3.30-3.20 (m, 4H), 3.18 (m, 8H), 3.12 (m, 2H), 3.05 (m, 1H), 2.86 (s, 2H), 2.75 (s, 1H), 2.40-2.30 (m, 1H), 1.73-1.65 (m, 9H), 1.60-1.50 (m, 3H), -2.33 (s, 1H), -2.51 (s, 1H).

[0280] Synthesis Example 20 - Synthesis of phyllochlorin methyl ester 3-pyridinium bromide propyl ether (Compound 20) [ka] Step 1: To a 50 mL RBF containing phyllochlorin methyl ester (0.50 g, 0.957 mmol, 1 equiv.) and a stir bar, HBr / AcOH (33% w / w, 5 mL) was added, and the dark blue mixture was stirred (300 rpm) under nitrogen at 30 °C for 2 h. A stream of nitrogen was passed through the sample for several minutes to remove some of the HBr, and the bulk was concentrated by rotary evaporation. The mixture was then heated under high vacuum (0.6 mbar) at 40 °C for 30 min to further dry. The residue was reconstituted in DCM (20 mL), followed by the addition of powdered K2CO3 (1.32 g, 9.57 mmol, 10 equiv.) followed by 3-bromo-propan-1-ol (1.22 mL, 14.35 mmol, 15 equiv.). The system was flushed with nitrogen, stoppered with a rubber septum, and the solution was stirred overnight at 30 °C in the dark under a nitrogen atmosphere. The reaction mixture was transferred to a separatory funnel and washed with HO (50 mL) and then brine (50 mL), before drying (NaSO) and concentrating by rotary evaporation to give the crude ether as a dark green oil (approximately 2.1 g). The residue was further dried under high vacuum (0.3 mBar) for 30 min with heating at 40-50 °C, leaving 0.95 g of a dark green residue. The residue was purified by column chromatography (4 x 18 cm) using 0-2% MeOH / DCM. The major dark green spot (R in 1% MeOH / DCM) f =0.6) were combined to give phyllochlorin methyl ester 3-bromopropyl ether as a dark green solid (305 mg, 51%).

[0281] 1H NMR (400 MHz, CDCl3) δ 9.95-9.73 (m, 2H), 8.88-8.80 (m, 2H), 6.04 (q, 1H), 4.60-4.47 (m, 2H), 3.99 (s, 3H), 3.90-3.80 (m, 3H), 3.78-3.70 (m, 2H), 3.66 (s, 3H), 3.58 (s, 3H), 3.55-3.50 (m, 4H), 3.39 (s, 3H), 2.60-2.47 (m, 2H), 2.30-2.20 (m, 2H), 2.18-2.14 (m, 3H), 2.14-2.00 (m, 2H), 1.81-1.75 (m, 6H), -2.15 (brs, 1H), -2.27 (brs, 1H).

[0282] Step 2: To a sealed tube (2.5 x 20 cm, with a Teflon screw cap) containing phyllochlorin methyl ester 3-bromopropyl ether (0.100 g, 0.151 mmol, 1 equiv.) and a stir bar, MeCN (5 mL) and pyridine (60 mg, 0.756 mmol, 5 equiv.) were added. After flushing the tube with nitrogen and sealing it, the dark green mixture was stirred (300 rpm) at 80 °C for 2 h and then at 90 °C for an additional 17 h. The mixture was cooled, diluted with DCM (25 mL), washed with 0.05 M HCl (20 mL), dried (NaSO), and concentrated by rotary evaporation to give the crude product as a dark green oil (113 mg). The residue was purified by column chromatography (3 x 15 cm) eluting with a gradient of 3-15% MeOH / DCM. The major green band (R in 10% MeOH / DCM) was f =0.1) were combined to give compound 20 as a dark green solid (70 mg, 74%) (HPLC purity: 97.8%).

[0283] 1H NMR (400MHz, CDCl3) δ 9.75 (m, 2H), 8.85 (m, 2H), 8.37 (dd, 2H), 6.66 (dt, 1H), 6.25 (m, 2H), 5.80 (m, 1H), 4.85 (m, 1H), 4.60-4.47 (m, 3H), 3.99 (s, 3H), 3.90-3.80 (m, 3H), 3.64 (s, 3H), 3.56 (m, 3H), 3.45-3.35 (m, 4H), 3.30 (m, 3H), 2.65-2.45 (m, 2H), 2.30-2.15 (m, 2H), 2.10 (m, 3H), 2.1-1.95 (m, 2H), 1.90-1.70 (m, 10H), -2.32 (brs, 1H), -2.38 (brs, 1H).

[0284] Synthesis Example 21 - Synthesis of phyllochlorin methyl ester 3-triphenylphosphonium bromide propyl ether (Compound 21) [ka]

[0285] To a sealed tube (2.5 x 20 cm, with a Teflon screw cap) containing phyllochlorin methyl ester 3-bromopropyl ether (0.100 g, 0.151 mmol, 1 equiv.) and a stir bar was added MeCN (5 mL), triphenylphosphine (44 mg, 0.166 mmol, 1.1 equiv.), and sodium iodide (4.5 mg, 0.030 mmol, 0.2 equiv.). The tube was flushed with nitrogen and, after sealing, the dark green mixture was stirred (300 rpm) at 90 °C for 22 h. The mixture was cooled, transferred to a RBF, and concentrated by rotary evaporation to give the crude product as a dark green oil. The residue was purified by column chromatography (3 x 16 cm), eluting with a gradient of 2-5% MeOH / DCM. The major green band (R in 5% MeOH / DCM) was f =0.15) were combined to give compound 21 as a dark green solid (102 mg, 86%) (HPLC purity: 98.0%).

[0286] 1 H NMR (400 MHz, CDCl3) δ 9.81 (s, 1H), 9.72 (s, 1H), 8.87 (s, 1H), 8.80 (s, 1H), 7.70-7.18 (m, 15H), 5.98 (q, 1H), 4.60-4.49 (m, 2H), 4.24 (m, 1H), 3.99 (s, 3H), 3.90-3.75 (m, 2H), 3.75-3.65 (m, 5H), 3.63-3.55 (m, 3H), 3.52-3.40 (m, 4H), 3.13 (m, 3H), 2.68-2.45 (m, 2H), 2.20 (m, 3H), 2.18-1.93 (m, 4H), 1.82-1.70 (m, 6H), -2.21 (brm, 1H), -2.28 (brm, 1H).

[0287] Synthesis Example 22 - Synthesis of phyllochlorin methyl ester 2-(2-pyridiniumethoxy)ethyl ether chloride (Compound 22) [ka]

[0288] Step 1: To a 50 mL RBF containing phyllochlorin methyl ester (0.50 g, 0.957 mmol, 1 equiv.) and a stir bar, HBr / AcOH (33% w / w, 5 mL) was added, and the dark blue mixture was stirred (300 rpm) under nitrogen at 30 °C for 2 h. A stream of nitrogen was passed through the sample for several minutes to remove some of the HBr, and then the volume was concentrated by rotary evaporation. The mixture was then heated under high vacuum (0.6 mbar) at 40 °C for 30 min to further dry. The residue was reconstituted in DCM (20 mL), followed by the addition of powdered K2CO3 (1.32 g, 9.57 mmol, 10 equiv.) followed by 2-(2-chloroethoxy)ethanol (1.79 g, 14.35 mmol, 15 equiv.). The system was flushed with nitrogen, stoppered with a rubber septum, and the solution was stirred overnight at 30 °C in the dark under a nitrogen atmosphere. The reaction mixture was transferred to a separatory funnel and washed with HO (50 mL) and then brine (50 mL), before being dried (NaSO) and concentrated by rotary evaporation (60 °C, absolute vacuum, 1 h) to give the crude ether as a dark green oil (approximately 1.1 g). The residue was purified by column chromatography (4 x 18 cm) using 0-2% MeOH / DCM. The major dark green spot (R in 1% MeOH / DCM) f =0.5) were combined to give phyllochlorin methyl ester 2-(2-chloroethoxy)ethyl ether as a dark green solid (310 mg, 50%).

[0289] 1 H NMR (400 MHz, CDCl3) δ 9.95 (s, 1H), 9.74 (s, 1H), 8.86-8.80 (m, 2H), 6.12 (q, 1H), 4.58 (m, 1H), 4.50 (q, 1H), 3.99 (s, 3H), 3.90-3.70 (m, 9H), 3.66 (s, 3H), 3.65-3.60 (m, 2H), 3.58 (m, 3H), 3.51 (s, 3H), 3.38 (s, 3H), 2.60-2.47 (m, 2H), 2.19 (m, 3H), 2.16-2.00 (m, 2H), 1.80-1.73 (m, 6H), -2.15 (brs, 1H), -2.28 (brs, 1H).

[0290] Step 2: To a sealed tube (2.5 × 20 cm, with a Teflon screw cap) containing phyllochlorin methyl ester 2-(2-chloroethoxy)ethyl ether (0.110 g, 0.170 mmol, 1 equiv.) and a stir bar, MeCN (5 mL), pyridine (134 mg, 1.70 mmol, 10 equiv.), and NaI (5 mg, 0.034 mmol, 0.2 equiv.) were added. The tube was flushed with nitrogen, and after sealing, the dark green mixture was stirred (300 rpm) at 95 °C for 16 h. An additional amount of NaI (45 mg, 0.31 mmol, 1.8 equiv.) was added, and the mixture was heated for an additional 24 h. The mixture was cooled, diluted with DCM (25 mL), washed sequentially with 0.05 M HCl (20 mL) and pH 7 phosphate buffer (20 mL), then dried (NaSO) and concentrated by rotary evaporation to give the crude product as a dark green oil. The residue was purified by column chromatography (3 x 15 cm) eluting with a gradient of 3-8% MeOH / DCM. The major green band (R f The fractions containing <0.1 were combined to give compound 22 as a dark green solid (48 mg, 39%) (HPLC purity: 98.5%).

[0291] 1H NMR (400 MHz,CDCl3) δ 10.11 (d, 1H), 9.69 (d, 1H), 8.87-8.80 (m, 2H), 7.12 (d, 1H), 7.05 (d, 1H), 6.31 (m, 1H), 5.81 (q, 1H), 5.23 (m, 2H), 4.64-4.50 (m, 3H), 3.99 (s, 3H), 3.88-3.75 (m, 4H), 3.69 (m, 1H), 3.63 (s, 3H), 3.60-3.55 (m, 3H), 3.51-3.45 (m, 3H), 3.42 (s, 3H), 3.38-3.27 (m, 5H), 2.69-2.45 (m, 2H), 2.26 (m, 3H), 2.22-1.94 (m, 3H), 1.84 (m, 1H), 1.76-1.65 (m, 6H) -2.21 (brm, 1H), -2.34 (brm, 1H).

[0292] Synthesis Example 23 - Synthesis of phyllochlorin methyl ester 2-(2-triphenylphosphonium ethoxy)ethyl ether chloride (Compound 23) [ka]

[0293] To a sealed tube (2.5 x 20 cm, with a Teflon screw cap) containing phyllochlorin methyl ester 2-(2-chloroethoxy)ethyl ether (120 mg, 0.185 mmol, 1 equiv.) and a stir bar was added MeCN (5 mL), triphenylphosphine (53 mg, 0.204 mmol, 1.1 equiv.), and sodium iodide (42 mg, 0.278 mmol, 1.5 equiv.). After flushing the tube with nitrogen and sealing it, the dark green mixture was stirred (300 rpm) at 90 °C for 72 h with HPLC monitoring. The mixture was cooled, transferred to a RBF, and concentrated by rotary evaporation to give the crude product as a dark green oil. The residue was purified by column chromatography (3 x 14 cm), eluting with a gradient of 2-3% MeOH / DCM. The major green band (R in 5% MeOH / DCM) wasf =0.15) were combined to give compound 23 as a dark green solid (108 mg, 64%) (HPLC purity: 96.4%).

[0294] 1 H NMR (400 MHz, CDCl3) δ 9.88 (s, 1H), 9.70 (s, 1H), 8.86-8.82 (m, 2H), 7.68 (m, 1H), 7.52-7.38 (m, 11H), 7.30-7.23 (m, 8H), 5.80 (q, 1H), 4.60-4.49 (m, 2H), 3.99 (s, 3H), 3.97-3.75 (m, 5H), 3.64 (m, 4H), 3.60-3.55 (m, 3H), 3.50-3.40 (m, 6H), 3.38-3.29 (m, 4H), 2.65-2.55 (m, 2H), 2.20-2.00 (m, 6H), 1.81-1.70 (m, 7H), -2.19 (brs, 1H), -2.31 (brs, 1H).

[0295] Synthesis Example 2: Synthesis of 4-phyllochlorin 13-hydroxymethyl N-methyl-N-3,6,9,12,15,18-hexaoxanonadecylpropylamide (Compound 24) [ka]

[0296] Step 1: To a 50 mL RBF equipped with a nitrogen inlet was added phyllochlorin (500 mg, 0.983 mmol, 1 equiv.), dichloromethane (15 mL), DMTMM (354 mg, 1.28 mmol, 1.3 equiv.), and N-methyl-3,6,9,12,15,18-hexaoxanonadecan-1-amine (365 mg, 1.18 mmol, 1.2 equiv.). The mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with DCM (15 mL) and washed with 0.5 M HCl (20 mL) and pH 7 buffer (20 mL). The organic layer was then dried (NaSO), filtered through Celite®, and concentrated by rotary evaporation to give the crude product as a dark blue viscous oil (0.86 g). The crude mixture was loaded directly onto a silica column (4 x 20 cm, pre-equilibrated with 1% MeOH / DCM) and eluted with the same solvent until the first light-colored band eluted. Then, once the darkest blue / green band began to elute, the solvent was incrementally changed to 1-3% MeOH / DCM. The product (major dark green-blue spot, R) was obtained in 5% MeOH in DCM. f =0.35) were combined and concentrated by rotary evaporation to give phyllochlorin N-methyl-N-3,6,9,12,15,18-hexaoxanonadecylpropylamide as a dark blue viscous oil (750 mg, 95%).

[0297] 1H NMR (400 MHz, CDCl3) δ 9.76-9.65 (m, 2H), 8.91-8.77 (m, 2H), 8.17 (dd, J = 17.8, 11.5 Hz, 1H), 6.38 (dd, J = 17.8, 1.6 Hz, 1H), 6.15 (dd, J = 11.5, 1.6 Hz, 1H), 4.70-4.62 (m, 1H), 4.54 (q, J = 7.2 Hz, 1H), 4.04-3.98 (m, 3H), 3.91-3.77 (m, 2H), 3.67-3.60 (m, 4H), 3.60-3.40 (m, 20H), 3.40-3.35 (m, 5H), 3.34 (s, 3H), 3.26-3.20 (m, 1H), 3.02-2.95 (m, 1H), 2.96-2.89 (m, 1H), 2.86-2.78 (m, 1H), 2.75 (s, 1H), 2.66-2.49 (m, 1H), 2.46 (s, 2H), 2.25-2.12 (m, 1H), 2.06-1.86 (m, 1H), 1.81-1.71 (m, 6H), 1.64 (s, 3H), -2.10 (s, 1H), -2.23 (s, 1H).

[0298] Step 2: To a 50 mL RBF was added phyllochlorin N-methyl-N-3,6,9,12,15,18-hexaoxanonadecylpropylamide (660 mg, 0.825 mmol, 1 equiv.), THF (15 mL), osmium tetroxide (2 mg, 0.008 mmol, 0.01 equiv.), deionized water (1 mL), AcOH (1 mL), and sodium periodate (441 mg, 2.06 mmol, 2.5 equiv.). The resulting mixture was stirred (400 rpm) under nitrogen in the dark at ambient temperature overnight. The reaction mixture was concentrated using a rotary evaporator to remove the THF, then redissolved in DCM (75 mL), transferred to a separatory funnel, washed with brine (30 mL), saturated NaHCO (30 mL), and water (40 mL), then dried (NaSO) and concentrated by rotary evaporation to give phyllochlorin 13-formyl-N-methyl-N-3,6,9,12,15,18-hexaoxanonadecylpropylamide as a reddish-brown powdery solid.

[0299] Step 3: Phyllochlorin 13-formyl-N-methyl-N-3,6,9,12,15,18-hexaoxanonadecylpropylamide (594 mg, 0.741 mmol, 1 equiv.) was added to 50 mL of RBF, MeOH (10 mL), DCM (5 mL), and sodium borohydride (56.0 mg, 1.48 mmol, 2 equiv.). The resulting mixture was stirred (420 rpm) at ambient temperature under nitrogen for 30 minutes. The reaction mixture was diluted with water (20 mL) and stirred for 10 minutes. The mixture was then extracted with DCM (3 × 20 mL). The combined DCM layers were washed with water (20 mL), dried (NaSO), and concentrated by rotary evaporation to give a dark green oil. The dark green oil was purified by silica gel column chromatography using a gradient of 1–7% MeOH / DCM. The product (major dark green spot, R in 5% MeOH / DCM) f =0.28) were combined to give compound 24 as a dark blue solid (231 mg, 35% over two steps).

[0300] 1H NMR (400 MHz, CDCl3) δ 9.75-9.65 (m, 2H), 8.86 (d, J = 3.1 Hz, 2H), 6.01-5.88 (m, 2H), 4.72-4.62 (m, 1H), 4.54 (dd, J = 7.5, 3.0 Hz, 1H), 4.02 (d, J = 3.5 Hz, 3H), 3.82 (q, J = 7.6 Hz, 2H), 3.67-3.61 (m, 3H), 3.60-3.38 (m, 17H), 3.37-3.32 (m, 7H), 3.31-3.27 (m, 1H), 3.15-3.09 (m, 1H), 2.90-2.72 (m, 2H), 2.70 (s, 1H), 2.66 (t, J = 5.0 Hz, 1H), 2.63-2.50 (m, 1H), 2.43 (s, 2H), 2.36 (dt, J = 15.2, 7.5 Hz, 1H), 2.25-2.13 (m, 1H), 1.97-1.84 (m, 1H), 1.81-1.69 (m, 6H), 1.65 (s, 2H), -2.25 (s, 1H), -2.41 (s, 1H).

[0301] Synthesis Example 2: Synthesis of 5-phyllochlorin 13-hydroxymethyl-β-D-glucoside ether-β-D-glucose-N-methyl-N-3,6,9,12,15,18-hexaoxanonadecylpropylamide (Compound 25) [ka]

[0302] Step 1: To a 25 mL RBF was added phyllochlorin 13-hydroxymethyl-N-methyl-N-3,6,9,12,15,18-hexaoxanonadecylpropylamide (compound 24) (200 mg, 0.249 mmol, 1 equiv.), glucose pentaacetate (146 mg, 0.374 mmol, 1.5 equiv.), and DCM (10 mL). The resulting mixture was stirred (420 rpm) under nitrogen while cooling to approximately 0 °C. Boron trifluoride diethyl etherate (0.2 mL) was added, stirring continued, and the solution was allowed to slowly warm to room temperature over 2 h, then stirred at room temperature in the dark for 18 h. Additional glucose pentaacetate (48 mg, 0.125 mmol, 0.5 equiv.) and boron trifluoride diethyl etherate (0.2 mL) were added, and the reaction was stirred for an additional 4 h. The reaction mixture was diluted with DCM (30 mL) and washed with saturated NaHCO (25 mL) and then water (20 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to give a blue-black film. The resulting residue was subjected to column chromatography (3 x 20 cm silica gel). The crude product was dissolved in DCM and eluted using a gradient of 1-6% MeOH / DCM to give phyllochlorin 13-hydroxymethyl-β-D-glucoside ether tetraacetate-β-D-glucose-N-methyl-N-3,6,9,12,15,18-hexaoxanonadecylpropylamide tetraacetate (300 mg) as a dark blue-green viscous syrup.

[0303] Step 2: To a solution of phyllochlorin 13-hydroxymethyl-β-D-glucoside ether tetraacetate-β-D-glucose-N-methyl-N-3,6,9,12,15,18-hexaoxanonadecylpropylamide tetraacetate (294 mg, 0.249 mmol, 1 equiv.) in MeOH (4 mL) and DCM (4 mL), NaOMe (4.6 M in MeOH, 0.054 mL, 0.249 mmol, 1 equiv.) was added, and the mixture was stirred (420 rpm) under N2 for 1 h. The reaction mixture was concentrated by rotary evaporation to give a black film-like residue. The residue was purified by column chromatography (3 x 20 cm silica gel) using an elution gradient of 5-7% MeOH in DCM, followed by 7% → 12% MeOH in DCM. In 10% MeOH / DCM, R f The fractions with HCl = 0.3 were combined to give compound 25 as a dark green viscous syrup (81 mg, 34% in two steps) (HPLC purity: 94.5%).

[0304] 1 H NMR (400 MHz, DMSO-d6) δ 9.86 (s, 1H), 9.76 (s, 1H), 9.07 (s, 2H), 6.08 (dd, J = 59.1, 12.2 Hz, 2H), 5.22-4.74 (m, 5H), 4.70-4.50 (m, 3H), 3.99 (d, J = 3.7 Hz, 3H), 3.92 (d, J = 11.5 Hz, 1H), 3.84 (q, J = 7.5 Hz, 2H), 3.70 (dd, J = 12.0, 5.7 Hz, 1H), 3.63 (s, 3H), 3.52 (s, 3H), 3.47-3.38 (m, 7H), 3.32-3.18 (m, 7H), 3.15 (d, J = 6.9 Hz, 3H), 2.93 (s, 2H), 2.81 (s, 3H), 2.47-2.35 (m, 0H), 1.70 (t, J = 7.8 Hz, 7H), -2.36 (s, 1H), -2.53 (s, 1H).

[0305] Synthesis Example 26 - Synthesis of 13-hydroxyethylphyllochlorin-β-D-1-thioglucose-N-methylpropylamide (Compound 26) [ka]

[0306] To a solution of (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-((3-((tert-butoxycarbonyl)(methyl)amino)propyl)thio)tetrahydro-2H-pyran-3,4,5-triyl triacetate (0.612 g, 1.14 mmol, 1.4 equiv) in DCM (5 mL) was added TFA (1 mL). The resulting solution was stirred (420 rpm) at ambient temperature for 1 h and then concentrated by rotary evaporation. The residue was resuspended and concentrated twice from chloroform (2 × 10 mL) to give a viscous oil, which was dissolved in DCM (2 mL) for the subsequent coupling reaction. To a 25 mL RBF was added phyllochlorin 13-(ethyl-1-acetate) (0.45 g, 0.791 mmol, 1 equiv.), PyBOP (0.494 g, 0.749 mmol, 1.2 equiv.), DCM (6 mL), and triethylamine (0.66 mL, 4.74 mmol, 6 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen at ambient temperature for 30 min, and then a prepared solution of the deprotected amine in DCM (2 mL) was added in one portion. The resulting mixture was stirred overnight. The reaction mixture was transferred to a separatory funnel and washed with 1 M HCl (2 × 10 mL) followed by pH 7 buffer (1 × 10 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to yield a blue-black film (approximately 1.15 g). The residue was purified by column chromatography (3x25cm) using 2-3% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) fFractions containing the major dark green spot (Rf = 0.6 in 10% MeOH / DCM) were combined to give compound 26 as a dark blue-black solid (398 mg, 54%). The solid was dissolved in a mixture of MeOH (5 mL) and DCM (5 mL), and NaOMe (4.6 M in MeOH, 0.43 mL, 1.98 mmol, 5 equiv.) was added. The mixture was stirred (200 rpm) under nitrogen for 90 min. The reaction was quenched with AcOH (4.11 mL, 71.81 mmol, 10 equiv.) and concentrated by rotary evaporation to give a black film. The residue was purified by column chromatography (3 × 21 cm) using 3–12% MeOH / DCM. Fractions containing the major dark green spot (Rf = 0.85 in 10% MeOH / DCM) were combined to give compound 26 as a dark blue-black solid (255 mg, 83%).

[0307] 1 H NMR (400 MHz, d6-DMSO) δ 10.05 (m, 1H), 9.74 (s, 1H), 9.05 (s, 1H), 9.00 (d, 1H), 6.41 (m, 1H), 6.10 (s, 1H), 5.20-4.91 (m, 3H), 4.64 (m, 1H), 4.58-4.47 (m, 2H), 4.28 (dd, 1H), 4.11 (q, 1H), 3.98 (d, 3H), 3.82 (q, 2H), 3.63 (brs, 3H), 3.50 (d, 3H), 3.20-3.15 (m, 2H), 3.15-3.05 (m, 2H), 2.90 (s, 2H), 2.81 (s, 1H), 2.70-2.53 (m, 2H), 2.42 (m, 1H), 2.03 (m, 3H), 1.81 (m, 1H), 1.75-1.61 (m, 8H), -2.34 (s, 1H), -2.43 (s, 1H).

[0308] Synthesis Example 27 - Synthesis of phyllochlorin 13-(ethyl-1-alcohol) (Compound 27) [ka]

[0309] Step 1: To a 50 mL RBF equipped with a gas inlet / outlet, a condenser with a bubbler, and a stir bar, was added phyllochlorin (500 mg, 9.87 mmol, 1 equiv.) and acetic acid (15 mL). The flask was then heated at 130 °C with stirring (400 rpm) overnight in the dark. After 27 h, the reaction was cooled and concentrated on a rotary evaporator to give a blue solid. This material was suspended in DCM (50 mL), washed with water (80 mL), dried (NaSO), filtered, and evaporated to give a dark blue glassy solid (1.1 g). The residue was purified by column chromatography (4 x 12 cm) using 2% MeOH / DCM. R in 5% MeOH / DCM was added. f Fractions containing a dark green spot at 0.3 were combined to give phyllochlorin 13-(ethyl-1-acetate) as a dark green solid (20 mg, 4%).

[0310] 1 H NMR (400 MHz, CDCl3) δ 9.92 (s, 1H), 9.76 (s, 1H), 8.85 (m, 2H), 7.40 (m, 1H), 4.61-4.55 (m, 1H), 4.53-4.46 m, 1H), 3.96 (s, 3H), 3.87 (q, 2H), 3.64 (s, 3H), 3.55 (s, 3H), 3.40 (s, 3H), 2.56-2.45 (m, 2H), 2.25 (m, 6H), 2.12-1.97 (m, 2H), 1.80-1.71 (m, 7H), -2.38 (brs, 1H).

[0311] Step 2: To phyllochlorin 13-(ethyl-1-acetate) (4.14 g, 7.28 mmol, 1 equiv.) in MeOH (40 mL) and DCM (20 mL) was added NaOMe (4.6 M, 2.37 mL, 1.5 equiv.), and the solution was stirred at room temperature for 30 min while being monitored by HPLC. AcOH (656 mg, 10.92 mmol, 1.5 equiv.) was added, and the solvent was removed by rotary evaporation to give a dark blue solid. The residue was subjected to column chromatography (silica gel, 6 x 20 cm) using 2-10% MeOH in DCM as the eluent. The product (major dark green spot, R in 5% MeOH / DCM) was obtained. f The fractions containing 27 (=0.31) were combined and concentrated by rotary evaporation. The solid was dried in a vacuum oven at 60° C. overnight to give compound 27 (1.37 g, 68%) as a dark blue solid (HPLC purity: 97.1%).

[0312] 1 H NMR (400 MHz, CDCl3) δ 9.80-9.53 (m, 2H), 8.85-8.76 (m, 2H), 6.07 (p, J = 6.7 Hz, 1H), 4.62-4.40 (m, 2H), 3.92 (s, 3H), 3.78 (h, J = 8.7, 8.2 Hz, 2H), 3.61-3.53 (m, 3H), 3.32 (d, J = 6.3 Hz, 3H), 3.24 (d, J = 2.0 Hz, 3H), 2.50-2.23 (m, 1H), 1.94 (t, J = 6.7 Hz, 3H), 1.79-1.64 (m, 5H), -2.43 (s, 1H).

[0313] Synthesis Example 28 - Synthesis of phyllochlorin methyl ester 3-picolinyl bromide propyl ether (Compound 28) [ka]

[0314] To a sealed tube (2.5 x 20 cm, with a Teflon screw cap) containing phyllochlorin methyl ester 3-bromopropyl ether (70 mg, 0.106 mmol, 1 equiv.) and a stir bar were added MeCN (4 mL) and 4-picoline (49 mg, 0.529 mmol, 5 equiv.). After flushing the tube with nitrogen and sealing it, the dark green mixture was stirred (300 rpm) at 90 °C for 22 h. The mixture was cooled, diluted with DCM (25 mL), washed with 0.05 M HCl (20 mL), dried (NaSO), and concentrated by rotary evaporation to give the crude product as a dark green oil (115 mg). The residue was purified by column chromatography (3 x 12 cm) using 8% MeOH / DCM as the eluent. f The starting material was eluted and purified using a gradient of 8-14% MeOH / DCM. Compound 28 (R in approximately 10% MeOH / DCM) was then purified. f =0.1) was eluted as a dark green solid (64 mg, 94%) (HPLC purity: 96.7% - 2 isomers, 1.4% DCM w / w).

[0315] 1 H NMR (400 MHz, CDCl3) δ 9.77 (m, 2H), 8.85 (m, 2H), 8.28 (m, 2H), 5.99 (m, 2H), 5.81 (m, 1H), 4.88 (m, 1H), 4.61-4.47 (m, 3H), 4.01-3.94 (m, 4H), 3.86 (m, 2H), 3.66 (s, 3H), 3.59 (m, 3H), 3.51-3.45 (m, 1H), 3.40 (s, 3H), 3.31 (m, 3H), 2.67-2.45 (m, 2H), 2.38-2.18 (m, 3H), 2.11 (m, 3H), 2.07-1.95 (m, 1H), 1.88-1.70 (m, 10H), -2.31 -2.45 (brm, 2H).

[0316] Synthesis Example 29 - Synthesis of phyllochlorin methyl ester 13-(2-methoxyethyl)carbamate (Compound 29) [ka]

[0317] To a 50 mL RBF was added phyllochlorin 13-hydroxymethyl-methyl ester (compound 3) (100 mg, 0.190 mmol, 1 equiv.), carbonyldiimidazole (62 mg, 0.380 mmol, 2 equiv.), DCM (10 mL), and DMAP (10 mg). The resulting mixture was stirred (300 rpm) under nitrogen for 2 h. 2-Methoxyethylamine (0.4 mL) was added, and stirring was continued for 3 h. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel, washed with water (2 x 40 mL), dried (NaSO), and concentrated by rotary evaporation to give a dark green residue (140 mg). The residue was purified by column chromatography (3 x 12 cm) using 2-5% acetone / DCM. The major dark green spot (R in 5% acetone / DCM) f =0.40) were combined to give compound 29 as a dark green solid (44 mg, 37%).

[0318] 1 H NMR (400 MHz, CDCl3) δ 9.75 (m, 2H), 8.89 (m, 2H), 6.49 (m, 2H), 5.20 (brs, 1H), 4.58 (m, 1H), 4.51 (m, 1H), 4.00 (s, 3H), 3.86 (q, 2H), 3.67 (s, 3H), 3.57 (m, 6H), 3.48 (m, 3H), 3.40 (s, 3H), 3.30 (s, 3H), 2.62-2.48 (m, 2H), 2.18-2.00 (m, 2H), 1.81-1.72 (m, 6H), -2.21 (brs, 1H), -2.38 (brs, 1H).

[0319] Synthesis Example 30 - Synthesis of phyllochlorin 13-formylmethyl ester (Compound 30) [ka] To a 250 mL RBF was added phyllochlorin methyl ester (2.00 g, 3.826 mmol, 1 equiv.), THF (75 mL), osmium tetroxide (5 mg, 0.038 mmol, 0.01 equiv.), deionized water (5 mL), AcOH (5 mL), and sodium periodate (1.80 g, 8.418 mmol, 2.2 equiv.). The resulting mixture was stirred under nitrogen in the dark at ambient temperature for 3 h. An additional portion of sodium periodate (0.35 g, 0.4 equiv.) was added, and the solution was stirred overnight. The reaction mixture was concentrated using a rotary evaporator to remove THF, then redissolved in DCM (60 mL), transferred to a separatory funnel, washed with brine (40 mL), saturated NaHCO (40 mL), and water (40 mL), then dried (Na SO ) and concentrated by rotary evaporation to give a reddish-brown powdery solid. The residue was purified by column chromatography using a gradient of 0-2% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) was f =0.7) were combined to give compound 30 as a reddish-brown solid (1.65 g, 82%).

[0320] 1 H NMR (400 MHz,CDCl3) δ 11.60 (s, 1H), 10.32 (s, 1H), 9.61 (s, 1H), 8.98 (s, 1H), 8.90 (s, 1H), 4.56 (m, 1H), 4.50 (m, 1H), 4.00 (s, 3H), 3.81 (m, 5H), 3.62 (s, 3H), 3.60 (s, 3H), 3.38 (s, 3H), 2.66-2.56 (m, 1H), 2.55-2.47 (m, 1H), 2.25-2.15 (m, 1H), 2.05-1.95 (m, 1H), 1.80-1.71 (m, 6H), -1.80 (s, 1H), -2.25 (s, 1H).

[0321] Synthesis Example 31: Synthesis of phyllochlorin 13-formyl N-3-hydroxypropyl-N-methylpropylamidoacetate (Compound 31) [ka]

[0322] Step 1: To a 100 mL RBF equipped with a nitrogen inlet and containing a small stir bar, phyllochlorin (2.00 g, 3.93 mmol, 1 equiv.), dichloromethane (50 mL), PyBOP (2.26 mg, 1.1 equiv.), triethylamine (1.64 mL, 3 equiv.), and 3-(methylamino)-propanol (0.42 g, 1.2 equiv.) were added. The mixture was stirred at room temperature for 3 h. Analysis by HPLC indicated the reaction was complete. The reaction mixture was transferred to a separatory funnel and washed with water (2 x 30 mL). The organic layer was dried (NaSO) and concentrated by rotary evaporation to give the crude product as a blue / brown film (5.1 g). The crude mixture was loaded directly onto a silica column and eluted with 1.5-2% MeOH / DCM. R by TLC was 0.01. f Pure fractions containing a green / blue spot at 0.30 (5% MeOH / DCM) were combined to give phyllochlorin N-3-hydroxypropyl-N-methylpropylamide (1.29 g, 57%).

[0323] 1 H NMR (400 MHz, CDCl3) δ 9.75-9.70 (m, 2H), 8.85 (br s, 1H), 8.16 (dd, 1H), 6.38 (dd, 1H), 6.15 (dd, 1H), 4.70-4.65 (m, 1H), 4.58-4.50 (m, 1H), 4.00 (s, 3H), 3.89-3.82 (m, 3H), 3.65 (s, 3H), 3.53 (s, 3H), 3.37 (s, 3H), 3.31-3.15 (m, 4H), 2.65-2.53 (m, 2H), 2.37-2.22 (m, 3H), 2.16 (3, 3H), 1.80 - 1.70 (m, 7H), 1.48-1.40 (m, 2H), -2.10 (s, 1H), -2.22 (m, 1H).

[0324] Step 2: To a 25 mL RBF was added phyllochlorin N-3-hydroxypropyl-N-methylpropylamide (300 mg, 0.517 mmol, 1 equiv.), pyridine (2 mL), acetic anhydride (0.49 mL, 5.17 mmol, 10 equiv.), and DMAP (1 mg). The solution was stirred at 30 °C for 1 h. Analysis by TLC indicated the reaction was complete. Ethyl acetate (15 mL) and water (10 mL) were added, and the mixture was stirred vigorously for 10 min. The layers were separated, and the ethyl acetate layer was washed with 0.5 M HCl (2 × 10 mL) and saturated NaHCO (2 × 10 mL), then dried (NaSO), and concentrated to give phyllochlorin N-3-hydroxypropyl-N-methylpropylamide acetate as a dark green solid, which was not further purified (288 mg, 89%).

[0325] Step 3: To a 100 mL RBF was added phyllochlorin N-3-hydroxypropyl-N-methylpropylamide acetate (280 mg, 0.450 mmol, 1 equiv.), THF (15 mL), osmium tetroxide (1 mg, 0.005 mmol, 0.01 equiv.), deionized water (1 mL), AcOH (1 mL), and sodium periodate (202 mg, 0.946 mmol, 2.1 equiv.). The resulting mixture was stirred overnight under nitrogen in the dark at ambient temperature. The reaction mixture was concentrated using a rotary evaporator to remove the THF, then redissolved in DCM (75 mL), transferred to a separatory funnel, washed with brine (30 mL), saturated NaHCO (30 mL), and water (40 mL), then dried (NaSO), and concentrated by rotary evaporation to give a reddish-brown powdery solid. The residue was purified by column chromatography eluting with a gradient of 1-2.5% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) f =0.65) were combined to give compound 31 as a reddish-brown powder (200 mg, 71%).

[0326] 1H NMR (400 MHz, CDCl3) δ 11.60 (s, 1H), 10.31 (s, 1H), 9.60 (s, 1H), 8.98 (s, 1H), 8.90 (s, 1H), 4.70-4.65 (m, 1H), 4.56-4.50 (m, 1H), 4.10 (t, 1H), 4.02 (m, 3H), 3.98-3.94 (m, 5H), 3.85-3.78 (m, 5H), 3.70 (m, 1H), 3.65-3.56 (m, 4H), 3.36 (s, 3H), 3.25 (t, 1H), 3.15 (s, 3H), 2.75-2.70 (m, 2H), 2.60-2.50 (m, 2H), 2.45-2.38 (m, 3H), 2.20-2.10 (m, 1H), 2.05 (s, 2H), 2.00-1.95 (m, 4H), 1.80-1.70 (m, 7H), 1.68 (m, 2H), -1.75 (s, 1H), -2.25 (s, 1H).

[0327] Synthesis Example 3: Synthesis of 2-phyllochlorin 13-hydroxymethyl-3-hydroxypropyl (Compound 32) [ka]

[0328] To a three-necked 100 mL RBF, lithium aluminum hydride (230 mg, 5.75 mmol, 10 equiv.) and THF (25 mL) were added, and the solution was stirred and cooled under nitrogen using an ice / water bath for 10 minutes. Phyllochlorin 13-hydroxymethylmethyl ester (compound 3) (300 mg, 0.370 mmol, 1 equiv.) was added in small portions over 2 minutes. After 30 minutes, the reaction flask was removed from the cold bath and stirring continued at room temperature. The flask was cooled (ice / water bath), and water (0.15 mL) was added, followed by 4 M NaOH (0.15 mL). After stirring for 10 minutes, additional water (0.5 mL) was added, and the solution was warmed to room temperature and stirred for 15 minutes. Sodium sulfate (approximately 5 g) was added, and the mixture was stirred for 10 minutes, then filtered and rinsed with DCM until no color eluted. The solvent was then removed under reduced pressure to give a residue which was purified by column chromatography eluting with a gradient of 1-5% MeOH / DCM. f =0.2) were combined to give compound 32 as a dark green solid (220 mg, 77%).

[0329] 1 H NMR (400 MHz, CDCl3) δ 9.71 (s, 1H), 9.61 (s, 1H), 8.86 (s, 1H), 8.84 (s, 1H), 5.85 (m, 2H), 4.51 (m, 2H), 3.95 (s, 3H), 3.83 (q, 2H), 3.63 (s, 3H), 3.60-3.50 (m, 2H), 3.46 (s, 3H), 3.32 (s, 3H), 2.22-2.15 (m, 1H), 2.05-1.95 (m, 1H), 1.82-1.70 (m, 8H), 1.52-1.42 (m, 2H), 1.20-1.10 (brs, 1H), -2.25 (brs, 1H), -2.39 (brs, 1H).

[0330] Synthesis Example 3: Synthesis of 3-phyllochlorin 13-hydroxymethyl-3-hydroxypropyl-bis-β-D-glucoside ether (Compound 33) [ka]

[0331] Step 1: To a 50 mL RBF was added 13-hydroxymethyl-3-hydroxypropyl phyllochlorin (compound 32) (120 mg, 0.241 mmol, 1 equiv.), glucose pentaacetate (282 mg, 0.722 mmol, 3 equiv.), and DCM (10 mL). The resulting mixture was stirred under nitrogen using an ice / water bath and cooled to approximately 0 °C. Boron trifluoride diethyl etherate (0.3 mL) was added, and stirring was continued. The solution was allowed to slowly warm to room temperature over 2 h and then stirred overnight at room temperature in the dark. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel, and washed with saturated NaHCO (20 mL) and then water (20 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to yield a blue-black film. The residue was purified by column chromatography eluting with a gradient of 0.5-1.5% MeOH / DCM. f =0.65) were combined to give phyllochlorin 13-hydroxymethyl-3-hydroxypropyl-bis-β-D-glucoside ether peracetate as a dark green solid (170 mg).

[0332] Step 2: To a solution of phyllochlorin 13-hydroxymethyl-3-hydroxypropyl-bis-β-D-glucoside ether peracetate (140 mg, 0.121 mmol, 1 equiv.) in MeOH (3 mL) and DCM (2 mL), NaOMe (4.6 M in MeOH, 0.026 mL, 0.121 mmol, 1 equiv.) was added, and the mixture was stirred under N2 for 1 h. The reaction was concentrated by rotary evaporation to give a black oil. The residue was purified by column chromatography (3 x 14 cm), eluting with a gradient of 10-20% MeOH / DCM. The product (R in 15% MeOH / DCM) was f =0.1) were combined to give compound 33 as a dark green solid (72 mg, 36% over two steps).

[0333] 1 H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 9.76 (s, 1H), 9.10 (s, 1H), 9.07 (m, 1H), 6.59 (d, 1H), 6.21 (d, 1H), 6.18 (d, 1H), 6.02 (d, 1H), 5.10 (d, 1H), 4.95 (m, 2H), 4.90-4.78 (m, 6H), 4.65-4.55 (m, 4H), 4.50-4.40 (m, 3H), 4.30-4.20 (m, 1H), 4.05 (d, 1H), 3.94 (m, 3H), 3.82 (m, 2H), 3.70-3.60 (m, 7H), 3.51 (m, 4H), 3.22-2.95 (m, 10H), 2.88 (m, 1H), 2.80 (m, 1H), 2.38 (m, 3H), 2.20-2.10 (m, 2H), 1.78-1.68 (m, 8H), -2.34 (brs, 1H), -2.55 (brs, 1H).

[0334] Synthesis Example 34 - Synthesis of フィロクロリン3-アセトキシプロピル-13-ヒドロキシメチル (Compound 34)

change

[0335] To a two-necked 500 mL RBF was added lithium aluminum hydride (670 mg, 16.8 mmol, 5 equiv.) and THF (200 mL), and the solution was stirred and cooled under nitrogen using an ice / water bath for 10 minutes. Phyllochlorin methyl ester (1.75 g, 3.35 mmol, 1 equiv.) was added in small portions over 5 minutes. After 30 minutes, additional lithium aluminum hydride (670 mg, 16.8 mmol, 5 equiv.) was added, and stirring was continued for 90 minutes, during which time the reaction warmed slightly. Analysis by TLC indicated the reaction was complete. The flask was cooled (ice / water bath), and water (1.3 mL) was added, followed by 4 M NaOH (1.3 mL). After stirring for 10 minutes, additional water (4 mL) was added, and the solution was warmed to room temperature and stirred for 15 minutes. Sodium sulfate was added and the mixture was stirred for 10 minutes before being filtered and rinsed with DCM until no more color was eluted. The solvent was then removed under reduced pressure to give the crude product, which was purified by column chromatography (4x11 cm) eluting with a gradient of 2-4% MeOH / DCM. The product (R in 5% MeOH / DCM) was f =0.4) were combined to give 3-hydroxypropyl phyllochlorin as a dark green solid (1.60 g, 97%).

[0336] 1 H NMR (400 MHz, CDCl3) δ 9.72 (m, 2H), 8.88 (s, 1H), 8.84 (m, 1H), 8.16 (dd, 1H), 6.48 (dd, 1H), 6.14 (dd, 1H), 4.51 (m, 2H), 3.94 (s, 3H), 3.85 (q, 2H), 3.63 (s, 3H), 3.60-3.50 (m, 5H), 3.38 (s, 3H), 2.21-2.612 (m, 1H), 1.85-1.72 (m, 8H), 1.52-1.40 (m, 2H), 1.12-1.05 (m, 1H), -2.10 (br, 1H), -2.22 (br, 1H).

[0337] Step 2: To a 25 mL RBF was added 3-hydroxypropyl phyllochlorin (100 mg, 0.202 mmol, 1 equiv.), pyridine (0.7 mL), acetic anhydride (0.2 mL, 2.11 mmol, 10 equiv.), and DMAP (0.5 mg). The solution was stirred at 30 °C for 1 h. Ethyl acetate (10 mL) and water (5 mL) were added, and the mixture was stirred vigorously for 10 min. The layers were separated, and the ethyl acetate layer was washed with 0.5 M HCl (3 × 5 mL), saturated NaHCO (3 × 5 mL), dried (NaSO), and concentrated to give phyllochlorin propan-3-ol acetate as a dark green, flaky solid (78 mg, 72%).

[0338] 1 H NMR (400 MHz, CDCl3) δ 9.72 (m, 2H), 8.86 (s, 1H), 8.84 (m, 1H), 8.16 (dd, 1H), 6.48 (dd, 1H), 6.13 (dd, 1H), 4.52 (m, 2H), 4.06 (t, 2H), 3.95 (s, 3H), 3.85 (q, 2H), 3.65 (s, 3H), 3.54 (s, 3H), 3.37 (s, 3H), 2.21-2.13 (m, 1H), 1.96 (s, 3H), 1.95-1.80(m, 2H), 1.80-1.72 (m, 6H), 1.62-1.50 (m, 2H), -2.10 (br, 1H), -2.22(br, 1H).

[0339] Step 3: To a 100 mL RBF was added phyllochlorin propan-3-ol acetate (340 mg, 0.633 mmol, 1 equiv.), THF (15 mL), osmium tetroxide (1.6 mg, 0.005 mmol, 0.01 equiv.), deionized water (1 mL), AcOH (1 mL), and sodium periodate (339 mg, 1.584 mmol, 2.5 equiv.). The resulting mixture was stirred overnight at ambient temperature under nitrogen in the dark. The reaction mixture was concentrated using a rotary evaporator to remove THF, then redissolved in DCM (75 mL), transferred to a separatory funnel, washed with brine (30 mL), saturated NaHCO3 (30 mL), and water (40 mL), then dried (Na2SO4) and concentrated by rotary evaporation to give phyllochlorin 3-acetoxypropyl-13-formyl as a reddish-brown powdery solid (approximately 0.4 g), which was used directly in the next step.

[0340] Step 4: To a 100 mL RBF was added 3-acetoxypropyl-13-formyl phyllochlorin (340 mg, 0.631 mmol, 1 equiv.), MeOH (10 mL), DCM (5 mL), and sodium borohydride (48 mg, 1.262 mmol, 2 equiv.). The resulting mixture was stirred under nitrogen at ambient temperature for 30 min. The reaction mixture was diluted with water (20 mL) and stirred for 10 min. The mixture was then extracted with DCM (3 x 15 mL), and the combined DCM layers were washed with water (20 mL), then dried (Na2SO4), and concentrated by rotary evaporation to give a dark green oil. The residue was purified by column chromatography (3 x 16 cm), eluting with a gradient of 1-2.5% MeOH / DCM. The product (R in 5% MeOH / DCM) was f =0.5) were combined to give compound 34 as a dark green solid (160 mg, 47% over two steps).

[0341] 1H NMR (400 MHz, CDCl3) δ 9.70 (s, 1H), 9.65 (m, 1H), 8.87 (s, 1H), 8.84 (s, 1H), 5.90 (m, 2H), 4.57-4.50 (m, 2H), 4.06 (m, 2H), 3.97 (s, 3H), 3.82 (q, 2H), 3.62 (s, 3H), 3.48 (m, 3H), 3.34 (s, 3H), 2.24-2.15 (m, 1H), 2.07-2.00 (m, 1H), 1.97 (s, 3H), 1.95-1.85 (m, 4H), 1.31 (d, 3H), 1.73 (t, 3H), 1.62-1.55 (m, 2H), -2.25 (brs, 1H), -2.40 (brs, 1H).

[0342] Synthesis Example 3: Synthesis of 5-phyllochlorin 3-hydroxypropyl-13-hydroxymethyl-β-D-glucoside ether (compound 35) [ka]

[0343] Step 1: To a 50 mL RBF was added 3-acetoxypropyl-13-hydroxymethyl phyllochlorin (compound 34) (160 mg, 0.296 mmol, 1 equiv.), glucose pentaacetate (173 mg, 0.443 mmol, 1.5 equiv.), and DCM (10 mL). The resulting mixture was stirred under nitrogen using an ice / water bath and cooled to approximately 0 °C. Boron trifluoride diethyl etherate (0.2 mL) was added, and stirring was continued, allowing the solution to slowly warm to room temperature over 2 h, then stirred overnight at room temperature in the dark. The reaction mixture was diluted with DCM (30 mL), transferred to a separatory funnel, and washed with saturated NaHCO (25 mL) and then water (20 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to yield a blue-black film. The residue was purified by column chromatography eluting with a gradient of 0.5-1.5% MeOH / DCM. Fractions containing phyllochlorin 3-acetoxypropyl-13-hydroxymethyl-β-D-glucoside ether tetraacetate were combined to give a dark green oil (260 mg) that was used directly in the next step.

[0344] Step 2: To a solution of phyllochlorin 3-acetoxypropyl-13-hydroxymethyl-β-D-glucoside ether tetraacetate (220 mg, 0.253 mmol, 1 equiv.) in MeOH (3 mL) and DCM (3 mL), NaOMe (4.6 M in MeOH, 0.055 mL, 0.253 mmol, 1 equiv.) was added, and the mixture was stirred under N2 for 1 h. The reaction was concentrated by rotary evaporation to give a black film. The residue was purified by column chromatography (3 x 16 cm), eluting with a gradient of 5-12% MeOH / DCM. The product (R in 10% MeOH / DCM) was f =0.25) were combined to give compound 35 as a dark green solid (100 mg, 51% over two steps).

[0345] 1H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 9.76 (s, 1H), 9.09 (m, 2H), 6.16 (d, 1H), 6.01 (d, 1H), 5.12 (d, 1H), 4.94 (t, 2H), 4.82 (t, 1H), 4.63-4.54 (m, 3H), 4.35 (t, 1H), 3.95-3.90 (m, 4H), 3.83 (q, 2H), 3.72-3.65 (m, 1H), 3.63 (s, 3H), 3.52 (s, 3H), 3.45-3.38 (m, 2H), 3.30-3.25 (m, 1H), 3.20-3.15 (m, 2H), 3.15-3.10 (m, 1H), 2.20-2.10 (m, 1H), 1.77-1.68 (m, 8H), 1.47-1.37 (m, 1H), -2.35 (s, 1H), -2.53 (s, 1H).

[0346] Synthesis Example 36 - Synthesis of phyllochlorin methyl ester 3-bromopropyl ether (Compound 36) [ka]

[0347] To a 50 mL RBF containing phyllochlorin methyl ester (0.50 g, 0.957 mmol, 1 equiv.) and a stir bar, HBr / AcOH (33% w / w, 5 mL) was added, and the dark blue mixture was stirred at 30 °C for 2 h under N . A stream of N was passed through the sample for several minutes to remove some of the HBr, after which the volume was concentrated by rotary evaporation. The mixture was then further dried under high vacuum (0.6 mbar) at an external temperature of 40 °C for 30 min. The residue was reconstituted in DCM (20 mL), followed by the addition of powdered K CO (1.32 g, 9.57 mmol, 10 equiv.) followed by 3-bromo-propan-1-ol (1.22 mL, 14.35 mmol, 15 equiv.). The system was flushed with N , stoppered with a rubber septum and nitrogen needle, and the solution was stirred at 30 °C in the dark overnight. The reaction mixture was transferred to a separatory funnel and washed with HO (50 mL) and then brine (50 mL), before being dried (NaSO) and concentrated by rotary evaporation to give the crude ether as a dark green oil, which was further dried under high vacuum (0.3 mbar) at an external temperature of 40-50 °C for 30 min to give a green oil (0.95 g). The residue was purified by column chromatography eluting with a gradient of 0.5-2% MeOH / DCM. The major green band (approximately 1% MeOH / DCM in R f =0.6) were combined to give compound 36 as a dark green solid (305 mg, 51%).

[0348] 1H NMR (400 MHz, CDCl3) δ 9.95-9.73 (m, 2H), 8.88-8.80 (m, 2H), 6.04 (q, 1H), 4.60-4.47 (m, 2H), 3.99 (s, 3H), 3.90-3.80 (m, 3H), 3.78-3.70 (m, 2H), 3.66 (s, 3H), 3.58 (s, 3H), 3.55-3.50 (m, 4H), 3.39 (s, 3H), 2.60-2.47 (m, 2H), 2.30-2.20 (m, 2H), 2.18-2.14 (m, 3H), 2.14-2.00 (m, 2H), 1.81-1.75 (m, 6H), -2.15 (brs, 1H), -2.27 (brs, 1H).

[0349] Synthesis Example 37 - Synthesis of phyllochlorin methyl ester 2-(2-chloroethoxy)ethyl ether (Compound 37) [ka]

[0350] To a 50 mL RBF containing phyllochlorin methyl ester (0.50 g, 0.957 mmol, 1 equiv.) and a stir bar, HBr / AcOH (33% w / w, 5 mL) was added, and the dark blue mixture was stirred at 30 °C for 2 h under N . A stream of N was passed through the sample for several minutes to remove some of the HBr, after which the volume was concentrated by rotary evaporation. The mixture was then further dried under high vacuum (0.6 mbar) at an external temperature of 40 °C for 30 min. The residue was reconstituted in DCM (20 mL), followed by the addition of powdered K CO (1.32 g, 9.57 mmol, 10 equiv.) followed by 2-(2-chloroethoxy)ethanol (1.79 g, 14.35 mmol, 15 equiv.). The system was flushed with N , stoppered with a rubber septum and nitrogen needle, and the solution was stirred at 30 °C in the dark overnight. The reaction mixture was transferred to a separatory funnel and washed with HO (50 mL) and then brine (50 mL), before being dried (NaSO) and concentrated by rotary evaporation (60 °C, absolute vacuum, 1 h) to give the crude ether as a dark green oil (approximately 1.1 g), which was purified by column chromatography eluting with a gradient of 0.5-1% MeOH / DCM. The major green band (approximately 1% MeOH / DCM, R f =0.5) were combined to give compound 37 as a dark green solid (310 mg, 50%).

[0351] 1 H NMR (400 MHz, CDCl3) δ 9.95 (s, 1H), 9.74 (s, 1H), 8.86-8.80 (m, 2H), 6.12 (q, 1H), 4.58 (m, 1H), 4.50 (q, 1H), 3.99 (s, 3H), 3.90-3.70 (m, 9H), 3.66 (s, 3H), 3.65-3.60 (m, 2H), 3.58 (m, 3H), 3.51 (s, 3H), 3.38 (s, 3H), 2.60-2.47 (m, 2H), 2.19 (m, 3H), 2.16-2.00 (m, 2H), 1.80-1.73 (m, 6H), -2.15 (brs, 1H), -2.28 (brs, 1H).

[0352] Synthesis Example 38 - Synthesis of phyllochlorin 13-(ethyl-1-acetate) (Compound 38) [ka]

[0353] To a 50 mL RBF equipped with a gas inlet / outlet, a condenser with a bubbler, and a stir bar was added phyllochlorin (500 mg, 9.87 mmol, 1 equiv.) and acetic acid (15 mL). The flask was then heated at 130 °C with stirring in the dark overnight. After 27 h, the reaction was cooled and concentrated on a rotary evaporator to give a blue solid. This material was suspended in DCM (50 mL) and washed with water (80 mL), then dried (Na2SO4), filtered, and evaporated to give a dark blue glassy solid. The residue was purified by column chromatography (4 x 12 cm) eluting with 2% MeOH / DCM. The major green band (R in 5% MeOH / DCM) was f =0.30) were combined to give compound 38 as a dark green solid (20 mg, 4%).

[0354] 1 H NMR (400 MHz, CDCl3) δ 9.92 (s, 1H), 9.76 (s, 1H), 8.85 (m, 2H), 7.40 (m, 1H), 4.61-4.55 (m, 1H), 4.53-4.46 (m, 1H), 3.96 (s, 3H), 3.87 (q, 2H), 3.64 (s, 3H), 3.55 (s, 3H), 3.40 (s, 3H), 2.56-2.45 (m, 2H), 2.25 (m, 6H), 2.12-1.97 (m, 2H), 1.80-1.71 (m, 7H), -2.38 (brs, 1H).

[0355] Synthesis Example 39 - Synthesis of phyllochlorin methyl ester 13-(6-triphenylphosphonium bromide)hexyl)carbamate (Compound 39) [ka] Step 1: To a 50 mL RBF was added (6-((tert-butoxycarbonyl)amino)hexyl)triphenylphosphonium bromide (1.00 g, 1.843 mmol, 9.7 equiv), DCM (10 mL), and TFA (2 mL). The resulting solution was stirred at ambient temperature for 1 h and then concentrated by rotary evaporation. The residue was resuspended and concentrated twice from chloroform (2 × 40 mL) to give 6-aminohexyltriphenylphosphonium bromide TFA as a viscous oil (1.50 g), which was dissolved in DCM (1 mL) for the subsequent coupling reaction.

[0356] Step 2: To a 50 mL RBF was added phyllochlorin 13-hydroxymethylmethyl ester (compound 3) (100 mg, 0.190 mmol, 1 equiv.), carbonyldiimidazole (62 mg, 0.380 mmol, 2 equiv.), DCM (5 mL), and DMAP (10 mg). The resulting mixture was stirred under nitrogen for 3 h with TLC monitoring. TEA (810 mg, 8.00 mmol) was added, followed by 6-aminohexyltriphenylphosphonium bromide (1.5 g in 1 mL DCM (containing approximately 0.69 g of TFA)), and stirring was continued for 3 days. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel, washed with 1 M HCl (25 mL), pH 7 phosphate buffer (25 mL), dried (NaSO), and concentrated by rotary evaporation to give a dark green residue. The residue was purified by column chromatography eluting with a gradient of 5-7% MeOH / DCM. The major green band (R f =0.30) were combined to give compound 39 as a dark green solid (96 mg, 51% over two steps).

[0357] 1H NMR (400 MHz, CDCl3) δ 9.73 (s, 1H), 9.69 (s, 1H), 8.85 (m, 2H), 7.65-7.51 (m, 8H), 7.50-7.35 (m, 7H), 6.44 (m, 2H), 5.60 (brs, 1H), 4.56 (m, 1H), 4.48 (m, 1H), 3.99 (s, 3H), 3.80 (q, 2H), 3.63 (s, 3H), 3.57 (s, 3H), 3.53 (s, 3H), 3.46 (m, 3H), 3.34 (s, 3H), 3.21 (m, 2H), 2.62-2.46 (m, 2H), 2.20-2.10 (m, 1H), 2.06-1.95 (m, 1H), 1.85-1.69 (m, 7H), 1.58-1.38 (m, 6H), 1.37-1.25 (m, 3H), -2.22 (brs, 1H), -2.39 (brs, 1H).

[0358] Synthesis Example 40 - Synthesis of phyllochlorin methyl ester 13-(N-(3-(3-triphenylphosphoniumpropoxy)propyl)chloride)carbamate (Compound 40) [ka]

[0359] Step 1: A 500 mL three-necked RBF equipped with a 3 cm stir bar was charged with bis(3-chloropropyl)ether (20.00 g, 70.15 mmol, 1.66 equiv), triphenylphosphine (18.40 g, 70.15 mmol, 1 equiv), sodium iodide (7.01 g, 46.77 mmol, 0.66 equiv), and acetonitrile (340 mL). The RBF was placed in an oil bath, fitted with an air-cooled condenser, and stirring (500 rpm) was initiated under N at an external temperature of 90 °C. The mixture was stirred for 72 h. At this point, the reaction flask was cooled to room temperature, and the suspension was filtered through a 2 cm plug of Celite®, washing with acetonitrile (250 mL). The pale yellow solution was then evaporated to dryness to give a dark yellow oil (44.40 g) which was subjected to column chromatography (silica gel, 9 x 12 cm) using 6% MeOH in DCM as eluent. f Fractions with a δ = 0.35 were combined and concentrated by rotary evaporation. The resulting residue was further purified by column chromatography (silica gel, 9 x 7 cm). DCM was used as the eluent until triphenylphosphine was no longer observed by TLC, after which the eluent was changed to 10% MeOH in DCM to remove the product from the column. The R was visualized by UV in 6% MeOH / DCM. f Fractions with HCl = 0.35 were combined and concentrated by rotary evaporation to give (3-(3-chloropropoxy)propyl)triphenylphosphonium chloride as a pale red solid (18.74 g, 62%).

[0360] 1 H NMR (400 MHz, CDCl3) δ 7.87-7.76 (m, 9H), 7.75-7.63 (m, 6H), 3.93-3.80 (m, 2H), 3.75 (td, J = 5.7, 1.3 Hz, 2H), 3.58 (q, J = 6.3 Hz, 4H), 2.05-1.88 (m, 4H).

[0361] Step 2: To a 50 mL RBF was added (3-(3-chloropropoxy)propyl)triphenylphosphonium chloride (4.0 g, 9.23 mmol, 1 equiv.), NaN3 (11.08 g, 1.2 equiv.), NaBr (38 mg, 0.04 equiv.), tetrapropylammonium bromide (49 mg, 0.02 equiv.), and water (10 mL). After connecting a water-cooled condenser, the flask was heated at 110 °C with stirring for 44 h. The mixture was then cooled, and EtOAc (50 mL) was added. The mixture was transferred to a separatory funnel and washed with water (3 × 30 mL) and brine (30 mL). The combined aqueous layers were extracted with DCM (3 × 20 mL). The combined organic layers were then dried (MgSO4), filtered, and concentrated to give (3-(3-azidopropoxy)propyl)triphenylphosphonium chloride as a pale yellow solid (3.20 g, 79%).

[0362] 1 H NMR (400 MHz, CDCl3) δ 7.86-7.77 (m, 9H), 7.73-7.66 (m, 6H), 3.90-3.80 (m, 2H), 3.75 (t, 2H), 3.53 (t, 2H), 3.33 (t, 2H), 1.99-1.89 (m, 2H), 1.82 (p, 2H).

[0363] Step 3: A three-necked 100 mL RBF was charged with (3-(3-azidopropoxy)propyl)triphenylphosphonium chloride (1.00 g, 2.273 mmol, 1 equiv.), 10% Pd / C (20 mg), methanol (10 mL), and a stir bar. A hydrogen balloon was connected to the center connection of the flask via a short, air-cooled condenser, and the side arm was connected to a three-way stopcock. The apparatus was evacuated and refilled with nitrogen (three times), and then evacuated and refilled with hydrogen (twice). The resulting solution was then stirred (550 rpm) under a hydrogen atmosphere at 35 °C for 2 h. The solution was then filtered through Celite® (0.5×3 cm), washed with chloroform (2×10 mL), and the solvent removed under reduced pressure to give (3-(3-aminopropoxy)propyl)triphenylphosphonium chloride as a viscous oil that solidified on standing (1.05 g, quantitative).

[0364] 1 H NMR (400 MHz, CDCl3) δ7.86-7.76 (m, 9H), 7.73-7.66 (m, 6H), 3.88-3.79 (m, 2H), 3.73 (t, 2H), 3.51 (t, 2H), 2.75 (t, 2H), 1.99-1.87 (m, 2H), 1.68 (p, 2H), 1.41 (brs, 2H).

[0365] Step 4: To a 25 mL RBF was added phyllochlorin 13-hydroxymethylmethyl ester (compound 3) (50 mg, 0.0949 mmol, 1 equiv.), carbonyldiimidazole (31 mg, 0.1899 mmol, 2 equiv.), DCM (3 mL), and DMAP (5 mg). The resulting mixture was stirred under nitrogen for 3 h with TLC monitoring. (3-(3-aminopropoxy)propyl)triphenylphosphonium chloride (196 mg, 0.4747 mmol, 5 equiv.) dissolved in DCM (1 mL) was added, and stirring was continued for 4 days. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel, and washed with 1 M HCl (2 × 20 mL), pH 7 phosphate buffer (30 mL), then dried (NaSO), and concentrated by rotary evaporation to give a dark green residue. The residue was purified by column chromatography eluting with a gradient of 3-5% MeOH / DCM. The major green band (R f =0.20) were combined to give compound 40 as a dark green solid (46 mg, 50%).

[0366] 1 H NMR (400 MHz, CDCl3) δ 9.70 (m, 2H), 8.87 (m, 2H), 7.61-7.50 (m, 6H), 7.49-7.36 (m, 9H), 6.41 (s, 2H), 5.39 (m, 1H), 4.57 (m, 1H), 4.50 (m, 1H), 3.99 (s, 3H), 3.81 (q, 2H), 3.64 (s, 3H), 3.60-3.52 (m, 7H), 3.52-3.46 (m, 5H), 3.40-3.34 (m, 2H), 3.32 (s, 3H), 2.62-2.46 (m, 2H), 2.20-2.12 (m, 1H), 2.07-1.96 (m, 1H), 1.80-1.69 (m, 9H), 1.69-1.55 (m, 4H), 0.90-0.80 (m, 1H), -2.23 (brs, 1H), -2.40 (brs, 1H).

[0367] Synthesis Example 41 - Synthesis of phyllochlorin 13-formyl N-methyl-N-3,6,9-trioxadecylpropylamide (Compound 41) [ka]

[0368] Step 1: To a 250 mL RBF equipped with a nitrogen inlet and containing a small stir bar was added phyllochlorin (2.00 g, 3.93 mmol, 1 equiv.), dichloromethane (50 mL), DMTMM (1.41 g, 5.11 mmol, 1.3 equiv.), and 2-(2-(2-(methylamino)ethoxy)ethoxy)ethanol (905 mg, 5.11 mmol, 1.3 equiv.). The mixture was stirred at room temperature for 2 h. The progress of the reaction was monitored by HPLC. The reaction mixture was then transferred to a separatory funnel and washed with 0.5 M HCl (2 x 50 mL) and pH 7 phosphate buffer (50 mL). The organic layer was dried (NaSO) and concentrated by rotary evaporation to give a dark green film (2.77 g), which was purified by column chromatography (silica gel, 4 x 20 cm) using 2-4% MeOH / DCM as an eluent gradient. R in 5% MeOH / DCM f Pure fractions containing a green spot by TLC at 0.40 were combined to give phyllochlorin N-methyl-N-3,6,9-trioxadecylpropylamide as a dark blue viscous syrup (2.61 g, quantitative) (HPLC purity: 96.7%).

[0369] 1H NMR (400 MHz, CDCl3) δ 9.78-9.65 (m, 2H), 8.85 (d, J = 2.2 Hz, 2H), 8.17 (dd, J = 17.8, 11.5 Hz, 1H), 6.38 (dd, J = 17.8, 1.6 Hz, 1H), 6.15 (dd, J = 11.5, 1.5 Hz, 1H), 4.72-4.62 (m, 1H), 4.55 (q, J = 7.2 Hz, 1H), 4.02 (d, J = 4.2 Hz, 3H), 3.90-3.81 (m, 2H), 3.66-3.60 (m, 3H), 3.54 (s, 3H), 3.51-3.41 (m, 4H), 3.41-3.34 (m, 5H), 3.27-3.22 (m, 4H), 3.21-3.15 (m, 1H), 2.97-2.86 (m, 1H), 2.83-2.77 (m, 1H), 2.74 (s, 1H), 2.64-2.51 (m, 1H), 2.46 (s, 2H), 2.44-2.35 (m, 1H), 2.26-2.11 (m, 1H), 2.05-1.86 (m, 1H), 1.81-1.71 (m, 6H), -2.07 (s, 1H), -2.21 (s, 1H).

[0370] Step 2: To a 100 mL RBF was added phyllochlorin N-methyl-N-3,6,9-trioxadecylpropylamide (2.46 g, 3.68 mmol, 1 equiv.), THF (100 mL), osmium tetroxide (9.4 mg, 0.0368 mmol, 0.01 equiv.), deionized water (8 mL), AcOH (8 mL), and sodium periodate (2.05 g, 9.57 mmol, 2.6 equiv.). The resulting mixture was stirred under nitrogen in the dark at ambient temperature for 18 h. The reaction mixture was concentrated using a rotary evaporator to remove THF, then redissolved in DCM (130 mL), transferred to a separatory funnel, washed with brine (70 mL), saturated NaHCO (70 mL), and water (100 mL), then dried (NaSO), and concentrated by rotary evaporation to give compound 41 as a dark blue solid (1.77 g, 72%).

[0371] 1 H NMR (400 MHz, CDCl3) δ 11.60 (s, 1H), 10.31 (d, J = 2.6 Hz, 1H), 9.60 (d, J = 3.7 Hz, 1H), 9.03-8.85 (m, 2H), 4.68-4.58 (m, 1H), 4.56-4.43 (m, 1H), 4.02 (d, J = 5.5 Hz, 3H), 3.82 (d, J = 2.2 Hz, 3H), 3.80-3.70 (m, 1H), 3.66 (d, J = 4.6 Hz, 2H), 3.63 (d, J = 4.3 Hz, 4H), 3.58-3.43 (m, 4H), 3.43-3.39 (m, 2H), 3.37 (s, 3H), 3.35-3.28 (m, 2H), 3.26 (d, J = 2.4 Hz, 3H), 3.21-2.86 (m, 4H), 2.79 (s, 1H), 2.59 (s, 2H), 2.57-2.41 (m, 2H), 2.20-1.97 (m, 1H), 1.89-1.83 (m, 2H), 1.81-1.62 (m, 6H), -1.78 (s, 1H), -2.25 (s, 1H).

[0372] Synthesis Example 42-Fluorum 13-Fluorum N-Fluor-N -Synthesis of 3,6,9-Torotron (compound 42)

change

[0373] To a 250 mL RBF was added phyllochlorin 13-formyl N-methyl-N-3,6,9-trioxadecylpropylamide (compound 41) (1.75 g, 2.61 mmol, 1 equiv.), MeOH (40 mL), DCM (20 mL), and sodium borohydride (197 mg, 5.22 mmol, 2 equiv.). The resulting mixture was stirred under nitrogen at ambient temperature for 1 h. The reaction mixture was diluted with water (50 mL) and stirred for 10 min. The mixture was then diluted with DCM (20 mL) and brine (20 mL). The DCM layer was collected, and the aqueous layer was further extracted with DCM (2 × 20 mL). The combined DCM layers were washed with brine (20 mL), dried (NaSO), and concentrated by rotary evaporation to give a dark green solid (1.21 g). The residue was purified by column chromatography (4 × 20 cm). It was dissolved in DCM and eluted with a gradient of 1.5 to 3.5% MeOH / DCM. The product (major dark green spot, R in 5% MeOH / DCM) was f =0.5) were combined to give compound 42 as a dark blue-green solid (548 mg, 31%).

[0374] 1H NMR (400 MHz, CDCl3) δ 9.69 (d, J = 3.4 Hz, 1H), 9.65 (d, J = 4.3 Hz, 1H), 8.84 (d, J = 2.7 Hz, 2H), 5.96-5.84 (m, 2H), 4.65 (dt, J = 8.0, 3.2 Hz, 1H), 4.56-4.48 (m, 1H), 4.46 (d, J = 5.8 Hz, 1H), 4.27 (dd, J = 10.0, 6.4 Hz, 1H), 4.01 (d, J = 3.3 Hz, 3H), 3.82 (q, J = 7.6 Hz, 2H), 3.62 (s, 3H), 3.56 (d, J = 1.7 Hz, 1H), 3.51-3.47 (m, 3H), 3.46-3.35 (m, 4H), 3.34 (s, 3H), 3.23 (d, J = 6.7 Hz, 4H), 3.12 (td, J = 5.1, 4.6, 2.1 Hz, 1H), 2.87-2.73 (m, 2H), 2.68 (s, 1H), 2.64 (t, J = 4.8 Hz, 1H), 2.59-2.48 (m, 1H), 2.42 (s, 2H), 2.35 (dt, J = 15.5, 6.6 Hz, 1H), 2.17 (tdt, J = 13.0, 8.8, 4.7 Hz, 1H), 1.94-1.81 (m, 1H), 1.80-1.69 (m, 6H), 1.61 (s, 2H), -2.23 (s, 1H), -2.39 (s, 1H).

[0375] Synthesis Example 4: Synthesis of 3-phyllochlorin 13-(6-(triphenylphosphonium bromide)hexyl)carbamate N-methyl-N-3,6,9-trioxadecylpropylamide (Compound 43) [ka]

[0376] Step 1: To a 50 mL RBF was added (6-((tert-butoxycarbonyl)amino)hexyl)triphenylphosphonium bromide (608 mg, 1.12 mmol, 5 equiv), DCM (10 mL), and TFA (1.2 mL). The resulting solution was stirred at ambient temperature for 1 h and then concentrated by rotary evaporation. The residue was resuspended and concentrated twice from chloroform (2 × 40 mL) to give 6-aminohexyltriphenylphosphonium bromide TFA as a viscous oil (1.207 g), which was dissolved in DCM (2 mL) for the subsequent coupling reaction.

[0377] Step 2: To a 50 mL RBF was added phyllochlorin 13-hydroxymethyl-N-methyl-N-3,6,9-trioxadecylpropylamide (compound 42) (150 mg, 0.224 mmol, 1 equiv.), carbonyldiimidazole (73 mg, 0.448 mmol, 2 equiv.), DCM (5 mL), and DMAP (10 mg). The resulting mixture was stirred under nitrogen for 3 h, and the reaction was monitored by TLC. TEA (821 mg, 8.11 mmol) was added, followed by 6-aminohexyltriphenylphosphonium bromide (1.207 g in 2 mL of DCM (containing approximately 711 mg of TFA)), and stirring was continued for 3 days. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel, washed with 1 M HCl (2 x 25 mL) and pH 7 phosphate buffer (25 mL), then dried (NaSO) and concentrated by rotary evaporation to give a dark green residue. The residue was purified by column chromatography (4 x 18 cm) using 5-10% MeOH / DCM as the loading eluent. The major dark green band (R in 5% MeOH / DCM) f =0.20) was concentrated by rotary evaporation to give compound 43 as a dark green solid (45 mg, 18% over two steps).

[0378] 1H NMR (400 MHz, CDCl3) δ 9.71 (dd, J = 25.2, 5.0 Hz, 2H), 8.85 (d, J = 5.0 Hz, 2H), 7.77-7.34 (m, 16H), 6.43 (s, 2H), 5.77-5.58 (m, 1H), 4.69-4.59 (m, 1H), 4.52 (q, J = 7.4 Hz, 1H), 4.01 (d, J = 4.2 Hz, 3H), 3.79 (q, J = 7.8 Hz, 2H), 3.61 (s, 3H), 3.55-3.30 (m, 11H), 3.22 (d, J = 7.3 Hz, 6H), 3.03-2.91 (m, 1H), 2.91-2.81 (m, 1H), 2.74 (s, 1H), 2.50 (s, 2H), 2.19-2.00 (m, 1H), 1.89 (s, 4H), 1.72 (dt, J = 23.6, 7.0 Hz, 6H), 1.61-1.37 (m, 5H), 1.37-1.04 (m, 5H), 0.93-0.75 (m, 1H), -2.29 (s, 1H), -2.43 (s, 1H).

[0379] Synthesis Example 4: Synthesis of 4-phyllochlorin 13-(N-(3-(3-triphenylphosphoniumpropoxy)propyl)chloride)carbamate N-methyl-N-3,6,9-trioxadecylpropylamide (Compound 44) [ka]

[0380] To a 50 mL RBF was added phyllochlorin 13-hydroxymethyl N-methyl-N-3,6,9-trioxadecylpropylamide (compound 42) (73 mg, 0.109 mmol, 1 equiv.), carbonyldiimidazole (35 mg, 0.218 mmol, 2 equiv.), DCM (3 mL), and DMAP (5 mg). The resulting mixture was stirred under nitrogen for 3 h, and the reaction progress was monitored by TLC. (3-(3-aminopropoxy)propyl)triphenylphosphonium chloride (225 mg, 0.544 mmol, 5 equiv., dissolved in 2 mL of DCM) was added, and stirring was continued for 16 h. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel, washed with 1 M HCl (2 × 20 mL) and pH 7 phosphate buffer (20 mL), then dried (NaSO), and concentrated by rotary evaporation to give a dark green residue. The residue was purified by column chromatography (3x22cm) using 5% MeOH / DCM as the loading solution for the eluent. f The fractions containing 44 (C = 0.2) were concentrated by rotary evaporation to give compound 44 as a dark green solid (35 mg, 29%).

[0381] 1H NMR (400 MHz CDCl3) δ 9.72 (d, J = 4.5 Hz, 2H), 8.88 (d, J = 6.2 Hz, 2H), 7.63-7.53 (m, 7H), 7.51-7.35 (m, 10H), 6.43 (s, 2H), 5.50 (d, J = 6.0 Hz, 1H), 4.66 (d, J = 8.2 Hz, 1H), 4.55 (q, J = 7.2 Hz, 1H), 4.04 (d, J = 4.3 Hz, 3H), 3.83 (q, J = 7.5 Hz, 2H), 3.65 (s, 3H), 3.58 (d, J = 5.7 Hz, 1H), 3.54-3.44 (m, 8H), 3.43-3.36 (m, 3H), 3.34 (s, 3H), 3.26 (s, 3H), 3.10-3.01 (m, 1H), 2.99-2.90 (m, 1H), 2.78 (s, 1H), 2.57 (s, 2H), 2.55-2.41 (m, 1H), 2.18-2.06 (m, 2H), 1.83-1.69 (m, 6H), 1.64 (s, 8H), -2.26 (s, 1H), -2.41 (s, 1H).

[0382] Synthesis Example 45 - Synthesis of phyllochlorin methyl ester 13-(N-(3-triphenylphosphoniumpropyl) bromide) carbamate (Compound 45) [ka]

[0383] To a 25 mL RBF was added phyllochlorin 13-hydroxymethylmethyl ester (compound 3) (75 mg, 0.142 mmol, 1 equiv.), carbonyldiimidazole (46 mg, 0.285 mmol, 2 equiv.), DCM (4 mL), and DMAP (5 mg). The resulting mixture was stirred under nitrogen for 3 h. (3-Aminopropyl)triphenylphosphonium bromide (285 mg, 0.712 mmol, 5 equiv.) was added, and stirring was continued at ambient temperature overnight. The reaction was then heated at 30 °C (heat block) for an additional 6 h. The reaction mixture was diluted with DCM (15 mL), transferred to a separatory funnel, and washed with 1 M HCl (2 × 10 mL) and pH = 7 phosphate buffer (25 mL), then dried (NaSO), and concentrated by rotary evaporation to give a dark green residue (approximately 210 mg). The residue was purified by column chromatography (3x12cm) eluting with a gradient of 3-9% MeOH / DCM. The major green band (R f =0.15) were combined to give compound 45 as a dark green solid (27 mg, 20%).

[0384] 1 H NMR (400 MHz, CDCl3) δ 9.87 (s, 1H), 9.70 (s, 1H), 8.84 (m, 2H), 9.68 (t, 1H), 7.44-7.37 (m, 6H), 7.19-7.10 (m, 9H), 6.92-6.85 (m, 1H), 6.70-6.58 (m, 1H), 6.44 (m, 2H), 4.55 (m, 1H), 4.49 (m, 1H), 3.99 (s, 3H), 3.80 (q, 2H), 3.64 (m, 5H), 3.60-3.50 (m, 9H), 3.35 (s, 3H), 2.62-2.46 (m, 2H), 2.20-2.12 (m, 1H), 2.06-1.95 (m, 1H), 1.92-1.84 (m, 4H), 1.80-1.65 (m, 9H), -2.22 (brs, 1H), -2.36 (brs, 1H).

[0385] Synthesis Example 46 - Synthesis of phyllochlorin methyl ester 13-(N-(2-triphenylphosphoniumethyl) bromide) carbamate (Compound 46) [ka]

[0386] To a 25 mL RBF was added phyllochlorin 13-hydroxymethylmethyl ester (compound 3) (125 mg, 0.237 mmol, 1 equiv.), carbonyldiimidazole (77 mg, 0.475 mmol, 2 equiv.), DCM (4 mL), and DMAP (5 mg). The resulting mixture was stirred under nitrogen for 3 h. (2-Aminoethyl)triphenylphosphonium bromide (458 mg, 1.187 mmol, 5 equiv.) was added, and stirring was continued at ambient temperature overnight. The reaction mixture was diluted with DCM (15 mL), transferred to a separatory funnel, washed with 1 M HCl (2 × 10 mL) and pH 7 phosphate buffer (25 mL), then dried (NaSO) and concentrated by rotary evaporation to give a dark green residue. The residue was purified by column chromatography eluting with a gradient of 4–7% MeOH / DCM. The major green band (in 10% MeOH / DCM, R f =0.15) were combined to give compound 46 as a dark green solid (52 mg, 23%).

[0387] 1H NMR (400 MHz, CDCl3) δ 9.77 (s, 1H), 9.71 (s, 1H), 8.87 (m, 2H), 7.65-7.54 (m, 6H), 7.46 (t, 1H), 7.40-7.31 (m, 9H), 6.86-6.75 (m, 1H), 6.62-6.50 (m, 1H), 6.32 (m, 2H), 4.61-4.48 (m, 2H), 3.99 (s, 3H), 3.86-3.70 (m, 7H), 3.64 (m, 4H), 3.57 (m, 4H), 3.52 (s, 3H), 3.39 (s, 3H), 2.64-2.46 (m, 2H), 2.20-2.12 (m, 1H), 2.08-1.97 (m, 1H), 1.93-1.81 (m, 3H), 1.80-1.70 (m, 8H), -2.24 (brs, 1H), -2.38 (brs, 1H).

[0388] Synthesis Example 47 - Synthesis of Fluorochrome 13-Fluminary (Compound 47)

change

[0389] To a 250 mL RBF was added phyllochlorin ethyl ester (2.25 mg, 1 equiv.), THF (75 mL), osmium tetroxide (10 mg, 0.01 equiv.), deionized water (5 mL), AcOH (5 mL), and sodium periodate (2.33 g, 2.2 equiv.). The resulting mixture was stirred overnight under nitrogen at ambient temperature in the dark. The reaction mixture was concentrated using a rotary evaporator to remove THF, then redissolved in DCM (60 mL), transferred to a separatory funnel, washed with brine (40 mL), saturated NaHCO3 (40 mL), and water (40 mL), dried (Na2SO4), and concentrated by rotary evaporation to give a reddish-brown powdery solid. The residue was subjected to column chromatography (4 x 15 cm). It was dissolved in DCM (using a minimal amount of MeOH to aid solubilization) and loaded onto a column pre-equilibrated with DCM. The column was eluted with a gradient of 1-2% MeOH / DCM. The product (major dark green spot, R in 5% MeOH / DCM) f =0.7) were combined to give compound 47 as a dark green solid (1.68 g, 75%).

[0390] 1 H NMR (400 MHz, CDCl3) δ 11.60 (s, 1H), 10.32 (s, 1H), 9.61 (s, 1H), 8.98 (s, 1H), 8.90 (s, 1H), 4.56 (m, 1H), 4.50 (m, 1H), 4.20 (m, 2H), 4.00 (s, 3H), 3.81 (m, 5H), 3.62 (s, 3H), 3.60 (s, 3H), 2.66-2.56 (m, 1H), 2.55-2.47 (m, 1H), 2.25-2.15 (m, 1H), 2.05-1.95 (m, 1H), 1.80-1.71 (m, 6H), 1.12 (t, 3H), -1.80 (s, 1H), -2.25 (s, 1H).

[0391] Synthesis Example 48 - Synthesis of phyllochlorin 13-hydroxymethylethyl ester (compound 48) [ka]

[0392] To a 250 mL RBF was added phyllochlorin 13-formylethyl ester (compound 47) (1.60 g, 1 equiv.), MeOH (35 mL), DCM (17 mL), and sodium borohydride (224 mg, 2 equiv.). The resulting mixture was stirred under nitrogen at ambient temperature for 1 h. The reaction mixture was diluted with water (100 mL) and stirred for 10 min. The mixture was diluted with DCM (30 mL) and brine (30 mL). The DCM layer was collected, and the aqueous layer was further extracted with DCM (2 x 20 mL). The combined DCM layers were washed with brine (30 mL), dried (NaSO), and concentrated by rotary evaporation to give a dark green solid. The residue was subjected to column chromatography (7 x 15 cm). It was dissolved in DCM and eluted with a gradient of 1-3% MeOH / DCM. The product (R in 5% MeOH / DCM) was f =0.7) were combined and concentrated by rotary evaporation to give compound 48 as a dark green solid (1.50 g, 93%).

[0393] 1 H NMR (400 MHz, CDCl3) δ 9.72 (s, 1H), 9.67 (m, 1H), 8.86 (m, 2H), 5.88 (m, 2H), 4.58 (m, 1H), 4.51 (m, 1H), 4.06 (m, 2H), 4.00 (s, 3H), 3.84 (q, 2H), 3.63 (s, 3H), 3.58 (s, 3H), 3.48 (m, 3H), 2.63-2.48 (m, 2H), 2.20-1.90 (m, 3H), 1.75 (d, 6H), 1.12 (t, 3H), -2.21 (brs, 1H), -2.37 (brs, 1H).

[0394] Synthesis Example 49 - Synthesis of phyllochlorin 13-hydroxymethyl-N-methyl-N-(2-methoxy)ethylpropylamide (Compound 49) [ka]

[0395] To a 25 mL RBF was added phyllochlorin 13-hydroxymethyl (compound 17) (250 mg, 1 equiv.), DMTMM (202 mg, 1.5 equiv.), DCM (10 mL), and 2-methoxy-N-methylethan-1-amine (65 mg, 1.5 equiv.). The resulting mixture was stirred under nitrogen at ambient temperature for 2 h. The reaction mixture was transferred to a separatory funnel, diluted with DCM (15 mL), and washed with 0.5 M HCl (20 mL). The aqueous layer was re-extracted with DCM (2 × 5 mL), and the combined organic layers were washed with pH 7 phosphate buffer (20 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to give a blue-black film. The residue was subjected to column chromatography (3 × 16 cm). It was dissolved in DCM and loaded onto a column pre-equilibrated with DCM. The column was eluted with a gradient of 1–6% MeOH / DCM. The product (major dark green spot, R f =0.5) were combined to give compound 49 as a dark green solid (270 mg, 95%).

[0396] 1 H NMR (400 MHz, CDCl3) δ 9.72 (m, 2H), 8.85 (m, 2H), 6.01 (s, 2H), 6.14 (dd, 1H), 4.62 (m, 1H), 4.50 (m, 1H), 4.05 (s, 1H), 3.85 (q, 2H), 3.64 (s, 3H), 3.53 (s, 3H), 3.38 (m, 5H), 3.20-3.03 (m, 2H), 3.01 (s, 3H), 2.80 (m, 1H), 2.58-2.48 (m, 3H), 2.22-2.10 (m, 2H), 1.81-1.72 (m, 6H), -2.21 (brs, 1H), -2.40 (brs, 1H).

[0397] Synthesis Example 50 - Synthesis of phyllochlorin N-methyl-N-(2-methoxy)ethylpropylamide 13-(N-(3-triphenylphosphoniumpropyl)bromide)carbamate (Compound 50) [ka]

[0398] To a 25 mL RBF was added phyllochlorin 13-hydroxymethyl-N-methyl-N-(2-methoxy)ethylpropylamide (compound 49) (150 mg, 0.256 mmol, 1 equiv.), carbonyldiimidazole (83 mg, 0.513 mmol, 2 equiv.), DCM (5 mL), and DMAP (5 mg). The resulting mixture was stirred under nitrogen in the dark at 25 °C for 3 h. (3-Aminopropyl)triphenylphosphonium bromide (514 mg, 1.284 mmol, 5 equiv.) was added, and stirring was continued at 25 °C overnight. The reaction mixture was diluted with DCM (15 mL), transferred to a separatory funnel, and washed with water (10 mL). The aqueous layer was re-extracted with DCM (2 × 10 mL), and the combined organic layers were dried (NaSO) and concentrated by rotary evaporation to give a dark green residue. The residue was subjected to column chromatography (3 × 12 cm). It was dissolved in DCM and loaded onto a column pre-equilibrated with DCM. The column was eluted with a gradient of 3-9% MeOH / DCM. The product (major dark green spot, R in 5% MeOH / DCM) was f =0.05) were combined to give compound 50 as a dark green solid (145 mg, 56%) (HPLC purity: 99.7%).

[0399] 1H NMR (400 MHz, CDCl3) δ 9.82 (s, 1H), 9.69 (m, 1H), 8.84 (m, 2H), 7.31-7.35 (m, 7H), 7.22-7.10 (m, 10H), 6.88-6.80 (m, 1H), 6.68-6.55 (m, 1H), 6.42 (m, 2H), 4.62 (m, 1H), 4.50 (m, 1H), 4.01 (m, 4H), 3.80 (q, 2H), 3.64 (m, 6H), 3.57 (m, 6H), 3.45-3.35 (m, 7H), 3.30-3.20 (m, 3H), 3.18 (m, 1H), 2.90 (m, 1H), 2.80 (m, 2H), 2.60-2.40 (m, 4H), 2.20 (m, 1H), 2.01 (m, 1H), 1.70-1.64 (m, 9H), -2.22 (brs, 1H), -2.37 (brs, 1H).

[0400] Synthesis Example 51: Synthesis of phyllochlorin 13-hydroxymethyl-N-(2-methoxy)ethylpropylamide (Compound 51) [ka]

[0401] To a 50 mL RBF was added 13-hydroxymethyl phyllochlorin (compound 17) (250 mg, 0.488 mmol, 1 equiv.), DMTMM (202 mg, 0.731 mmol, 1.5 equiv.), DCM (8 mL), and 2-methoxyethan-1-amine (55 mg, 0.731 mmol, 1.5 equiv.). The resulting mixture was stirred under nitrogen at ambient temperature for 3 h. The reaction mixture was transferred to a separatory funnel, diluted with DCM (15 mL), and washed with 0.5 M HCl (20 mL). The aqueous layer was re-extracted with DCM (2 × 5 mL), and the combined organic layers were washed with pH 7 phosphate buffer (20 mL), dried (NaSO), and concentrated by rotary evaporation to give a blue-black film, which was purified by column chromatography (3 × 15 cm) eluting with a gradient of 1–3% MeOH / DCM. The major green band (in 5% MeOH / DCM, R f =0.15) were combined to give compound 51 as a dark green solid (170 mg, 61%).

[0402] 1 H NMR (400 MHz, CDCl3) δ 9.72 (s, 1H), 9.51 (s, 1H), 8.83 (m, 2H), 5.71 (s, 2H), 5.21 (m, 1H), 4.61 (m, 1H), 4.49 (m, 1H), 3.97 (s, 3H), 3.95 (s, 3H), 3.82 (q, 2H), 3.63 (s, 3H), 3.41 (s, 3H), 3.30 (s, 3H), 3.18-2.99 (m, 4H), 2.98 (s, 3H), 2.55-2.47 (m, 1H), 2.20-2.10 (m, 2H), 1.81-1.72 (m, 6H), -2.22 (brs, 1H), -2.36 (brs, 1H).

[0403] Synthesis Example 5: Synthesis of 2-phyllochlorin N-(2-methoxy)ethylpropylamide 13-(N-(3-triphenylphosphoniumpropyl)bromide)carbamate (Compound 52) [ka]

[0404] To a 25 mL RBF was added phyllochlorin 13-hydroxymethyl-N-(2-methoxy)ethylpropylamide (compound 51) (150 mg, 0.263 mmol, 1 equiv.), carbonyldiimidazole (85 mg, 0.527 mmol, 2 equiv.), DCM (4 mL), and DMAP (5 mg). The resulting mixture was stirred under nitrogen in the dark at 23 °C for 3 h. (3-Aminopropyl)triphenylphosphonium bromide (527 mg, 1.316 mmol, 5 equiv.) was added, and stirring was continued at 23 °C overnight. The reaction mixture was diluted with DCM (15 mL), transferred to a separatory funnel, and washed with 1 M HCl (10 mL) and pH 7 phosphate buffer (25 mL). The aqueous layer was extracted with DCM (3 × 5 mL), and the combined organic layers were dried (NaSO) and concentrated by rotary evaporation to give a dark green residue. The residue was purified by column chromatography (3x12cm) eluting with a gradient of 3-9% MeOH / DCM. The major green band (R f =0.05) were combined to give compound 52 as a dark green solid (9 mg, 3%).

[0405] 1H NMR (400 MHz, CDCl3) δ 9.82 (s, 1H), 9.69 (s, 1H), 8.84 (m, 2H), 7.80-7.50 (brm, 1H), 7.45 (t, 1H), 7.41-7.35 (m, 6H), 7.22-7.10 (m, 10H), 6.88-6.80 (m, 1H), 6.68-6.55 (m, 1H), 6.22 (m, 2H), 5.38 (m, 1H), 4.60 (m, 1H), 4.48 (m, 1H), 3.99 (m, 4H), 3.80 (q, 2H), 3.64 (m, 4H), 3.55 (m, 8H), 3.34 (m, 4H), 3.25-3.05 (m, 6H), 3.04 (s, 3H), 2.51 (m, 1H), 2.30-2.18 (m, 2H), 2.16-2.07 (m, 2H), 1.85-1.65 (m, 21H), -2.22 (brs, 1H), -2.37 (brs, 1H).

[0406] Synthesis Example 5: Synthesis of 3-phyllochlorin ethyl ester 13-(N-(3-triphenylphosphoniumpropyl) bromide) carbamate (Compound 53) [ka]

[0407] To a 25 mL RBF was added phyllochlorin 13-hydroxymethylethyl ester (compound 48) (200 mg, 1 equiv.), carbonyldiimidazole (119 mg, 2 equiv.), DCM (4 mL), and DMAP (5 mg). The resulting mixture was stirred under nitrogen for 3 h. (3-Aminopropyl)triphenylphosphonium bromide (740 mg, 5 equiv.) was added, and stirring was continued overnight at ambient temperature. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel, washed with water (20 mL), dried (Na2SO4), and concentrated by rotary evaporation to give a dark green residue. The residue was subjected to column chromatography. It was dissolved in DCM and loaded onto a column pre-equilibrated with DCM. The column was eluted with a gradient of 3-7% MeOH / DCM. The product (major dark green spot, R in 5% MeOH / DCM) was obtained. f =0.15) were combined to give compound 53 as a dark green solid (222 mg, 62%).

[0408] 1 H NMR (400 MHz, CDCl3) δ 9.87 (s, 1H), 9.70 (s, 1H), 8.84 (m, 2H), 7.44-7.37 (m, 6H), 7.19-7.10 (m, 9H), 6.92-6.85 (m, 1H), 6.70-6.58 (m, 1H), 6.44 (m, 2H), 4.55 (m, 1H), 4.49 (m, 1H), 3.99 (m, 5H), 3.80 (q, 2H), 3.64 (m, 5H), 3.60-3.50 (m, 9H), 3.35 (s, 3H), 2.62-2.46 (m, 2H), 2.20-2.12 (m, 1H), 2.06-1.95 (m, 1H), 1.92-1.84 (m, 4H), 1.80-1.65 (m, 9H), 1.12 (t, 3H), -2.22 (brs, 1H), -2.38 (brs, 1H).

[0409] Synthesis Example 54 - Synthesis of phyllochlorin 13-(N-methylamino)methyl ester (Compound 54) [ka]

[0410] To a 25 mL RBF was added phyllochlorin 13-formylmethyl ester (compound 30) (100 mg, 0.191 mmol, 1 equiv.), DCM (1 mL), methanol (3 mL), TEA (58 mg, 0.572 mmol, 3 equiv.), and methylamine hydrochloride (39 mg, 0.572 mmol, 3 equiv.). The resulting mixture was stirred under nitrogen in the dark for 1 h, and then an additional portion of methylamine hydrochloride (39 mg, 0.572 mmol, 3 equiv.), TEA (58 mg, 0.572 mmol, 3 equiv.), and 4 Å sieves (100 mg) was added, and stirring was continued for 3 h. NaBH4 (72 mg, 1.906 mmol, 10 equiv.) was added, and stirring was continued for 30 min. The reaction was acidified with 2 M HCl (1 mL) and stirred for 10 min. Phosphate buffer pH=7 (15 mL) was added, and the mixture was extracted with DCM (3×5 mL). The combined organic layers were dried (NaSO) and concentrated by rotary evaporation to give a dark green residue. The residue was purified by column chromatography (3×14 cm) eluting with a gradient of 3–7% MeOH / DCM. The major green band (R f =0.30) were combined to give compound 54 as a dark green solid (54 mg, 52%).

[0411] 1H NMR (400 MHz, CDCl3) δ 9.51 (s, 1H), 9.46 (s, 1H), 8.75 (s, 1H), 8.69 (s, 1H), 4.82 (brm, 2H), 4.50 (m, 1H), 4.41 (m, 1H), 3.92 (s, 3H), 3.71 (q, 2H), 3.62-3.51 (m, 4H), 3.42 (s, 3H), 3.36 (s, 3H), 3.22 (s, 3H), 2.59-2.38 (m, 6H), 2.13-2.05 (m, 1H), 1.96-1.86 (m, 1H), 1.78-1.60 (m, 7H), -2.32 (brs, 1H), -2.55 (brs, 1H).

[0412] Synthesis Example 5: Synthesis of 5-phyllochlorin 13-(N-methyl-5-triphenylphosphonium bromide pentanamide) methyl ester (Compound 55) [ka]

[0413] To a 25 mL RBF was added phyllochlorin 13-(N-methylamino)methyl methyl ester (compound 54) (50 mg, 0.0926 mmol, 1 equiv.), 4-(carboxybutyl)triphenylphosphonium bromide (82 mg, 0.1853 mmol, 2 equiv.), DCM (2 mL), and DMTMM (55 mg, 0.1853 mmol, 2 equiv.). The resulting mixture was stirred under nitrogen at ambient temperature in the dark. After 3 h, TEA (5 drops) was added, and stirring was continued for another 1 h. The reaction mixture was transferred to a separatory funnel, diluted with DCM (15 mL), and washed with 0.5 M HCl (10 mL). The aqueous layer was re-extracted with DCM (2 × 5 mL), and the combined organic layers were washed with pH 7 phosphate buffer (10 mL) followed by 1 M NaHCO (10 mL). The organic phase was dried (Na2SO4) and concentrated by rotary evaporation to give a blue-black film. The residue was purified by column chromatography (3 x 13 cm) eluting with a gradient of 4-7% MeOH / DCM. The major green band (Rf =0.30) were combined to give compound 55 as a dark green solid (51 mg, 57%).

[0414] 1 H NMR (400 MHz, CDCl3) δ 9.81 (s, 1H), 9.68 (s, 1H), 8.86-8.80 (m, 2H), 7.75-7.67 (m, 6H), 7.55-7.45 (m, 9H), 5.91 (brm, 2H), 4.58-4.47 (m, 2H), 3.98 (s, 3H), 3.86-3.77 (m, 4H), 3.63 (s, 3H), 3.58 (s, 3H), 3.45 (s, 3H), 3.26 (s, 3H), 3.09 (s, 3H), 2.73 (t, 2H), 2.51-2.46 (m, 2H), 2.20-2.10 (m, 3H), 2.09-1.98 (m, 1H), 1.90-1.68 (m, 13H), -2.22 (brs, 1H), -2.32 (brs, 1H).

[0415] Synthesis Example 56 - Synthesis of phyllochlorin 13-(N-methyl-ethylcarbamate) aminomethyl methyl ester (Compound 56) [ka]

[0416] To a 25 mL RBF was added phyllochlorin 13-(N-methylamino)methyl methyl ester (compound 54) (50 mg, 0.0926 mmol, 1 equiv.), DCM (2 mL), and diethyl dicarbonate (75 mg, 0.4632 mmol, 5 equiv.). The resulting mixture was stirred under nitrogen at ambient temperature. After 30 min, the reaction mixture was diluted with pH 7 phosphate buffer (10 mL), transferred to a separatory funnel, extracted with DCM (2 x 5 mL), and the combined organics were dried (Na2SO4) and concentrated by rotary evaporation to give a dark green oil. The residue was purified by silica gel column chromatography using 0.5-1% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM)f =0.75) were combined to give compound 56 as a dark green solid (37 mg, 65%).

[0417] 1 H NMR (400 MHz, CDCl3) δ 9.91-9.67 (m, 2H), 8.88-8.82 (m, 2H), 5.90 (brm, 2H), 4.61-4.38 (m, 4H), 4.01 (s, 3H), 3.87 (q, 2H), 3.67 (s, 3H), 3.58 (s, 3H), 3.51 (s, 3H), 3.39 (s, 3H), 2.99-2.89 (m, 3H), 2.62-2.48 (m, 2H), 2.20-2.00 (m, 2H), 1.82-1.74 (m, 6H), 1.65-1.55 (m, 2H), 1.42-1.36 (m, 2H), -2.15 (brs, 1H), -2.30 (brs, 1H).

[0418] Synthesis Example 57 - Synthesis of phyllochlorin 13-(N-3-triphenylphosphonium bromide) aminomethyl methyl ester (Compound 57) [ka]

[0419] To a 25 mL RBF was added phyllochlorin 13-formylmethyl ester (compound 30) (50 mg, 0.0953 mmol, 1 equiv.), DCM (1 mL), MeOH (3 mL), (3-aminopropyl)triphenylphosphonium bromide (57 mg, 0.1430 mmol, 1.5 equiv.), sodium cyanoborohydride (18 mg, 0.2860 mmol, 3 equiv.), and 4A sieves (400 mg). The resulting mixture was stirred under nitrogen in the dark at 22 °C. After 6 h, (3-aminopropyl)triphenylphosphonium bromide (57 mg, 0.1430 mmol, 1.5 equiv.) and sodium cyanoborohydride (18 mg, 0.2860 mmol, 3 equiv.) were added, and stirring was continued for 4 days. Water (10 mL) was added, and the mixture was stirred for 10 minutes, then extracted with DCM (3 × 10 mL). The combined organic extracts were washed with saturated aqueous NaHCO (2 × 15 mL), then dried (NaSO) and concentrated by rotary evaporation to give a dark green residue. The residue was purified by column chromatography using 3-5% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) f =0.20) were combined to give compound 57 as a dark green solid (18 mg, 21%).

[0420] 1 H NMR (400 MHz, CDCl3) δ 9.82 (s, 1H), 9.70 (s, 1H), 8.86 (s, 1H), 8.78 (s, 1H), 7.31-7.26 (m, 3H), 7.13-7.06 (m, 12H), 5.12 (brm, 2H), 4.59-4.47 (m, 2H), 4.00 (m, 4H), 3.80 (q, 3H), 3.67 (m, 4H), 3.59 (m, 4H), 3.42 (s, 3H), 3.23 (s, 3H), 3.16-3.10 (m, 2H), 2.66-2.48 (m, 3H), 2.24-2.17 (m, 1H), 2.05-1.95 (m, 3H), 1.80-1.60 (m, 1H), -2.28 (brm, 2H).

[0421] Synthesis Example 58 - Synthesis of phyllochlorin 13-(N-3-triphenylphosphonium bromide ethylcarbamate) aminomethyl methyl ester (Compound 58) [ka]

[0422] To a 25 mL RBF was added phyllochlorin 13-(N-3-triphenylphosphonium bromide) aminomethylmethyl ester (compound 57) (15 mg, 0.0165 mmol, 1 equiv.), DCM (2 mL), and diethyl dicarbonate (13 mg, 0.0825 mmol, 5 equiv.). The resulting mixture was stirred under nitrogen at ambient temperature. After 30 min, the reaction mixture was diluted with pH 7 phosphate buffer (10 mL), transferred to a separatory funnel, and extracted with DCM (3×5 mL). The combined organics were dried (NaSO) and concentrated by rotary evaporation to give a blue-black oil. The residue was purified by column chromatography using 3–5% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) f =0.15) were combined to give compound 58 as a dark green solid (12 mg, 75%).

[0423] 1 H NMR (400 MHz, CDCl3) δ 9.86-9.55 (m, 2H), 8.92-8.85 (m, 2H), 6.70-6.52 (m, 3H), 6.50-6.25 (m, 12H), 5.95 (d, 1H), 5.81 (d, 1H), 4.65-4.52 (m, 3H), 4.31 (m, 1H), 4.05 (s, 3H), 3.81 (m, 4H), 3.68-3.63 (m, 6H), 3.56 (s, 3H), 3.32-3.23 (m, 3H), 2.75-2.65 (m, 1H), 2.60-2.50 (m, 1H), 2.40-2.30 (m, 1H), 2.00-1.91 (m, 1H), 1.83-1.79 (m, 3H), 1.75-1.55 (m, 9H), -2.41 (brm, 2H).

[0424] Biological experiment details

[0425] Example 1 - Determination of the solubility of phyllochlorin analogues

[0426] The absorbance maxima were used as a proxy measure of solubility. Relevant phyllochlorin analogs were diluted to 50 μM in PBS (phosphate-buffered saline) solutions containing decreasing amounts of DMSO from 100% to 0%.

[0427] Where necessary, polyvinylpyrrolidone (K30) was added to a final concentration of 1% w / v. Absorbance was measured using a Cytation 3 Multimode Plate Reader (Biotek) in spectral scan mode, capturing spectra from 500 to 800 nm in 2 nm increments. An equivalent volume of blank solution was also measured and subtracted accordingly. Each spectrum was normalized, with the minimum signal set to 0 and the maximum signal set to 100 for pure DMSO solution (maximally soluble).

[0428] Results - Solubility and absorbance maxima of phyllochlorin analogues The absorbance spectrum of Compound 1 was measured in the presence of 1% PVP (w / v). Compound 1 had an absorbance maximum at 650±2 nm.

[0429] The solubility of compound 1 was evaluated in solutions containing DMSO as the organic solvent. Compound 1 (final concentration 50 μM) was resuspended in 100% DMSO, and compound 1 was completely dissolved in the presence or absence of 1% PVP (w / v). The concentration of compound 1 was maintained at 50 μM, and the DMSO percentage was gradually decreased from 100% to 0%. All solutions were vortex mixed and then centrifuged for 2 minutes to pellet insoluble material. 150 μl aliquots were transferred to individual wells of a 96-well clear microplate, and absorbance spectra were collected from 500 to 800 nm in 2 nm increments. Equivalent volumes of solutions containing decreasing DMSO percentages served as background controls.

[0430] At a DMSO concentration of more than 70%, Compound 1 was completely dissolved, but at a DMSO concentration of less than 40%, its apparent solubility decreased to about 45%. The addition of 1% PVP improved the solubility in aqueous solution (i.e., without DMSO) to a maximum of about 75%. Thus, the addition of PVP improved the solubility of Compound 1.

[0431] Example 2 - Cytotoxicity, Phototoxicity and Therapeutic Index

[0432] Preparation of photosensitizer stock solution Photosensitizers (e.g., phyllochlorin analogs, chlorin e4 disodium (provided by Advanced Molecular Technologies, Scoresby) or talaporfin sodium (purchased from Focus Bioscience, catalog number HY-16477-5MG)) were resuspended in 100% dimethyl sulfoxide (DMSO) at a concentration of 5.5 mM. Samples were stored at 4°C protected from light.

[0433] Preparation of photosensitizers for in vitro testing For in vitro experiments, the photosensitizer (stock solution, 5.5 mM in 100% DMSO) was diluted 1:100 in concentrated excipient solution (10% w / v Kollidon-12, 42.4% w / v polysorbate 80, 0.6% w / v anhydrous citric acid, 40% w / v ethanol, 1.0% DMSO, final concentration of 55 μM photosensitizer). Serial dilutions were prepared at 1:55 dilutions in cell culture medium (Dulbecco's modified Eagle's medium / nutrient mixture F-12 (DMEM / F-12)) supplemented with 10% v / v fetal bovine serum, 100 U / mL penicillin, 100 μg / mL streptomycin, and the same excipient solution.

[0434] cell culture The human ovarian cancer cell line SKOV3 (ATCC #HTB-77) was maintained in Dulbecco's modified Eagle's medium / nutrient mixture F-12 (DMEM / F-12) supplemented with 10% v / v fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin. Monolayer cultures were grown in a humidified incubator at 37°C and 5% CO2. When cells reached approximately 80% confluence, the spent medium was replaced with medium containing the required concentration of photosensitizer, and the cells were incubated for the desired period to allow for photosensitizer uptake.

[0435] statistical analysis All data were analyzed using GraphPad PRISM v8.3.1(549) (GraphPad Software, CA). Spectral absorbance and viability measurements were normalized to a range of 0–100%, with the minimum value set to 0 and the maximum value determined from the data set. Dose responses were determined using sigmoidal four-point nonlinear regression with variable slope, and IC10 or IC90 values ​​were calculated for each compound. All data are presented as mean ± SD (where applicable).

[0436] cytotoxicity SKOV3 cells were seeded into 96-well black-walled plates (Greiner #655090) at a cell density of 5000 cells per well in 100 μl of medium. Upon reaching approximately 60% confluence, the medium was aspirated and replaced with fresh medium containing 0–100 μM of the relevant phyllochlorin analogue in DMSO. Cells were incubated for an additional 24 h to allow for uptake of the phyllochlorin analogue.

[0437] To test the intrinsic cytotoxicity (i.e., "dark toxicity") of phyllochlorin analogs, the medium was replaced with fresh medium containing 10% (v / v) AlamarBlue Cell Viability Reagent (ThermoFisher) after 24 hours, and the cells were incubated at 37°C for 6 hours. Untreated cells were used as a control. Fluorescence emission (Ex 555 nm / Em 596 nm) was measured using a Cytation 3 Cell Imaging Multi-Mode Reader (Biotek), and cytotoxicity was assessed by the percentage of viable cells remaining. All measurements were performed in quadruplicate.

[0438] phototoxicity SKOV3 cells were seeded into 96-well black-walled plates (Greiner #655090) at a cell density of 5000 cells per well in 100 μl of medium. Upon reaching approximately 60% confluence, the medium was aspirated and replaced with fresh medium containing 0–100 μM of the relevant phyllochlorin analogue in DMSO. Cells were incubated for an additional 24 h to allow for uptake of the phyllochlorin analogue.

[0439] To test for phototoxicity, cells incubated with phyllochlorin analogues (0–10 μM in DMSO) were incubated for 24 h with a medium change (as above) and then exposed to 50 mW / cm 2 The samples were exposed to a 660 nm laser (Invion) ​​or a light-emitting diode (LED) panel (Invion) ​​for 5 min at a light power density of 15 J / cm (total 15 J / cm ). 2 ). Exposure to laser and LED induces comparable responses in terms of phototoxicity. After activation, cells were cultured for an additional 24 hours. The medium was then replaced with fresh medium containing AlamarBlue, and the survival rate of viable cells was assessed as described above. Controls included cells treated with phyllochlorin analogs but not activated by laser light, cells not treated with phyllochlorin analogs but treated with laser light, and an untreated control. All measurements were performed in quadruplicate.

[0440] Toxicity profiles of phyllochlorin analogues The phototoxicity and intrinsic cytotoxicity (i.e., "dark toxicity") of phyllochlorin analogs were evaluated using SKOV3 ovarian cancer cells as previously described. For comparison purposes, phyllochlorin analogs were compared with chlorin e4 disodium and talaporfin sodium, a clinically approved photosensitizer used in the photodynamic therapy of lung cancer. Phototoxicity IC90 and dark toxicity IC10 values ​​were calculated using the log[inhibitor]-versus-normalized dose-response curve and variable slope according to the formula Y = 100 / (1 + (IC90 / X)^HillSlope(phototoxicity IC90)) or Y = 100 / (1 + (IC10 / X)^HillSlope(dark toxicity IC10)).

[0441] Phototoxicity and dark toxicity values ​​are shown in Table 1. With only three exceptions (compounds 10, 16, and 30), all phyllochlorin analogs had phototoxicity IC90 values ​​in the nM range, with 18 compounds having IC90s below 50 nM and 6 compounds having IC90s below 2 nM (Table 1). These were significantly superior to chlorin e4 disodium (IC90 21.32 μM) or talaporfin sodium (IC90 22.83 μM). Furthermore, the best compound (compound 53) achieved phototoxicity levels five orders of magnitude higher than talaporfin sodium. Thus, phyllochlorin analogs achieved up to approximately 30,000-fold increased phototoxicity compared to talaporfin sodium, a clinically approved photosensitizer.

[0442] Significant variation in the dark toxicity of the phyllochlorin analogs of the present invention was observed (Table 1). However, the high phototoxicity of the phyllochlorin analogs of the present invention is expected to offset any dark toxicity issues by reducing the required doses during use.

[0443] Therapeutic index of phyllochlorin analogues To assess the therapeutic potential of phyllochlorin analogs, the therapeutic index (TI) was calculated. TI provides a quantitative measure that describes relative drug safety by comparing the drug concentration required for the desired effect with the concentration that results in undesired off-target toxicity. TI was calculated using the phototoxicity IC90 versus the dark toxicity IC10.

[0444] The TI values ​​are shown in Table 1. Talaporfin sodium has a low therapeutic index (TI = 0.49), and chlorin e4 disodium is only slightly better (TI = 1.89), indicating that they have low relative cytotoxicity but a small potential therapeutic window for use. Most of the phyllochlorin analogs of the present invention had significantly improved TIs and significantly higher phototoxicity (Table 1).

[0445] Therefore, the phyllochlorin analogs of the present invention have a desirable therapeutic index superior to that of clinically applied photosensitizers. Furthermore, the greater phototoxicity of phyllochlorin analogs suggests the possibility of using them at significantly reduced doses in vivo. Therefore, phyllochlorin analogs have a therapeutic profile suitable for clinical application. [Table 1] TIFF2024544615000102.tif33159

[0446] Example 3 - Phyllochlorin glucose analogues are actively transported into cancer cells

[0447] method: SKOV3 cells were seeded in 96-well black-walled plates (Greiner #655090) at a cell density of 5,000 cells per well in 100 μl of medium. Upon reaching approximately 60% confluence, the medium was aspirated and replaced with fresh medium containing Compound 1 or chlorin e4 disodium at 5 μM. Cells were incubated for up to 18 hours. At 10, 20, 30, 60 minutes, 2, 4, and 18 hours, the medium was removed and the cells were lysed in 100 μl of lysis buffer (PBS + 1% SDS + 1% PVP + benzonase nuclease 500 units / mL). Samples were quickly frozen on dry ice until use.

[0448] Eight-point standard curves were generated using compound 1 or chlorin E4 disodium over the range of 0 to 10 μM using serial dilutions in lysis buffer. Cell lysates (100 μl) were thawed, centrifuged at room temperature (21,000 g for 10 minutes), and the supernatants were transferred to new tubes. 100 μl of each supernatant was added directly to a 96-well microplate, and absorbance at 405 nm was measured using a Cytation 3 multimode plate reader. All wells were measured against blank wells containing buffer only, and background values ​​measured using untreated cells were subtracted from all samples. The concentration of each chlorin species was determined in each case against the appropriate standard curve.

[0449] result: It was hypothesized that conjugation of a glucose moiety to phyllochlorin would facilitate active uptake into cancer cells via interaction with one or more glucose transporters present on the cell surface. To assess the kinetics of photosensitizer uptake in vitro, SKOV3 ovarian cancer cells were incubated for up to 18 hours in the presence of 5 µM compound 1. Chlorin E4 disodium (which enters cells via a passive diffusion process) was included as a comparison standard, and untreated cells were used as a control. Cells were harvested at periods ranging from 10 minutes to 18 hours after addition of the photosensitizer, lysed, and the supernatant was measured for photosensitizer uptake against an appropriate standard curve.

[0450] Consistent with passive uptake, chlorin e4 disodium was not detected until 1 h of incubation and accumulated slowly, reaching a maximum at 18 h.

[0451] On the other hand, compound 1 was observed intracellularly within 10 min of incubation, and its uptake rate was significantly faster than that of chlorin E4 disodium, and this rate was maintained for 2–4 h after addition of the photosensitizer. The amount of compound 1 recovered in the cell lysate also reached relatively high concentrations, supporting an active uptake process compared to the simple passive equilibrium observed with unconjugated chlorins.

[0452] Thus, the phyllochlorin glucose analogues are actively transported into cancer cells and reach higher intracellular concentrations than the unconjugated form.

[0453] Example 4 - Phyllochlorin glucose analogues are absorbed by bacterial cells

[0454] method: E. coli DH5α cells were seeded in LB medium and incubated overnight (shaking at 37°C) in the presence of 50 μM compound 1 or chlorin e4 disodium. Untreated cells served as a control. The following day, cells were harvested by centrifugation (5,000 g, 10 min, room temperature) and lysed by adding PBS + 1% SDS (w / v) + 1% PVP-17 (w / v). Insoluble material was pelleted by centrifugation at 21,000 g (10 min, benchtop centrifuge), and the supernatant was transferred to a new tube. 100 μl aliquots were added to a clear 96-well microtiter plate, and absorbance spectra were measured from 600 to 700 nm using a Cytation 3 multimode plate reader. The optical density (OD) in each case was plotted against wavelength to determine the uptake of the photosensitizer into the cells.

[0455] result: Conjugation of a glucose moiety to phyllochlorin analogs promoted active uptake into cancer cells (see above). Therefore, we tested whether this also promoted uptake into bacterial cells, a critical step required for the application of phyllochlorin analogs as antibacterial agents. Compound 1 was clearly detectable in bacterial lysates after the incubation period. In comparison, chlorin E4 disodium (taken up into cancer cells by passive diffusion) was detected only slightly above background. Therefore, similar to cancer cells, phyllochlorin glucose analogs are likely absorbed into bacteria via an active transport process, potentially providing additional applications as antibacterial agents.

[0456] It will be understood that the present invention has been described above by way of example only, and that the examples are not intended to limit the scope of the invention. Various modifications and embodiments can be made without departing from the scope and spirit of the invention, which is defined solely by the claims that follow.

Claims

1. A compound of formula (I) or a complex of formula (II), 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, -R 1 is -CH 2 OR 2 , -CH 2 S.R. 2 , -CH 2 S(O)R 2 , -CH 2 S (O) 2 R 2 , -CH 2 N (R 2 ) 2 , -R 2 , —C(O)—OR 3 , —C(O)—SR 3 , -C(O)-N(R 3 ) 2 , -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 ) 2 is selected from -R 2 is, independently of each other, -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 ), 2 , -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 ), 2 , -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O) 2 R β , -R α -NH 2 , -R α -NH(R β ), -R α -N(R β ), 2 , -R α -X, -R α -[N(R 5 ), 3 Y, -R α -[P(R 5 ), 3 Y, -R α -[R 7 , -R α -[N(R 5 ), 2 (R 5’ ), -R α -[P(R 5 ), 2 (R 5’ ), or -R α -[R 7’ and is selected from -R 3 and -R 4 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S (O) 2 R β , -R α -NH 2 , -R α -NH(R β ), -R α -N(R β ) 2 , -R α -X, -R α -[N(R 5 ) 3 ]Y, -R α - [P(R 5 ) 3 ]Y, -R α - [R 7 ]Y, -R α -[N(R 5 ) 2 (R 5’ )], -R α - [P(R 5 ) 2 (R 5’ ) or -R α - [R 7’ ] is selected, -R α - is independently C 1 -C 42 alkylene groups, said alkylene groups optionally being selected from one or more C 1 -C 4 Alkyl, C 1 -C 4 may be substituted with a haloalkyl or halo group, and one or more carbon atoms of the backbone of said alkylene group may be optionally replaced by a heteroatom or group independently selected from O, S, NH or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group, said hydrocarbyl group may be optionally substituted, and said hydrocarbyl group may optionally include one or more heteroatoms N, O, S, P or Se in its carbon backbone; -R 5 are each independently 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, -(CH 2 CH 2 O) n -H, -(CH 2 CH 2 O) n -CH 3 , phenyl or C 5 -C 6 heteroaryl, wherein said phenyl or C 5 -C 6 Heteroaryl optionally includes one or more C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, —O(C 1 -C 6 alkyl), -O(C 1 -C 6 haloalkyl), halo, -CO 2 H, -CO 2 Z, -CO 2 N.H. 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 may be substituted with a group, -R 5’ is C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, -(CH 2 CH 2 O) n -H, -(CH 2 CH 2 O) n -CH 3 , phenyl or C 5 -C 6 heteroaryl, each of which is —CO 2 - and the phenyl or C 5 -C 6 Heteroaryl optionally includes one or more C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, —O(C 1 -C 6 alkyl), -O(C 1 -C 6 haloalkyl), halo, -CO 2 H, -CO 2 Z, -CO 2 N.H. 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 may be further substituted with a group, -R 6 is -OR 2 , -N(R 2 ) 2 , -SR 2 , -S(O)R 2 , -S(O) 2 R 2 , or -X; -R 7 is one or more C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, —O(C 1 -C 6 alkyl), -O(C 1 -C 6 haloalkyl), halo, -CO 2 H, -CO 2 Z, -CO 2 N.H. 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 -N-, optionally substituted with a group 5 H 5 ], -R 7’ is -CO 2 - and optionally one or more C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, —O(C 1 -C 6 alkyl), -O(C 1 -C 6 haloalkyl), halo, -CO 2 H, -CO 2 Z, -CO 2 N.H. 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 is further substituted with a -[NC 5 H 5 ], -R 9 is hydrogen or methyl, or -R 6 and -R 9 together form an oxo (=O) group, n is 1, 2, 3, 4, 5 or 6; X is a halo group; Y is a counter anion; Z is a counter cation, and M 2+ is a metal cation, or a pharma- ceutically acceptable salt thereof.

2. Each -R α - but independently, C 1 ~C 6 2. The compound or complex of claim 1, wherein the alkylene is selected from the group consisting of aryl, ... and alkylene.

3. -R 2 , -R 3 and -R 4 At least one of the following is -R α -OR β , -R α -SR β , -R α -S(O)R β Or -R α -S (O) 2 R β -R β 4. A compound or complex according to any preceding claim, wherein is a saccharidyl group.

4. -R β but, 【Chemistry 2】 4. The compound or complex of claim 3, wherein the saccharidyl group is selected from:

5. The saccharidyl group is 【Chemistry 3】 5. The compound or complex of claim 4,

6. -R β but, 【Chemistry 4】 (In the formula, -R 8 is C 1 ~C 4 alkyl) 4. The compound or complex of claim 3, wherein the saccharidyl group is selected from:

7. -R 8 7. The compound or complex of claim 6, wherein is methyl.

8. -R 1 is -C(O)-OR 3 and -R 3 Ga-R β and -R β C 1 -C 4 2. A compound or complex according to any preceding claim which is an alkyl group.

9. -R 1 is -C(O)-OR 3 , —C(O)—SR 3 or -C(O)-N(R 3 ) (R 3’ ) selected from -R 3 But, -R α -OR β , -R α -SR β , -R α -S(O)R β Or -R α -S (O) 2 R β -R β is a saccharidyl group, -R 3’ is H or C 1 ~C 4 8. The compound or complex of claim 1, which is alkyl.

10. -R 6 But, -OR 2 or -SR 2 -R 2 But, -R α -OR β , -R α -SR β , -R α -S(O)R β Or -R α -S (O) 2 R β -R β 4. A compound or complex according to any preceding claim, wherein is a saccharidyl group.

11. The compound or the complex is 【Chemistry 5】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 or a metal cation complex thereof, or a pharma- ceutically acceptable salt thereof.

12. 10. A compound or complex according to any preceding claim for use in medicine.

13. 10. A compound or complex according to any of the preceding claims for use in photodynamic therapy or cytoluminescent therapy.

14. atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Herpes zoster; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant cell hyperproliferation or 13. A compound or complex as claimed in any of the preceding claims for use in the treatment of a disease characterised by areas of angiogenesis; a benign or malignant tumour; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumour; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

15. 10. A compound or complex according to any of the preceding claims for use in the treatment of a disease characterised by benign or malignant cellular hyperproliferation or by areas of neovascularisation.

16. 10. A compound or complex according to any preceding claim for use in the treatment of benign or malignant tumors.

17. 13. A compound or complex as claimed in any of the preceding claims for use in the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureters, kidneys, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

18. 10. A compound or complex according to any preceding claim for use in photodynamic diagnosis.

19. 10. A compound or complex according to any preceding claim, wherein the compound is adapted to be administered prior to administration of radiation.

20. 20. The compound or complex of claim 19, wherein the radiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.

21. A pharmaceutical composition comprising a compound or complex according to any of the preceding claims and a pharma- ceutically acceptable carrier or diluent.

22. 22. The pharmaceutical composition of claim 21, further comprising polyvinylpyrrolidone.

23. 23. The pharmaceutical composition of claim 21 or 22, further comprising an immune checkpoint inhibitor.

24. 24. The pharmaceutical composition of claim 23, wherein the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, or ipilimumab.

25. A pharmaceutical composition according to any one of claims 21 to 24 for use in photodynamic therapy or cytoluminescence therapy.

26. atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Herpes zoster; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant cell hyperproliferation or blood 26. A pharmaceutical composition according to any one of claims 21 to 25 for use in the treatment of a disease characterised by areas of neovascularisation; a benign or malignant tumour; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumour; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureters, kidneys, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

27. A pharmaceutical composition according to any one of claims 21 to 26 for use in the treatment of a disease characterised by benign or malignant cellular hyperproliferation or by areas of neovascularisation.

28. A pharmaceutical composition according to any one of claims 21 to 27 for use in the treatment of benign or malignant tumors.

29. 29. A pharmaceutical composition according to any one of claims 21 to 28 for use in the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

30. 23. A pharmaceutical composition according to claim 21 or 22 for use in photodynamic diagnosis.

31. The pharmaceutical composition according to any one of claims 21 to 30, wherein the pharmaceutical composition is adapted for administration prior to administration of radiation.

32. The pharmaceutical composition of claim 31, wherein the radiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.

33. 33. The pharmaceutical composition according to any one of claims 21 to 32, wherein the pharmaceutical composition is in a form suitable for oral, parenteral (including intravenous, subcutaneous, intramuscular, intradermal, intratracheal, intraperitoneal, intratumoral, intraarticular, intraperitoneal, intracranial and epidural), transdermal, airway (aerosol), rectal, vaginal or topical (including buccal, mucosal and sublingual) administration.

34. 34. The pharmaceutical composition of claim 33, wherein the pharmaceutical composition is in a form suitable for oral or parenteral administration.

35. atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Herpes zoster; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant cell hyperproliferation or areas of angiogenesis.

21. Use of a compound or complex according to any one of claims 1 to 20 in the manufacture of a medicament for the treatment of a disease characterized by a range of conditions; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

36. 21. Use of a compound or complex according to any one of claims 1 to 20 in the manufacture of a phototherapeutic agent for use in photodynamic therapy or cytoluminescence therapy.

37. The phototherapy agent may be used to treat a variety of conditions, including but not limited to atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Herpes zoster; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant 37. The use according to claim 36 for the treatment of diseases characterized by areas of hyperproliferation of cells or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

38. The use according to any one of claims 35 to 37, wherein said medicament or said phototherapeutic agent is intended for the treatment of a disease characterized by benign or malignant cellular hyperproliferation or by areas of neovascularization.

39. The use according to any one of claims 35 to 38, wherein the medicament or phototherapeutic agent is intended for the treatment of benign or malignant tumors.

40. 40. The use according to any one of claims 35 to 39, wherein the medicament or phototherapy agent is for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

41. 21. Use of a compound or complex according to any one of claims 1 to 20 in the manufacture of a photodiagnostic agent for use in photodynamic diagnosis.

42. The use according to any one of claims 35 to 41, wherein the medicament, phototherapeutic agent or photodiagnostic agent is adapted for administration prior to the administration of radiation.

43. The use according to claim 42, wherein the radiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.

44. atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Herpes zoster; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; diseases characterised by areas of benign or malignant cellular hyperproliferation or angiogenesis; 23. A method of treating a benign or malignant tumor; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas, comprising administering to a human or animal in need of treatment a therapeutically effective amount of a compound or complex according to any one of claims 1 to 20.

45. A method for photodynamic or cytoluminescent therapy of a disease in humans or animals, said method comprising administering to a human or animal in need of treatment a therapeutically effective amount of a compound or complex according to any one of claims 1 to 20.

46. The human or animal disease may be atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infection; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Herpes zoster; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or non-cancerous conditions. or a disease characterized by areas of malignant cellular hyperproliferation or angiogenesis; a benign or malignant tumor; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.

47. The method of any one of claims 44 to 46, wherein the human or animal disease is characterized by benign or malignant cellular hyperproliferation or by areas of neovascularization.

48. The method according to any one of claims 44 to 47, wherein the human or animal disease is a benign or malignant tumor.

49. 49. The method of any one of claims 44 to 48, wherein the human or animal disease is early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.

50. A method for the photodynamic diagnosis of a disease in a human or animal, said method comprising administering to said human or animal a diagnostically effective amount of a compound or complex according to any one of claims 1 to 20.

51. A method according to any one of claims 44 to 50, wherein after administration of a compound or complex according to any one of claims 1 to 20, the human or animal is subjected to irradiation.

52. 52. The method of claim 51, wherein the radiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.

53. (a) a compound or complex according to any one of claims 1 to 20; (b) a co-drug that is an immune checkpoint inhibitor; A pharmaceutical combination or kit comprising:

54. 54. The pharmaceutical combination or kit of claim 53, wherein the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab or ipilimumab.

Citation Information

Patent Citations

  • Dihydroporphin compound as well as preparation method and application thereof

    CN113461697A

  • Novel chlorin e4 derivative, pharmaceutically acceptable salt thereof, and preparation methods and application of novel chlorin e4 derivative and thepharmaceutically acceptable salt thereof

    CN113527319A

  • Novel dihydroporphine e6 derivatives and pharmaceutically acceptable salts thereof, their preparation method and use

    JP2019533635A